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Abstract 
Defining the Properties and Toxicity Mechanisms of Non-Canonical Translation 
Products Associated with ALS and Huntington’s Disease Using C. elegans 
 
Paige Davison Rudich, Ph.D. 
 
University of Pittsburgh, 2019 
 
 
 
Expanded guanine/cytosine (G/C)-rich nucleotide repeats are the underlying 
genetic cause of many age-dependent neurodegenerative diseases.  An emerging 
mechanism underlying disease pathology is an unusual type of protein translation called 
Repeat-Associated non-AUG (RAN) translation.  RAN translation requires extended G/C-
rich repeats and occurs independently of a canonical start codon, allowing translation in 
all three reading frames.  Antisense RNA from G/C-rich repeats also gives rise to RAN 
products, causing up to six distinct protein products from one repeat expansion.  The 
toxicity of RAN products in vivo is beginning to be explored.  We created codon-varied 
RAN product models for two different repeats: an intronic GGGGCC repeat expansion 
that is the most common genetic cause of Amyotrophic Lateral Sclerosis (ALS), and the 
CAG repeat expansion that causes Huntington’s disease (HD).   
In our C. elegans ALS model, we discovered that the arginine-containing 
dipeptides, proline-arginine (PR) and glycine-arginine (GR), were the most toxic 
dipeptides.  PR and GR exhibited age-dependent toxicity when expressed in multiple cell 
types, including motor neurons.  Both PR and GR exhibited nuclear localization that was 
necessary for toxicity.  An unbiased whole-genome RNAi screen for suppressors of PR 
toxicity identified twelve genes.  Four of the genes were previously identified in PR 
modifier screens performed in other systems, suggesting mechanisms of PR toxicity are 
conserved.   
My studies are the first to model codon-varied CAG RAN polypeptides in a 
multicellular animal.  Every polypeptide, except for polyLeucine (polyLeu), formed 
immobile protein aggregates at ~38 repeats.  Surprisingly, polyLeu was the most toxic 
HD RAN polypeptide in every tissue studied.  A forward mutagenesis screen combined 
with a candidate RNAi screen identified three genes that suppressed polyLeu toxicity.  
Two of the genes encoded transmembrane proteins, and the third gene encoded a 
 v 
deubiquitinase enzyme, suggesting that polyLeu toxicity occurs via disrupted folding of 
transmembrane proteins.  Understanding how different RAN products contribute to HD 
and ALS is vital for developing appropriate treatments for these diseases. 
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1.0 Introduction 
Neurodegenerative diseases (NDDs) are affecting an expanding percentage of the 
world population [1]. This is due to an increase in the percentage of the population who 
is most at risk for NDDs, the aging population.  There are twice as many people over the 
age of 60 alive today compared to 1980 [2], and that population is predicted to double 
again by 2050 [2].  This is a growing health crisis as there are no curative treatments for 
any NDD, and the majority of NDDs are fatal.  Despite intensive research, the initiating 
cellular causes of most NDDs are unknown.  To identify druggable targets, the known 
genetic causes of NDDs have been modeled and studied.  However, the mechanism(s) 
by which these genetic mutations lead to disease is poorly understood.   
One type of genetic mutation, nucleotide repeat expansions, is specifically 
associated with NDDs.  Repetitive DNA or DNA derived from repeats [3] comprises up to 
60% of the human genome.  However, DNA repeats can expand to pathogenic lengths, 
which predominantly cause NDDs.  The link between repeat expansions and NDDs is 
unclear, but a recent discovery may be the key.  The Ranum lab discovered that 
guanine/cytosine (G/C)-rich nucleotide repeat expansions can undergo a unique type of 
translation, Repeat-Associated non-AUG (RAN) translation [4].  RAN translation occurs 
independently of a start codon and can consequently occur in any of the three possible 
reading frames [4].  Antisense RNA is commonly transcribed from nucleotide repeat 
expansions [5-7] and can also undergo RAN translation.  Thus, six possible RAN products 
are produced from one repeat expansion [4].  RAN translation has been predominantly 
observed in neuronal tissue, and it is unclear if it occurs at similar levels in other tissues.  
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Either RAN translation itself or the RAN products may be why repeat expansions 
predominantly cause neurodegeneration.   
To better define how RAN products cause toxicity, I focused my thesis research 
on RAN products from two prominent repeat expansions that cause NDDs.  The first 
mutation, a GGGGCC (G4C2) repeat expansion in chromosome 9 open reading frame 72 
(C9orf72), is the most common genetic cause of Amyotrophic Lateral Sclerosis (ALS), as 
well as Frontotemporal Dementia (FTD) [8, 9].  G4C2 RAN products can be highly toxic 
and are associated with neurodegeneration [10].  The second genetic mutation I focused 
on is a CAG repeat expansion, which causes thirteen different NDDs depending on the 
genetic location of the repeat expansion [11].  RAN products have been identified in three 
of these diseases, including the most commonly studied CAG repeat expansion disease, 
Huntington’s disease (HD) [12].  My work creating and characterizing C. elegans models 
of RAN products from these two mutations will aid in identifying molecular pathways that 
may be relevant to patients.  
1.1 Common Features of Repeat Expansions 
Over 30 nucleotide repeat expansions cause age-dependent neurodegenerative 
or neuromuscular diseases (Appendix B-Table 4.1).  Interestingly, repeat expansions are 
commonly the only mutation of the relevant gene that causes a neurodegenerative or 
neuromuscular disease.  For example, the most common genetic cause of ALS, a G4C2 
repeat expansion in C9orf72, is the only mutation in C9orf72 that has been proven to 
cause ALS.  In contrast, the second most common genetic cause of ALS is mutations in 
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superoxide dismutase 1 (sod1), with over 150 identified point mutations, insertions, 
deletions and truncations in sod1 that cause ALS [13].  Therefore, nucleotide repeat 
expansions having toxic properties beyond disrupting their respective gene and 
nucleotide repeat expansions are innately toxic.  To determine how the repeat expansions 
are toxic, it is first important to understand the common features of disease-causing 
repeat expansions.  
1.1.1  High G/C Content Causes Repeat Instability 
The most noticeable feature of toxic repeat expansions is that most have a high 
G/C content (Appendix B-Table 4.1).  This attribute drives the instability of the repeats.  
Guanines and cytosines form strong bonds that can cause improper interactions between 
DNA and RNA during transcription [14] or mismatching between the sense and antisense 
strand of DNA (slipped-strand DNA) during DNA synthesis [15].  To resolve these 
improper interactions, DNA repair pathways are activated, such as the double-strand 
break repair pathway [16].  However, the repetitive nature of the DNA can cause defects 
in DNA repair and give rise to shrinkage or expansion of the DNA repeats.  For example, 
G/C-rich DNA and its transcribed G/C-rich RNA can form hybrid structures called R loops 
[14].  While R loops are normally removed by RNA helicases, remaining R loops activate 
DNA repair mechanisms, which cause expansion or shrinkage of the repeat [14].  Further 
evidence of the interrelationship between DNA repair pathways and repeat expansions is 
that a mismatch repair factor, MSH3, is required for CAG repeat expansions within the 
pathological and pre-pathological range of repeats [17].  Genes in the double-strand 
break repair pathway have also been identified as modifiers of HD [18].  These repair 
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pathways can be activated and cause repeat expansions during mitosis, meiosis, or 
transcription [14, 19].  Interestingly, G/C-rich repeats are only unstable after the repeat 
passes a certain length.  In the HD-associated CAG repeat, CAG repeats up to a length 
of 35 repeats exhibit high intergenerational stability.  However, CAG repeats in the 
potentially pathogenic range of 36-39 CAG repeats exhibit low intergenerational stability 
and thus expand [20].  Although the precise mechanism(s) underlying pathogenic repeat 
expansion is not definitively established, the change in stability is likely due to expanded 
repeats being more likely to activate DNA repair pathways.  Thus, expanded CAG repeats 
are susceptible to further repeat expansions during meiosis [21]. 
Most disease-causing repeat expansions are hereditary mutations [22, 23] or occur 
during germline replication [24].  Therefore, every cell contains the repeat expansion.  The 
effects of germline expansion were documented in HD before the genetic cause of HD 
was known.  Successive generations of HD patients had earlier onsets of the disease, 
known as genetic anticipation [25].  Genetic anticipation is now understood to be caused 
by repeat instability and intergenerational expansion of the CAG repeats, as described 
above.  In some, but not all, repeat expansion diseases, repeat length is directly 
associated with disease onset and/or severity.  For example, repeat length is inversely 
associated with the age of onset in HD [25].  However, repeat length is not a clearly 
established predictor of age-of-onset or disease severity in another repeat expansion 
disease, C9orf72-associated ALS/FTD [26-29].  
Somatic repeat expansions can modify the severity or age of onset in diseases 
with repeat length associated toxicity, such as HD [30, 31].  A postmortem study of 48 HD 
patients found that every patient had somatic instability of the CAG repeat within the 
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mutant huntingtin (mHTT) in neurons [30].  The somatic repeat expansions ranged from 
1 additional repeat to >55 additional repeats, but the majority of somatic repeat 
expansions were <10 repeats [30].  Larger somatic repeat expansions were correlated 
with an earlier age of onset.  Somatic repeat instability and an earlier age of onset are 
both associated with mutations in double-strand break repair machinery [17, 18].  
Unstable G/C-rich repeats can expand at any stage of development and those 
expansions can not only cause neurodegeneration but also modify the age of onset of 
NDD symptoms.   
1.1.2  Repeat Expansions Can Occur in Any Genetic Context 
Nucleotide repeat expansions happen in every genetic context and can be toxic 
even when located in introns or untranslated regions (UTRs).  The first identified disease-
associated repeat expansions were a CGG repeat expansion in a 5’UTR (fragile X 
syndrome (FXS) [32]) and a CAG repeat expansion in an exon (spinal-bulbar muscular 
atrophy (SBMA) [33]).  Since then, 18 exonic repeat expansions and 16 intronic/UTR 
localized repeat expansions have been identified (Appendix B-Table 4.1).  Exonic repeat 
expansions are either polyglutamine-encoding CAG repeat expansions (‘polyQ’ diseases) 
or polyalanine-encoding GCC repeat expansions.  Unlike exonic CAG repeat expansions 
and most intronic/UTR repeat expansions, polyalanine (GCC) repeat expansions cause 
developmental defects and do not cause neurodegeneration.  For these reasons, 
polyalanine diseases are likely toxic through distinct mechanisms compared to exonic 
CAG repeat expansions and untranslated repeat expansions.   
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In contrast, exonic CAG repeat expansions and untranslated repeat expansions 
share many features, which will be discussed in-depth in the following sections.  They 
exhibit age-dependent toxicity of the associated NDDs, even though the repeat 
expansions are present embryonically.  The length of the repeat expansions can also 
modify the age of onset for many of these diseases.  Antisense RNA transcription (see 
below) occurs in both exonic repeat expansions and untranslated repeat expansions.  
Due to these shared features, it is likely that exonic CAG repeat expansions and 
untranslated repeat expansions have some shared pathological mechanisms 
1.1.3  Bidirectional Transcription of Repeat Expansions 
Bidirectional transcription of nucleotide repeat expansions, producing both sense 
and antisense RNA, was first noted in 2005 with the 5’ CTG repeat expansion that causes 
myotonic dystrophy type 1 (DM1) [7].  Interestingly, the bidirectional transcription was not 
dependent on the length of the repeat expansion, as similar levels of antisense RNA were 
transcribed in wild-type cells.  Antisense RNA has since been identified in most nucleotide 
repeat expansions, including HD [5] and C9orf72 [6].  In some repeat expansion diseases, 
such as HD, the repeat expansion causes a decrease in antisense RNA [5], while in other 
diseases, such as C9orf72-ALS, the repeat expansion causes an increase in antisense 
RNA [34].  Therefore, repeat expansions can be modifiers of bidirectional transcription, 
but the mechanism of modification is not consistent between diseases or well understood. 
Bidirectional transcription occurs in 10-40% of protein-coding genes in the human 
genome [35, 36] and is not unique to pathogenic repeat expansions [35, 36].  Bidirectional 
transcription is a general feature observed in most, if not all, cells.  However, the genes 
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undergoing bidirectional transcription differ depending on cell type [36].  As native 
antisense RNA production is widespread, the antisense RNA is likely to serve a biological 
function.  The role of native antisense RNA is varied and can either inhibit or stimulate 
transcription of the corresponding sense RNA [5, 37] or RNA with high homology to the 
sense RNA [38].  Antisense RNA is well known to suppress the expression of the sense 
RNA through RNAi, but the other regulatory methods of antisense RNA are not as well 
understood.  Antisense RNA can stabilize the sense RNA or spliced versions of the sense 
RNA, leading to increased expression of spliced versions of the gene.  Antisense RNA 
does this through binding to and ‘masking’ the sense RNA to prevent binding of splicing 
elements or other regulatory elements [39, 40].  Most commonly, antisense RNA causes 
silencing of the sense gene through epigenetic changes, such as methylation of 
promoters or heterochromatin modifications [7, 41, 42].  Depending on the disease, 
repeat expansions can either increase or decrease the levels of native antisense RNA, 
causing the epigenetic effects of the antisense RNA to cause a corresponding increase 
in sense RNA production (HD [5]) or decrease in sense RNA production (FXS [42]).  The 
biological role of native antisense RNA is just beginning to be understood, and the 
ramifications of alterations to the endogenous level of antisense RNA need to be 
individually studied with each NDD-associated repeat expansion.  
1.2 Shared Disease Characteristics of Repeat-Expansion-Associated NDDs 
Like the disease-causing repeat expansions, the diseases caused by repeat 
expansions also have shared characteristics.  Repeat expansion associated NDDs 
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typically occur during advanced age, even though the causative mutation is present since 
birth.  The length of the repeat expansion can also modify the age when the NDD occurs.  
Finally, the repeat expansion, which is present in every cell, only causes toxicity in a 
subset of neurons.  Many mechanisms have been identified that may lead to the temporal 
and tissue specificity of these NDDs.  However, it is still unclear which feature or 
combination of features is the causative mechanism. 
1.2.1  Age-Associated Toxicity of Repeat Expansions 
While repeat expansions are present from before birth, they do not typically cause 
neurodegeneration until middle to late age (Appendix B-Table 4.1).  The delayed 
manifestation of the diseases with age could be due to many features of aging neurons.  
Two possible factors are that aging neurons accumulate somatic mutations [43] and that 
aging neurons have increased damage from reactive oxygen species (ROS) [44].  Both 
issues can increase levels of misfolded proteins by altering the protein structure directly 
(somatic mutations) or by altering the protein folding environment (oxidative stress 
induced global protein damage due to ROS).  These and possibly other factors may 
contribute to why aging causes an increase in misfolded proteins and protein aggregates 
[45].  Other effects of aging likely contribute to neurodegeneration beyond inhibiting 
protein folding.  However, the relationship between aging, neurodegeneration, and 
misfolded proteins is a well-established feature of most NDDs.  
 Misfolded proteins and protein aggregates are pathological characteristics of 
many neurodegenerative diseases.  For example, polyQ aggregates form in 
HD [21], TDP-43 aggregates form in ALS [46], and amyloid plaques form in Alzheimer’s 
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Disease [25].  Manipulations that inhibit misfolded protein clearance mechanisms, such 
as defects in the autophagy pathway [47, 48] or the proteasome pathway [49], cause 
neurodegeneration in mice.  Mutations in protein degradation pathways can also directly 
cause neurodegenerative diseases (e.g., mutations in genes associated with mitophagy 
in Parkinson’s disease [50] and mutations in genes associated with autophagy in ALS 
[51]). Conversely, increased proteasome activity [52, 53] or chaperones [54] can 
suppress age-induced protein aggregation.  While it is not clear what the initiating factor 
is that causes age-induced toxicity of repeat expansions, defects in the degradation of 
misfolded proteins and protein aggregates are likely a contributing factor.  
1.2.2  Length-Dependent Toxicity of Repeat Expansions 
Another modifier of the toxicity of repeat expansion mutations is the length of the 
repeat.  Many repeat expansion diseases, such as the CAG/CTG repeat expansion 
diseases, have a clear inverse correlation between the length of the repeat and the age 
of onset of the disease [55, 56].  This relationship was first discovered with the CAG 
repeat expansion in HD, where CAG repeat length explains 50-70% of the variation in 
disease onset [57].  For example, the average HD patient has 42 CAG repeats and an 
age onset of ~40 years old, but the youngest documented HD patient had 210-250 CAG 
repeats and an age onset of 18 months [58].  On the other hand, some repeat expansion 
diseases, such as the C9orf72 G4C2 repeat expansion, do not have clear length-
dependent toxicity.  For example, G4C2 repeat lengths do not consistently correlate with 
the age-of-onset of neurodegeneration or predict which regions of the brain will be 
affected [26, 29].  The lack of length-dependent toxicity from the G4C2 repeat expansion 
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is not due to the untranslated nature of the repeat, as length-dependent toxicity is 
observed in the 3’UTR localized CTG repeat expansion that causes DM1 [59].  While 
most repeat expansions have an inverse correlation between repeat length and age of 
disease onset, G4C2 diseases are unique in having an unclear interaction between repeat 
length and disease characteristics. 
1.2.3  Tissue Specificity of Repeat Expansion Diseases 
Disease-causing repeat expansions affect a subset of neurons, even though the 
mutation is normally present in every cell of the body.  The likely causes for this selective 
vulnerability vary based upon the disease and are still not clearly understood.  For 
example, in HD, the huntingtin protein (HTT) is expressed ubiquitously, yet γ-aminobutyric 
acid (GABA) producing medium spiny neurons in the striatum are the most severely 
affected cells [60].  This is not due to higher expression of HTT in the striatum, as HTT is 
expressed at higher levels in other brain regions [61].  Instead, the susceptibility of 
medium spiny GABAergic neurons may be due to an increased sensitivity to toxicity from 
overactivation of glutamate receptors (excitotoxic stress).  Consistent with this 
hypothesis, HD neurodegeneration can be mimicked in mice through neural injections of 
glutamate or glutamate analogs [62, 63].  Additional factors may enhance the vulnerability 
of these neuronal populations or be the main cause of vulnerability.   
In contrast to HD, the vulnerability of specific neurons in C9orf72-associated 
ALS/FTD patients does appear to be affected by expression patterns of the gene 
containing the repeat expansion.  The most sensitive neuronal population also has the 
highest expression of C9orf72 [64].  However, expression level alone does not explain 
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C9orf72-associated neurodegeneration, as different neuronal populations are susceptible 
in patients who display ALS, FTD, or ALS/FTD [65].  The C9orf72 repeat expansion may 
also cause neurodegeneration in other brain regions, as it has been linked with 
Alzheimer’s Disease [66] and Huntington-like diseases [67].  The additional 
environmental or genetic factors that determine the vulnerable neuronal populations are 
not known.   
In addition to gene expression and vulnerability to excitotoxic stress, there are 
several other factors that may impact the selective vulnerability of neurons.  In contrast 
to stress from overactivation of excitatory receptors, stress may also be caused by 
inhibitory receptors.  For instance, neuronal expression of inhibitory GABA receptors 
strongly correlates with neuronal susceptibility to degeneration in ALS patients [68].  
Another factor that may contribute to differential vulnerability is that neurons have different 
rates of misfolded protein clearance, which could affect the susceptibility of neurons.  For 
example, striatal neurons clear polyglutamine more slowly than cortical neurons [69]. This 
may be one explanation as to why HD and several other polyQ diseases cause striatal 
degeneration.  Differences in the ability of neuronal populations to neutralize oxidative 
stress are also likely to affect the susceptibility of neurons.  Increased oxidative stress is 
seen in many neurodegenerative diseases [70-72], and differences in susceptibility to 
oxidative stress are seen in neuronal tissues [73].  Overall, a single overarching cause of 
selective neuron vulnerability does not appear to exist.  Instead, multiple weaknesses 
likely synergize to sensitize specific neuronal populations to repeat expansion toxicity. 
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1.3 Repeat Expansions: Mechanisms of Toxicity 
Neurodegenerative repeat expansions cause a gain-of-function (GOF) toxicity, as 
both intronic and exonic repeat expansion mutations are toxic when present in only one 
allele of a gene.  Initially, the cause of gain-of-function toxicity was thought to differ based 
on the genetic context of the repeat expansions.  Untranslated repeats were thought to 
be primarily toxic through RNA-based GOF toxicity, while exonic repeats were thought to 
be primarily toxic through protein-based GOF toxicity.  RNA toxicity was due to the G/C-
rich nature of the RNA.  RNA toxicity was first described in DM1, where a CTG repeat 
expansion occurs in the 3’UTR of DM1 protein kinase (DMPK) [59].  The CTG repeat 
expansion was toxic independent of its genetic context, as the CTG repeat was toxic 
when cloned into the UTR of an unrelated gene [74].  The repetitive RNA also formed 
RNA foci in patient tissue and sequestered RNA splicing regulators [59].  RNA foci are a 
common feature of repeat expansions and are associated with RNA toxicity.   
While RNA foci also occur with exonic repeat expansions, the repetitive amino acid 
sequence produced from exonic repeat expansions are also innately toxic and were thus 
thought to be the driving cause of protein GOF toxicity.  A classic example of these protein 
GOF diseases is HD.  The expanded CAG repeat in the first exon of mHTT encodes a 
polyglutamine repeat that causes aggregation of the mutant huntingtin protein (mHTT).  
The aggregated mHTT sequesters chaperone resources, leading to a global disruption of 
protein folding [75-77].  The aggregation of mHTT depends on the age of the animals as 
well as the length of the CAG repeat, mimicking HD age-dependent toxicity and repeat 
length dependency [55, 75].  Exonic CAG repeat expansions in other diseases are also 
thought to be toxic due to the glutamine repeats produced from the repeat. 
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Until recently, these two modes of toxicity were accepted as the predominant 
drivers of repeat expansions toxicity.  However, in 2011, an unusual type of protein 
translation called RAN translation was discovered to occur in repetitive G/C-rich RNA [4]. 
RAN translation produces six peptides from six distinct sense and antisense reading 
frames and can occur in RNA from either exons or untranslated RNA, making it a unifying 
feature of repeat expansion diseases.  My studies focus on this recently discovered class 
of proteins produced through RAN translation, many of which are now known to be highly 
toxic.   
1.4 RAN Translation 
RAN translation does not require a start codon [4]. Therefore, RAN translation can 
occur in the 0, +1, and +2 reading frame leading to three potential protein products from 
one strand of RNA.  As mentioned above, repeat expansions are commonly transcribed 
in the antisense direction as well [5, 7, 78-80].  As the antisense RNA of a G/C-rich repeat 
is also G/C-rich and repetitive, it also undergoes RAN translation in all three reading 
frames.  Consequently, six genetically distinct protein products are produced from one 
nucleotide repeat expansion (Figure 1.1).  RAN translation has so far been detected in 
seven repeat expansion diseases: C9orf72-ALS/FTD [81, 82], DM1 [4], myotonic 
dystrophy type 2 (DM2) [83], fragile x-associated tremor/ataxia syndrome (FXTAS) [84] 
Fuchs Endothelial Corneal Dystrophy (FECD) [85], HD [12], and spinocerebellar ataxia 
type 8 (SCA8) [4]. 
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Figure 1.1 Example Diagram of RAN Translation Products 
The six possible RAN products of a CAG repeat expansion.  From the sense RNA strand, 
polyGlutamine is translated in the 0 reading frame, polySerine is translated in the +1 
reading frame, and polyAlanine is translated in the +2 reading frame.  From the antisense 
RNA strand, polyLeucine is translated in the 0 reading frame, polyCys is translated in the 
+1 reading frame, and polyAlanine is translated in the +2 reading frame. 
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 The molecular biological and biochemical requirements for RAN translation are 
beginning to be elucidated.  Cellular models of RAN translation suggest that RAN 
translation initiates from alternate start codons upstream of the repetitive sequence [86, 
87], and the initiating codon varies between reading frames [87].  As a result, the 
efficiency of RAN translation between reading frames is highly variable, resulting in 
dramatic differences in RAN peptide accumulation [86, 87].  The site of termination of 
RAN products is unknown, as translation could end due to either a stop codon or stalling 
of translation machinery because of tertiary structures formed by the repetitive RNA, such 
as G-quadruplexes [88].  In cellular models, RAN translation increases with activation of 
the integrated stress response system [86, 89, 90].  Therefore, the level of expression of 
RAN products is not static throughout the progression of a disease and likely increases 
as cells undergo escalating levels of stress. 
To better understand RAN translation, it has been studied in several cellular and 
animal models expressing repeat expansion sequences [12, 86, 87, 89, 91, 92].  While 
most of these models were generated after the discovery of RAN translation, some were 
generated prior to this discovery [12].  In these models, toxicity was previously only 
considered to be due to repeat bearing RNA or protein.  However, RAN translation has 
now been shown to occur in yeast [91], C. elegans [91], Drosophila [93], and mice [12].  
Therefore, earlier repeat models need to be reexamined in order to determine whether or 
not they produce RAN peptides from these repeat sequences.  For example, a recent 
reexamination of a CAG repeat mouse model (N171-82Q) revealed that the CAG repeat 
construct undergoes RAN translation and produced multiple RAN peptides beyond just 
polyGln, as was previously assumed [12].  Further studies are needed to determine if 
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other existing cell and animal models expressing repeat expansions are purely RNA 
toxicity models, purely protein toxicity models, or are RAN models as well.   
1.4.1  Modeling RAN Products 
To understand the specific toxic properties of RAN products, they need to be 
modeled independently of RNA toxicity.  Creating RAN-only models is challenging as 
RAN translation depends on the G/C-rich repetitive nature of the RNA [4], which also 
causes RNA toxicity.  Therefore, the RAN peptide amino acid sequence needs to be 
preserved, but the repetitive and G/C rich nature of the DNA and RNA needs to be 
eliminated.  To accomplish this, the degenerative nature of the genetic code is commonly 
utilized [12, 94-97], as up to 6 different codons can encode the same amino acid.  By 
varying the underlying genetic code while preserving the overlying encoded amino acid, 
RAN peptides can be individually expressed in the absence of any repetitive, G/C rich 
RNA repeats.  While powerful, this approach has several caveats.  First, codon-varied 
RAN products are usually overexpressed at non-physiological levels, which may drive 
aspects of toxicity that are not normally present in patients.  Second, RAN products are 
often, but not always, co-expressed in patient tissue [34].  Individual RAN peptide 
expression is not sufficient to mimic any possible functional interactions between the RAN 
peptides that might synergistically enhance or suppress toxicity in patients [96], so, 
studying each RAN product individually does not precisely model the condition in patients.  
Finally, most codon-varied RAN peptide models lack upstream and downstream genetic 
context, which is unique to each peptide.  Such sequences might dramatically alter the 
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toxicity of the peptide.  Despite these caveats, characterizing each RAN product 
individually is an important first step in understanding the toxicity of the RAN products. 
While methods of modeling individual RAN products have limitations, they are 
crucial tools for developing a general understanding of the toxicity of individual RAN 
products.  Findings from these simplistic models will aid in identifying the cellular 
pathways disrupted by RAN products in each disease.  The first question to address with 
RAN products is if and how they are toxic.  As our understanding of RAN translation and 
RAN products grows, genetic models used to study RAN products will need to be adjusted 
to better model disease relevant length, genetic context, and peptide-peptide interactions.  
To address these questions, several cellular or animal models expressing codon-varied 
RAN products from different repeats have been developed, including in yeast, worms, 
fruit flies, zebrafish, rodents and human-induced pluripotent stem cells (iPSCs) [10, 95, 
98-100].  
 In my research, I focus on RAN products from two different repeat expansions, 
the ALS-associated G4C2 repeat expansion and the HD-associated CAG repeat 
expansion.  There are twelve other CAG/CTG repeat expansions diseases (Appendix B-
Table 4.1), two of which are also confirmed to undergo RAN translation [4].  Multiple 
CAG/CTG diseases can phenocopy HD (e.g., Huntington disease-like 2 (HDL2), SCA17, 
DM1, and dentatorubral-pallidoluysian atrophy (DRPLA)), suggesting CAG/CTG 
diseases may have similar disease mechanisms independent of genetic context [101].  
One such common mechanism may be the production of RAN peptides.  Despite both 
CAG and G4C2 repeats undergoing repeat expansion and RAN translation, the respective 
NDDs, repeats, and RAN products are distinct.  To understand the cellular characteristics 
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of the RAN products from each of these diseases and to study their toxicity in a 
multicellular system, we modeled RAN products from each repeat expansion in C. 
elegans. 
1.5 Using C. elegans to Model NDDs 
C. elegans have been used to model a wide variety of NDDs, as they have unique 
features that make them advantageous for studying aging-associated diseases with 
neurodegeneration [102].  C. elegans are small (1 mm long), transparent nematodes that 
have been studied as a genetic model system for over 40 years [103].  Worms offer 
several advantages not present in other model systems for the study of RAN products 
and repeat-associated genetic disorders.  First, transgenic methods in C. elegans are 
highly efficient.  Following the creation of a suitable DNA expression construct, transgenic 
worms expressing a repeat sequence of interest are obtained in ∼1 week [104].  Second, 
C. elegans are optically transparent across their entire lifespan, facilitating observation of 
neuron and tissue morphology in living animals, as well as the subcellular localization of 
GFP fusion proteins.  Third, C. elegans have a highly conserved genome with humans, 
with 60–80% of the ∼20,000 worm genes having a human homologue [105].  Fourth, the 
function of these genes can be rapidly inhibited, either using chemically or CRISPR 
induced mutations or RNA interference (RNAi) [106, 107].  Finally, aging, which is a major 
risk factor for all repeat expansion diseases, has been extensively studied in C. elegans 
as worms have a short lifespan of ~3 weeks [108].   
 19 
In addition to their short lifespan, several signaling pathways are known to regulate 
the aging process in worms, as well in other species.  One of these pathways, the insulin 
pathway, was first discovered in nematodes [109, 110].  The insulin signaling pathway is 
now the most well-characterized pathway that regulates lifespan and youthfulness from 
worms to humans [111].  Mutations in this pathway are thought to extend lifespan by 
promoting a youthful cellular physiological state and can be used to separate 
chronological and physiological states of aging.  In C. elegans, the daf-2 gene encodes 
the homolog of the insulin/IGF receptor.  Loss of function mutations in daf-2 exert their 
effects via signaling-dependent activation of the FOXO transcription factor daf-16, as well 
as the heat shock transcription factor hsf-1 [112].  Mutations in daf-16 and hsf-1 suppress 
phenotypes associated with daf-2 mutations and accelerate the rate of aging [111].  Thus, 
the role of aging in a neurodegenerative pathway can be studied in C. elegans by using 
daf-2 mutants to delay cellular aging or daf-16 or hsf-1 to accelerate cellular aging.   
Despite these experimental advantages, worm models have several caveats for 
modeling NDDs.  C. elegans motor neurons lack astrocytes and glia, which play a 
significant functional role in several NDDs [113].  While worms possess a conserved 
primitive innate immune system [114], they lack adaptive immunity, which contributes to 
many pathological aspects of repeat expansion disorders [115].  Similar limitations impact 
other model systems that are used to investigate repeat-associated NDDs [91, 98, 99, 
116-118].  Despite these limitations, C. elegans is a uniquely valuable model system 
whose experimental advantages complement many of the limitations present in other 
systems for the study of repeat expansion disorders.   
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1.5.1  Previous Models of mHTT in C. elegans  
Several models of HD and other CAG repeat expansion disorders have been 
developed in C. elegans.  Most of the models have the CAG repeat within the surrounding 
HTT sequence, as genetic context can either enhance and suppress the toxicity of 
repeats [119].  In one model, 150 pure CAG repeats were set in the genetic context of 
the sequence encoding the first 171 amino acids of HTT [120].  The mHTT was expressed 
in amphid neurons with single ciliated endings (ASH neurons).  Cellular dysfunction could 
be detected by impaired dye filling of the ASH neurons.  This model facilitated both biased 
and unbiased genetic screens, as well as small molecule drug screens, for suppressors 
of CAG repeat expansion toxicity.  For example, Bates et al. discovered that histone 
deacetylases (HDACs) can modify mHTT toxicity [121].  HDACs are now known to play 
significant roles in the pathogenesis of polyQ toxicity across a wide range of cellular and 
animal model systems [122, 123].   
Another model for HD in C. elegans modeled ‘early-onset’ aspects of CAG/polyQ 
pathology.  128 pure CAG repeats were placed within the coding sequence of the first 57 
amino acids of HTT [124].  In contrast to the previous model expressed in ASH sensory 
neurons, this model was expressed in a different class of sensory neurons called touch 
neurons.  Inhibition of touch neuron function rendered animals unable to respond to light 
touch by altering their direction of movement [125].  Lejeune et al. utilized RNAi screening 
and sensitized genetic backgrounds in this system to identify suppressors and enhancers 
of expanded CAG toxicity [126].  Many of the 662 genes identified in this screen were 
previously known to be involved in HD or other NDDs, including 49 that are dysregulated 
in the striatum of HD mouse models [126].  This demonstrates that for CAG repeat 
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expansion toxicity, RNAi screens performed in C. elegans lead to the identification of 
conserved pathological mechanisms that play similar biological roles in higher organisms, 
including mammals.   
1.5.2  Modeling Repeat Expansions Independent of Genetic Context  
The models just described examined CAG repeats in the presence of the HTT 
sequence.  However, there are nine other age-dependent NDDs caused by CAG repeat 
expansions, suggesting the CAG repeat itself, in multiple genetic contexts, is sufficient to 
cause age-dependent toxicity.  To explore CAG toxicity independent from these different 
contexts, a pure C. elegans CAG model was generated [127].  In this model, CAG repeats 
are fused with YFP in the polyQ reading frame and expressed in muscle tissue [75].  
Although HD is thought of as a purely neurodegenerative disease, patients also have 
muscle wasting and cardiac defects, making muscle expression of CAG repeats relevant 
to patients [128, 129].  Expression of CAG in the muscle tissue of C. elegans also provides 
several experimental advantages (large cell size, sensitivity to feeding-based RNAi gene 
knockdown, sensitive age-dependent phenotypic outputs, etc.) that are not available 
when CAG is expressed in neurons.  The degeneration of muscle cells leads to easily 
observable movement disruptions and paralysis that can be monitored across the lifespan 
of the animals.  In this model, aggregation of polyQ is repeat-length dependent, with Q82 
causing complete polyQ aggregation in young animals, and Q33 being diffuse in young 
animals.  Q40 is initially localized in a diffuse manner in young animals, but the protein 
transitions from a soluble to an aggregated state as animals age [75].  PolyQ aggregate 
formation coincides with the onset of motility defects, suggesting a link between polyQ 
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aggregation and toxicity.  However, recent work implies that polyQ aggregation and 
toxicity are genetically separable events [130].  Therefore, mechanisms other than polyQ 
aggregation may contribute to toxicity in this model [131].  The toxicity and aggregation 
of these pure polyQ proteins are strongly influenced by the aging process, as mutants 
that modify aging (i.e., in insulin/IGF signaling pathway) also modify polyQ aggregation 
and CAG toxicity [112, 132-134].  More than any other repeat expansion model, the 
context-independent pure CAG repeat model has played a profound role in advancing 
our understanding of the roles of aging, protein aggregation, and repeat expansion 
associated toxicity.  For example, expression of expanded CAG repeats in neurons, the 
major cell type affected in HD and other CAG repeat expansion disorders, shows 
heterogeneous aggregation and toxicity depending on the neuron type [135].  While 
demonstrating that the behavior of CAG repeat expansion proteins depends on cellular 
context, these observations significantly complicate efforts to identify genes that might 
modify the aggregation and/or toxicity of polyQ proteins (or other CAG-derived translation 
products) in neurons. 
1.5.3  Screening Strategy 
Because of the heterogeneous toxicity of CAG in various neuronal subtypes, C. 
elegans muscle cells have provided a more amenable and homogenous cellular context 
for in vivo genetic screens that have ultimately informed our understanding of CAG toxicity 
in neurons.  For example, in one of the first examples of genome-wide RNAi screening in 
C. elegans, Nollen et al. screened ∼17,000 gene knockdowns for enhancers of muscle 
polyQ aggregation, identifying proteins whose normal function is to oppose polyQ 
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aggregation [136].  These findings revealed that the breadth of the machinery regulating 
protein misfolding extends far beyond chaperones and the protein degradation machinery 
and involves a wide variety of biological processes, including RNA synthesis and 
processing, protein biosynthesis, and protein trafficking [136] (Figure 1.2).  Subsequently, 
many of the proteins identified in this screen have been shown to play roles in mediating 
polyQ aggregation and/or toxicity in mammalian cells, thus validating that screens utilizing 
C. elegans muscle models of repeat expansion diseases have high translational 
relevance [136-138]. 
  
 24 
 
 
 
Figure 1.2 Possible Mechanisms of Toxicity of PolyQ and RAN HD PolyPeptides 
Defects in protein quality control, autophagy, and mitochondria dynamics have been 
observed in multiple HD models.  It is unclear if one pathway is the driving cause of 
neurodegeneration, or if their synergistic interactions are required for toxicity.  The HD 
RAN peptides may act through similar pathways as polyQ or through polyQ-independent 
pathways.  
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 Although the identification of genes that modify muscle-based phenotypes of toxic 
proteins is a powerful screening tool, it is also important to determine if the modifier is 
muscle specific or if it also modifies the toxic phenotype in neuronal cells.  The neuronal 
system of C. elegans is well defined, and there is a complete connectome map of all 302 
neurons in the adult hermaphrodite [139-141].  The position of neurons is conserved 
between different animals, thus making measurements of neurodegeneration possible at 
the single neuron level.  C. elegans neurons also utilize the same neurotransmitters used 
by human neurons; GABA, acetylcholine, 5-HT, glutamate, and catecholamines [142].  
This allows modeling of NDDs in disease-relevant neurons, such as modeling HD in 
GABAergic neurons or modeling ALS in motor neurons.   
C. elegans GABAergic neurons have been used to  model multiple types of NDDs 
as they exhibit robust cellular and phenotypic defects upon degeneration [143, 144].  
GABA is an inhibitory neurotransmitter in the human central nervous system [145].  In C. 
elegans, GABA is most often at neuromuscular junctions and can be used as either an 
inhibitory or an excitatory neurotransmitter [146].  At a C. elegans neuromuscular junction, 
GABA acts as an inhibitor of muscle contraction and counteracts acetylcholine, which 
causes muscle contractions [146].  Therefore, degeneration of GABAergic neurons has 
a strong observable phenotype due to disruption in the balance of excitatory acetylcholine 
and inhibitory GABA signaling at the neuromuscular junction [147].  Defects in GABA 
signaling lead to overactive acetylcholine signaling and muscle hypercontraction, causing 
worms to paralyze and appear shrunken from excessive contraction [147].  Loss of 
GABAergic motor neurons most severely affects directional reversal, since the 
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coordination between dorsal and ventral muscle activity required for directional changes 
is lost [148].  Neurodegeneration is easily detectable at the cellular level as well.  Motor 
neurons run along the ventral nerve cord (VNC), a longitudinal nerve tract that extends 
along the ventral side from the pharynx to the tail of the C. elegans.  However, the motor 
neurons need to synapse onto the muscle cells, which are on both the dorsal and ventral 
sides of the worm.  Consequently, motor neurons extend single axons, known as 
commissures, which synapse onto the muscle cells on the dorsal side of the C. elegans 
(Figure 1.3).  These axons are easily observed in live animals by expressing GABAergic-
neuron specific GFP reporters and imaging optically transparent animals under 
fluorescence microscopy [146].  There are 16 discrete GABAergic commissures along 
the length of a worm that can be observed for neurodegenerative phenotypes such as 
blebbing or breakage at the level of single axons [146].  Thus, degeneration of GABAergic 
neurons is easily observable at both the phenotypic and cellular level, making these cells 
good models for NDDs that affect GABAergic neurons, such as HD, or motor neurons, 
such as ALS. 
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Figure 1.3 Fluorescent Commissure Within a Whole, Living C. elegans 
Fluorescent image of C. elegans with motor neurons in green (unc-47p::GFP) and muscle 
in red (myo-3p::RFP).  Arrows mark commissures.  Asterisks mark cell soma.  Ventral 
nerve cord is along the lower edge of the worm.  Scale bar=10 μm. 
1.6  ALS/FTD 
ALS is an extremely rapidly progressing neurodegenerative disease, with 50% of 
patients succumbing to the disease within three years of diagnosis [149].  Roughly 95% 
of ALS cases are sporadic with no family history of ALS [150].  The largest risk factor for 
ALS is aging [151], with ALS symptoms commonly appearing between ages 40 to 70 
[152].  In familial ALS cases, single gene genetic mutations are known for almost 50% of 
the cases [153].  Depending on the population studied, 40-60% of familial ALS cases are 
caused by the C9orf72 G4C2 repeat expansion, making it the most common inherited 
cause of ALS/FTD [8, 9].  The environmental causes of sporadic ALS are poorly 
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understood.  Cigarette smoking is a confirmed environmental risk factor for ALS [154], 
while lead exposure [155] and pesticide exposure [156] are possible environmental risk 
factors.  In addition, there are recent data linking traumatic brain injury and ALS pathology 
[157].  Because ALS environmental factors exhibit highly variable penetrance, genetic 
models of ALS have been predominantly used to study this disease.   
1.6.1  ALS Physiology 
The first symptom of ALS is typically weakness in a limb or the jaw and rapidly 
progresses to paralysis and complete loss of voluntary motor control [158].  The paralysis 
is caused by the degeneration of the upper and lower motor neurons typical of ALS.  The 
upper motor neurons are located in the motor region of the cerebral cortex and innervate 
the lower motor neurons in the ventral horns of the spinal cord and within brainstem motor 
nuclei.  The upper motor neurons modulate the response of the lower motor neurons, and 
ALS patients who predominantly have degeneration of the upper motor neurons exhibit 
muscle stiffness as the muscles are overactivated [159].  The lower motor neurons 
innervate the muscles, and degradation of lower motor neurons causes loss of reflexes 
and muscle tone, eventually leading to muscle atrophy.   
While ALS is thought of as a pure motility disease, 15% of ALS patients also 
develop FTD [160].  FTD is a common type of early-onset dementia where the frontal and 
temporal lobes of the cerebral cortex undergo degeneration.  Patients display social 
dysfunction, such as loss of empathy and decreased social interaction, and they also 
often have repetitive behaviors and a lack of inhibition [161].  Ten to fifteen percent of 
FTD patients have a family history of FTD or ALS [160].  In both ALS and FTD, TDP-43 
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aggregates occur in degenerating neurons, suggesting a shared disease pathway [162].  
In addition, some mutations can cause either ALS or FTD, suggesting ALS and FTD are 
represent phenotypic bookends of a disease spectrum.  The most prominent shared 
mutation, the C9orf72 repeat expansion, is the most common genetic cause of each 
disease, and 80% of ALS/FTD patients carry the C9orf72 repeat expansion [162].   
1.6.2  The C9orf72 G4C2 Repeat Expansion 
The G4C2 repeat expansion in C9orf72 was associated with ALS in 2011 [8, 9], five 
years after the linkage of chromosome 9p21 was first identified in a Dutch ALS and FTD 
kindred [163].  The G4C2 repeat expansion is in the first intron of C9orf72 and is 10–20 
repeats in unaffected individuals, but expands to 30-1000s of repeats in ALS patients [8, 
9].  The C9orf72 repeat expansion causes up to 45% of all inherited cases of ALS and 
25% of FTD cases [9, 164].  The C9orf72 repeat expansion is also found in ~6% of 
sporadic ALS cases [164].  The high frequency of C9orf72 repeat expansions in ALS/FTD, 
as well as its association with several other less common neurodegenerative conditions 
[165], makes the C9orf72 repeat expansion one of the most common known NDD 
mutations. 
One proposed mechanism for C9orf72-G4C2 repeat expansion toxicity was loss of 
function.  The G4C2 repeat expansion causes a decrease in C9orf72 RNA expression [8] 
and C9ORF72 protein levels [166] in patients.  C9ORF72 appears to be involved in 
autophagy initiation [167-170].  However, loss-of-function of C9ORF72 does not appear 
to be the driving cause of ALS/FTD as C9orf72-null murine models develop autoimmune 
defects, but not ALS/FTD-like symptoms [171-173].  In addition, a patient homozygous 
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for the C9orf72-G4C2 repeat expansion did not have a severe form of ALS/FTD [174], as 
would be expected if the repeat expansion was toxic due to inhibiting C9orf72 expression.  
More importantly, loss-of-function point mutations have not been identified in any 
ALS/FTD patients.  Therefore, the C9orf72-G4C2 repeat expansion is likely toxic through 
gain-of-function mechanisms. 
Indeed, the clinical presentation of C9orf72 repeat expansion carriers is consistent 
with an autosomal dominant genetic pattern that could manifest pathologically through at 
least two nonexclusive molecular mechanisms [162].  First, given that the repeat 
expansion is within an intron, one hypothesis is that toxicity is mediated through a repeat-
containing RNA.  In patients, pathologically expanded RNAs form nuclear foci, while non-
expanded RNAs do not form nuclear foci [6, 175].  Although the significance of these RNA 
foci remains unknown, G4C2 RNA binds several RNA-binding proteins, including some 
that regulate the nuclear import/export cycle and nuclear pore complex function [6, 175].  
G4C2 RNA induced disruption of neuronal nuclear transport may play a pathological role 
in disease onset and/or severity.  A second potential mechanism involves RAN translation 
in all three reading frames of both the sense and antisense transcript [6], leading to six 
distinct dipeptide repeat proteins (DPRs) [176].  RAN DPRs appear to be translated from 
the spliced out G4C2-containing intron [89, 177].  However, factors that promote the 
cytoplasmic localization of the repeat-bearing RNA appear to facilitate RAN translation.  
Therefore, the observed nuclear RNA foci may serve a protective role and the RAN 
translation products are toxic [177, 178].  Taken together, significant evidence suggests 
that specific C9orf72-derived RAN DPRs are toxic and may play a pathological role in the 
development of ALS/FTD. 
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While RAN DPRs are thought to play a significant role in the toxicity of the C9orf72 
repeat expansion, there is evidence against DPRs having a causal role in disease.  For 
example, in postmortem brain samples from C9orf72 patients, anti-DPR antibody staining 
patterns are not well correlated with tissue neurodegeneration [179-181].  One possible 
explanation for this discrepancy is that cells exhibiting robust RAN translation undergo 
cell death throughout the progression of ALS, which results in low levels of observable 
DPRs in postmortem tissue.  Supporting this, a murine model has detectable DPRs in 
brain regions that will degenerate early in the disease course, but the DPRs cannot be 
detected in those same brain regions late in the disease [10].  A G4C2 Drosophila model 
of RNA only toxicity versus RNA+DPR found that RNA alone caused no toxicity, while 
RNA+DPRs caused strong toxicity [93].  Every model system tested has found the same 
two DPRs, proline-arginine (PR) and glycine-arginine (GR), to be toxic [10, 95, 98, 182, 
183].   
1.6.3  C9orf72 RAN Dipeptide Repeats 
Unlike the other DPRs, both sense-derived GR and antisense-derived PR can 
phase separate, as they are charged due to the arginine amino acids [184].  The 
separation of oil and water when mixed is a simple type of phase separation.  Protein 
phase separation is more complex as ionic strength, protein concentration, temperature, 
and post-translational modifications all regulate the phase separation of proteins [185, 
186].  There are two types of proteins that phase separate.  One type of phase-separating 
proteins is multi-domain proteins that undergo regulated phase separation depending on 
the number of bound ligands.  The second type is intrinsically disordered proteins with a 
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low sequence complexity that phase separates independently of ligands [186].  The 
biological role of phase separation is to concentrate proteins performing a specific task, 
such as splicing factors in nuclear speckles [187], while still allowing rapid interchange 
between the structure and the surrounding environment.  Other phase-separating cellular 
structures are stress granules, nuclear pores, and the nucleolus [188-190].  Disrupted 
phase separation can cause cellular dysfunction.  This occurs in multiple NDD models 
where phase-separated structures lose their fluid characteristics and shift to having a 
hydrogel nature and eventually form aggregates, trapping the bound proteins [191-194].  
Interestingly, C9orf72-associated arginine-rich dipeptides localize to multiple phase-
separated structures, including the nucleolus, stress granules, and the nuclear pore [195].  
PR/GR disrupts the function of these structures [195].  Consistent with these interactions, 
disruption of nucleocytoplasmic transport genes have been identified in PR/GR 
suppressor screens performed in both yeast and Drosophila [98, 118].  PR/GR also 
disrupt nucleolar function and prevent stress granule disassembly [195, 196].  It is 
unknown whether PR/GR interactions with phase-separated domains in general cause 
neurodegeneration or if PR/GR interactions with a specific phase-separated domain is 
the main cause.  Further screens will help identify the sequence of events that leads to 
neurotoxicity.  C. elegans models have previously helped to identify disease pathways 
and could serve the same role here. 
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1.7 HD 
I also created a C. elegans model for CAG RAN products, as CAG/CTG repeat 
expansions in different genes cause 13 repeat expansion diseases: FECD, HD, HDL2, 
DM1, SBMA, and SCA Types 1, 2, 3, 6, 7, 8, 12, and 17 [11].  RAN translation has thus 
far been confirmed in four of these diseases: FECD, HD, DM1, and SCA8 [4, 12, 85].  The 
CAG repeats encode polyglutamine, which facilitates protein-protein interactions [197].  
Polyglutamine is ‘sticky’ and interacts with other polyglutamine repeats, stabilizing protein 
binding [197].  However, in repeat expansion diseases the CAG repeat is expanded to 
≥40 repeats depending on the disease, and the ‘sticky’ nature of the polyglutamine 
becomes toxic, as it forms oligomers (low molecular weight homopolymers) and 
aggregates [198, 199].  It is currently thought that polyglutamine is the driving cause of 
toxicity in these diseases [200, 201], even though neurodegeneration is not always linked 
to polyglutamine aggregation [12].  In HD, degenerating brain regions that lack 
polyglutamine have significant expression of other CAG/CTG-derived RAN products, 
strongly suggesting that the RAN products could be contributing to the disease [12].  Most 
of the CAG/CTG diseases lack treatments, making it imperative to understand the 
molecular pathways required for CAG RAN toxicity in these diseases. 
HD is a monogenic disease caused by a CAG repeat expansion in the first exon 
of the HTT gene [202]. HD is a progressive and incurable neurodegenerative condition 
that typically occurs in middle to late age [203].  However, up to 10% of patients develop 
a more aggressive form of the disease called Juvenile Huntington’s disease (JHD) [204].  
Unaffected individuals have 10-25 CAG repeats in HTT, while people with 35-39 CAG 
repeats in HTT are at risk of developing HD in adulthood [205, 206].  Patients with ≥40 
 34 
repeats will develop HD and typically exhibit symptoms between 30-50 years of age, 
depending on repeat length and other factors [55].  JHD patients usually have >60 repeats 
and develop symptoms before the age of 20.  In all cases, the disease follows an 
autosomal dominant inheritance pattern, suggesting that a gain-of-function mechanism 
underlies both HD and JHD.   
1.7.1  HD Physiology 
HD causes a wide range of symptoms, including cognitive and motility defects, 
which vary based on the type of HD.  Adult HD patients are diagnosed with HD once they 
develop motility defects, such as chorea.  The motility impairments change to immobility 
by the end of the disease [202].  HD patients also develop personality changes and 
undergo cognitive declines up to ten years before they are officially diagnosed with HD 
[207, 208].  In adult HD, neurodegeneration begins in the striatum and spreads in a 
predictable pattern to other regions in the basal ganglia, and distally to brain regions such 
as the frontal cortex [209-211].  The neurodegeneration ultimately leads to death ~20 
years after the appearance of motor symptoms [203].  JHD patients have a shorter 
disease duration of ~15 years after diagnosis [212].  This decrease may be due to delayed 
diagnosis of JHD, as it is extremely rare [212].  Interestingly, JHD patients do not exhibit 
chorea or have a spreading pattern of degeneration.  Instead of developing chorea, JHD 
patients present with rigidity, seizures, and severe psychiatric defects [212].  Patients with 
JHD also have smaller brain sizes with relatively enlarged cerebellum [213] and have 
degeneration in both the striatum and the cerebellum [214].  The reason for the 
differences in symptoms and degeneration patterns between HD and JHD is unknown.  
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Taken together, the clinical data suggest that the increased number of CAG repeats drive 
a distinct spectrum of symptoms in JHD even though both HD and JHD are caused by 
similar CAG repeat expansion mutations in the HTT gene.  
1.7.2  HTT 
The HTT gene encodes a large, 348 kilodalton protein that is conserved in 
metazoans [215].  However, the disease-causing polyQ stretch in the first exon of HTT 
does not appear in all HTT orthologs [216].  The polyQ repeats are predominantly found 
in mammals, and the length of the repeat increases with higher species [217].  This may 
be due to the role of HTT in neurodevelopment, as HTT appears to have key roles in 
neurodevelopment and heterozygous HTT null mice have neuronal defects [218, 219].  
Homozygous HTT null mice are embryonic lethal, which may be due to other roles of the 
ubiquitously expressed HTT [219].  In addition to the polyQ domain, HTT has multiple 
HEAT repeats that act as flexible scaffolding allowing HTT to interact with over 200 
proteins [220, 221].  Through these interactions, HTT traffics vesicles and organelles 
along axons [222].  The polyQ repeat expansion can cause defects in many of HTTs 
normal roles and interactions [223, 224], which may contribute to HD even if it is not the 
driving mechanism. 
1.7.3  PolyQ 
Oligomerizing/aggregating polyQ proteins cause toxicity through many pathways.  
PolyQ models exhibit disruption of protein folding and degradation [225, 226], inhibition 
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of autophagy [227], and abnormal mitochondrial dynamics and quality control [228].  
PolyQ proteins are thought to be toxic due to low molecular weight homopolymers of 
polyQ, known as oligomers, while large aggregates exhibit less toxicity and possibly have 
a protective role [229-231].   
The expanded polyQ protein is the focus of most HD research.  This is primarily 
because it exhibits length-dependent toxicity and aggregation that closely matches the 
course of the disease in HD patients [232].  However, in JHD, the cerebellum and frontal 
cortex lack detectable polyQ, but still undergo significant neurodegeneration [233].  Some 
affected brain regions in adult HD, such as the white matter regions of the caudate and 
putamen of the striatum, also express little to no polyQ protein [233-237].  This suggests 
that mechanisms other than polyQ toxicity drive toxicity in JHD and contribute to toxicity 
in adult HD.   
1.7.4  CAG RAN Peptides 
Recently, Bañez-Coronel and colleagues discovered that expanded CAG repeats 
in the mHTT mRNA, as well as the antisense CUG repetitive mRNA, can undergo RAN 
translation [233].  RAN translation of the sense CAG repeats, as well as the antisense 
CUG repeats, produces five polypeptides: polyGlutamine, polyAlanine, polySerine, 
polyLeucine, and polyCysteine (Figure 1.1).  Analysis of postmortem tissue samples 
shows that RAN polypeptides are abundantly expressed throughout the striatum, frontal 
cortex, and cerebellum and are qualitatively present at elevated levels in JHD patients 
(age range 8-23) [12].  RAN polypeptides were also present in similar tissues in adult HD 
patients, although their levels were lower, and their occurrence was less common 
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compared to JHD patients [12].  RAN polypeptides were not detected in control patients 
[233].  Since polyQ levels and aggregation are not major features of JHD, these 
observations suggest that CAG-derived RAN polypeptides could play a significant but 
previously unappreciated role in JHD and may be a contributing feature to adult HD.  
Although RAN polypeptides exhibit a striking correlation with neurotoxicity in JHD and 
HD, it was not known if these polypeptides confer toxicity in an in vivo setting. 
1.8 Conclusions 
The exact mechanism of toxicity of repeat expansion NDDs is unknown.  Initial 
studies focused on testing mechanisms related to protein gain-of-function toxicity or RNA 
gain-of-function toxicity.  Recently, the discovery of RAN translation has offered another 
potential cause of toxicity.  Determining if and how RAN products cause toxicity in their 
respective NDD is important to find treatments for these currently untreatable diseases.  
To aid in determining how the RAN products are toxic, we created RAN models for two 
different types of repeat expansions, the ALS-associated C9orf72 G4C2 repeat expansion, 
and the widespread CAG repeat expansion, seen in HD and 12 other CAG/CTG repeat 
expansion diseases.  In both cases, we studied the toxicities of the different RAN products 
and proceeded to perform a suppressor screen to identify proteins required for the toxicity 
of the RAN product.  Using this approach, we discovered both unique and common 
cellular pathways that contribute to RAN peptide toxicity.   
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2.0 Arginine-Rich ALS RAN Dipeptides Exhibit Age-Dependent Toxicity 
2.1  Introduction 
Amyotrophic lateral sclerosis (ALS) is a rapid, devastating neurodegenerative 
disease that lacks effective treatments.  Within three years of presenting with a slight 
weakness in a limb, patients typically develop complete loss of voluntary motor control 
and succumb to this disease [149].  The pathogenic mechanisms that drive ALS 
progression are unknown.  However, cellular dysfunction associated with ALS is 
commonly studied through investigations of genetic mutations that cause ALS.  Most 
recently, these studies are focused on the most common genetic cause of ALS, a G4C2 
repeat expansion in the C9orf72 gene [8, 9].  The C9orf72 G4C2 repeat expansion occurs 
in the first intron of the C9orf72 gene.  Affected patients carry one normal allele with less 
than 30 G4C2 repeats and one expanded allele with 30-1000s of repeats [8, 9].  The 
precise number of repeats required to cause disease is difficult to determine due to 
somatic and germline mosaicism of the repeat.  However, repeat lengths of up to 27 do 
not appear to show somatic instability [238, 239].  These data have led the field to 
conclude that at least 30 G4C2 repeats are required to cause ALS. 
The mechanism(s) by which 30 G4C2 repeats cause disease is not well understood.  
One emerging mechanism is the unusual translation of the intronic repeat expansion by 
a novel type of translation called Repeat-Associated non-AUG (RAN) translation [81, 82].  
RAN translation occurs in long, G/C-rich repeats and does not require a start codon [4].  
Due to the lack of a start codon, the reading frame of RAN translation is not defined, and 
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translation can be initiated in any of the three reading frames.  Initiation most likely occurs 
within or very close to the 5’ end of the repeat [86], although the precise site of initiation 
has not been defined in patients.  Therefore, RAN translation of the single G4C2 RNA 
repeat gives rise to three distinct dipeptide repeat proteins (DPRs): glycine-arginine (GR), 
glycine-proline (GP) and glycine-alanine (GA) [81, 82].  The expanded G4C2 repeat is also 
transcribed in the antisense direction [34].  The corresponding antisense RNA is a G2C4 
repeat and is thus also G/C-rich.  Therefore, the antisense RNA also undergoes RAN 
translation, creating three more DPRs: proline-arginine (PR), proline-alanine (PA) and 
glycine-proline (GP) [82] (Figure 2.1 A).  All six RAN DPRs contain distinct protein 
sequences downstream of the repeat since they are each in a different reading frame.  
The most common genetic cause of ALS, a single repeat expansion, thus gives rise to six 
potentially pathogenic DPRs. 
The arginine-rich DPRs, PR and GR, have been identified as the most toxic 
C9orf72 DPRs through work in yeast, zebrafish, Drosophila, and cells [94, 98, 182, 184, 
240].  Because these DPRs are toxic at 50 repeats in a wide range of organisms [94, 98, 
195], the DPRs are typically modeled at 50 repeats.  The arginine-rich DPRs exhibit 
several properties that may explain their toxicity.  For example, PR/GR can phase 
separate [195, 241], similar to other neurodegenerative proteins such as TDP-43, FUS, 
and tau [184, 191].  GR/PR localize to phase-separated structures such as the nucleolus 
[184], the nuclear pore [242], and stress granules [195].  PR/GR localization disrupts the 
function of each of these phase-separated structures [98-100, 195, 243].  It is currently 
unclear if DPR-induced defects in one or more of these structures are the driving cause 
of the pathogenesis of the arginine-rich dipeptides. 
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An unbiased genetic screen performed in a multicellular organism could provide 
unique insights into the primary causes of toxicity due to the arginine-rich DPRs.  A screen 
could determine if specific cellular structures or structural components are required for 
PR/GR toxicity or if a previously unidentified pathway(s) is more integral to PR/GR 
toxicity.  To date, unbiased screens of PR toxicity have only been performed in single-cell 
systems, such as yeast [98] and mammalian cells [100].  To determine the genetic 
requirements for arginine-rich DPRs in a multicellular organism, we created C. elegans 
models of each RAN DPR and characterized the cellular requirements for toxicity.  In 
addition, we studied whether PR/GR toxicity is impacted by aging since the strongest risk 
factor for ALS is aging, and the role of aging and aging pathways in DPR toxicity was not 
known.  After establishing the cellular requirements for arginine-rich DPR toxicity, we 
performed a whole-genome RNAi screen to identify the genetic requirements for arginine-
rich DPR toxicity.  Our screen identified highly conserved genes required for PR toxicity, 
including known DPR modifiers, such as nuclear transport and RNA binding proteins, and 
novel genetic pathways, including a nuclear ubiquitination pathway. 
2.2  Results 
To understand the cellular, temporal, and genetic requirements for toxicity of the 
arginine-rich dipeptides, we created a C. elegans model expressing individual RAN 
translation products in the absence of repeat-containing RNA [95].  In this model, the 
nucleotide repeat was eliminated, but the amino acid repeat was maintained by varying 
the codon usage for the amino acids.  The disruption of the G4C2 sequence removes 
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potential RNA secondary structures and possible RNA-based toxicity.  The reading frame 
was defined using a canonical start codon and Kozak sequence.  Four C9orf72-derived 
dipeptide sequences (GA, GR, PA, PR; all 50 repeats and lacking additional C9orf72 
context) were tagged with GFP at the C-terminus and FLAG at the N-terminus and 
expressed individually either in muscle cells or in motor neurons (Figure 2.1 A).  We 
generated transgenic animals expressing each individual DPR. 
2.2.1   Toxicity of C9orf72 Dipeptides in Motor Neurons 
Consistent with previous studies [94, 98, 182, 184], we found that expression of 
the arginine-rich DPRs in motor neurons under the unc-47 promoter was highly toxic in 
C. elegans.  Animals expressing arginine-rich DPRs in the motor neurons were viable, 
consistent with previous studies showing that unc-47 motor neurons are not required for 
viability in C. elegans [244].  However, motor neuron expression of either (PR)50 or (GR)50 
led to significant reductions in motility, which was measured in thrashing assays (Figure 
2.1 B).  Motor neurons expressing (PR)50 and (GR)50 exhibited morphological signs of 
degeneration commonly observed in other C. elegans models of neurodegenerative 
diseases [245-247], including commissure degeneration and membrane blebbing that 
were not observed in control animals or in animals expressing either (PA)50 or (GA)50 
(Figure 2.1 C, D).  These data show that arginine-rich DPRs cause motility defects and 
neurodegenerative morphological changes when expressed in C. elegans motor neurons.  
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Figure 2.1 Arginine-Containing DPRs Are Toxic in Motor Neurons 
(A) Molecular strategy for expression of codon-varied DPRs in C. elegans.  (B) Liquid 
thrashing quantification of transgenic animals expressing the indicated DPR under the 
motor neuron-specific unc-47 promoter.  N=20 animals per genotype.  Each symbol 
represents quantification for one animal; the horizontal line indicates the population 
median.  ***P<0.001 versus GFP control (one-way non-parametric ANOVA with Dunn’s 
post hoc test).  (C) Representative images of unc-47+ motor neurons in animals 
expressing the indicated DPR and unc-47p::GFP to mark the commissures.  Arrow points 
to an example of membrane blebbing.  Arrowhead points to examples of commissure 
breaks.  Scale bar=10 μm.  (D) Quantification of commissure breaks and (E) membrane 
blebbing in each of the indicated strains.  For each animal, we counted the total number 
of commissures with blebbing or breaks and divided by the total number of detectable 
commissures.  Unc-47p::GFP was used to mark the commissures.  N=20 animals per 
genotype.  Each symbol represents quantification for one animal expressed as a 
percentage.  The horizontal line indicates the population median with the interquartile 
range.  ****P<0.0001 versus GFP control (one-way non-parametric ANOVA with a post 
hoc Dunn’s multiple comparison test).  N=20 animals per genotype.  
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2.2.2   Toxicity of C9orf72 Dipeptides in Muscle Cells 
C. elegans motor neurons are extremely small (2–3 μm in diameter), making cell 
biological analysis of DPR localization in these cells difficult.  Additionally, C. elegans 
neurons are highly resistant to RNA-interference-mediated gene knockdown, which is 
commonly used to explore mechanisms of protein toxicity in C. elegans disease models 
[136, 248].  To overcome these limitations, we expressed the DPRs in the larger muscle 
cells under the myo-3 promoter.  Muscle cells regulate motility and are a common site of 
expression for other C. elegans disease models [127, 249, 250].  As we observed in motor 
neurons, muscle expression of arginine-rich DPRs was highly toxic.  Expression of either 
(PR)50 or (GR)50 in muscle led to completely penetrant embryonic and larval lethality that 
could be suppressed by feeding animals gfp(RNAi)-expressing bacteria (Figure 2.2 A).  
gfp(RNAi)-sensitive embryonic or larval lethality was not observed in animals expressing 
either (PA)50 or (GA)50.  (PR)50 or (GR)50 animals that were removed from gfp(RNAi) after 
embryonic development survived and went on to develop into adults. 
However, these DPR-expressing adults exhibited age-dependent paralysis (Figure 
2.2 B).  (PR)50 animals also showed a significantly reduced lifespan that was not observed 
in (GR)50 expressing animals (Figure 2.2 C).  The enhanced paralysis observed in (PR)50 
and (GR)50 animals was not due to higher protein levels since in vivo imaging and flow 
cytometry quantification showed that (PR)50-GFP and (GR)50-GFP fluorescence levels 
were significantly below those of all other DPRs (Figure 2.3 A, B).  It was also not due to 
higher mRNA expression, since qPCR showed that all DPRs were expressed at similar 
levels (Figure 2.3 C).  The toxicity phenotype required protein production and was not 
due to any potential RNA effects, since (PR)50 transgenic animals lacking a start ATG 
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exhibited no detectable toxicity (Figure 2.3 D).  (PR)50 toxicity was dependent on the 
number of repeats, as animals expressing 5, 15 or 25 repeats did not exhibit embryonic 
lethality [number of viable transgenic progeny (>L4)/total transgenic progeny after 72h—
(PR)5-GFP—139/145; (PR)15-GFP—68/75; (PR)25-GFP—114/117; P>0.1, Fisher’s exact 
test].  Adults expressing (PR)5-GFP exhibited robust expression that appeared 
concentrated within almost all nuclei (Figure 2.4 A).  Adults expressing both (PR)15-GFP 
and (PR)25-GFP expressed much lower levels of GFP when compared with (PR)5-GFP, 
although the protein that was present also appeared to be concentrated within the nucleus 
and nucleolus (Figure 2.4 A, B).  Adults expressing (PR)25 and (PR)50, but not those 
expressing (PR)5 or (PR)15, exhibited accelerated age-dependent paralysis (Figure 2.4 
C), even though (PR)25 was present at dramatically lower levels than (PR)5 (Figure 2.4 
B).  Together, these studies show that arginine-containing dipeptides exhibit 
developmental and post-developmental age-dependent toxicity in C. elegans, and in the 
case of the PR dipeptide, this toxicity is repeat-length-dependent.  
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Figure 2.2 Muscle-Expressed Arginine-Rich Dipeptides Are Toxic in C. elegans 
(A) Brood size for worms expressing each integrated dipeptide protein in the absence or 
presence of gfp(RNAi) at 25°C.  Data for each strain are normalized to the mean brood 
size of animals grown on gfp(RNAi).  ***P<0.001 (one-way ANOVA with post hoc Tukey’s 
test).  (B) Paralysis assay for adult animals raised in the absence of gfp(RNAi).  N=43–
49 animals per genotype.  ***P<0.001 (Log-rank test with Bonferroni adjusted P-value).  
(C) Lifespan for worms expressing each integrated dipeptide protein in the absence of 
gfp(RNAi) at 25°C, N=50 animals per genotype.  ***P<0.001 (Log Rank Test with -
Bonferroni adjusted P-value) 
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Figure 2.3 Toxicity of PR Was Not Due to Increased Levels of PR or RNA Toxicity 
(A) Expression-matched representative images of transgenic animals expressing each 
dipeptide under the myo-3 promoter.  (B) Average fluorescence of GFP in a worm, as 
measured by the COPAS Biosorter through measuring the total fluorescence of the worm 
and dividing it by the time of flight of the worm.  (C) Relative mRNA expression of the 
different dipeptides divided by the control, myo-3p::GFP.  Actin was used as a control.  
(D) Paralysis assay for adult animals raised in the absence of gfp(RNAi).  
(N=50/genotype) ***P<0.001 (Log-rank test with Bonferroni adjusted P-value).  
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Figure 2.4 The Toxicity of PR is Length Dependent 
(A) Fluorescent microscopy of Day 1 adult hermaphrodites expressing (PR)5-GFP, (PR)15-
GFP, (PR)25-GFP or (PR)50-GFP (green) in the muscle.  Muscle DNA (marked by a myo-
3p::his-58-mCherry reporter) is in red.  Arrows point to sites of nuclear GFP puncta.  Scale 
bar=10 μm.  All images were acquired using identical exposure settings.  The row labeled 
‘myo-3p::(PR)50 (enhanced)’ was adjusted for brightness and contrast in the GFP channel 
differently from the other images so that the (PR)50-GFP signal is observable.  (B) 
Quantification of the GFP levels from the indicated PR repeat animals.  Each point shows 
the measured value for a single nucleus; the horizontal line indicates the population 
median with the interquartile range.  **P<0.01, ****P<0.0001 versus GFP control (one-
way non-parametric ANOVA with a post hoc Dunn’s multiple comparison test).  (C) 
Paralysis assay of animals expressing the indicated number of (PR) repeats under the 
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control of the myo-3 promoter.  ‘Day 0’ animals were isolated as L4 stage animals.  N=48–
50 animals per genotype.  ***P<0.001 versus GFP control (Log-rank test with Bonferroni 
adjusted P-value). 
 
2.2.3   Toxic PR and GR Are Enriched in the Nucleolus 
To gain insight into the cell biological properties of (PR)50 and (GR)50 proteins, we 
examined their subcellular localization patterns in live animals expressing each DPR in 
the muscle.  Animals expressing both GFP and non-toxic (PA)50-GFP exhibited diffuse 
nuclear and non-nuclear GFP expression that was always excluded from the histone-free 
nucleolar region (Figure 2.5 A, B).  Muscle expressed (GA)50-GFP formed intense non-
nuclear puncta.  In some cases, we noted (GA)50-GFP signal in the nucleus, but this 
nuclear localization was always diffuse and never in puncta (Figure 2.5 A, B).  Muscle 
expressed (GR)50-GFP and (PR)50-GFP both exhibited substantially lower GFP levels 
than either of the other DPRs, despite their similar mRNA expression levels (Figure 2.3 
C), and appeared to be predominantly localized to the histone-free nucleolar region of the 
nucleus (Figure 2.5 A, B).  Non-nuclear localization was always observed in (GR)50 
animals but was never observed in (PR)50 animals (Figure 2.5 A, B). 
The motility of the DPRs that form puncta (GA50, PR50, and GR50) was unclear.  
Immobile puncta (aggregates) are a common feature of neurodegenerative diseases [46, 
199, 251].  To determine whether C9orf72 DPRs also form protein aggregates, we 
performed fluorescence recovery after photobleaching (FRAP) to assay their respective 
motility.  Non-nuclear (GA)50-GFP exhibited little recovery after FRAP (Figure 2.6 A, B), 
 50 
suggesting these puncta are highly immobile protein aggregates.  In contrast, the 
nucleolar accumulations of (GR)50 and (PR)50 exhibited substantial fluorescence recovery 
(Figure 2.6), which is inconsistent with the known biophysical properties of bona fide 
aggregates [252].  Since both (PR)50 and (GR)50 appeared to be localized to the 
nucleolus, we compared their FRAP dynamics with those of FIB-1, which is homologous 
to the mammalian nucleolar protein fibrillarin [253].  FIB-1 exhibited recovery kinetics 
similar to those of (GR)50 and (PR)50, suggesting that the dynamics of these two DPRs 
behave similarly to a bona fide nucleolar protein (Figure 2.6 C).  
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Figure 2.5 (PR)50/(GR)50 Are Localized to the Nucleolus in C. elegans Muscle Cells 
(A) Imaging of live, anesthetized Day 1 adult C. elegans hermaphrodites expressing the 
indicated dipeptide.  Green shows dipeptide-GFP localization expressed in muscle, red 
shows histone-tagRFP within the muscle nucleus.  Arrowhead points to the histone-free 
nucleolar region.  Scale bar=10 μm.  (B) Quantification of DPR–GFP signal that is 
observed in the nucleoplasm, nucleolus, and non-nuclear cellular compartments.  N=55–
78 nuclei from five to six animals.  Data shown are means ± S.D. 
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Figure 2.6 Arginine-Rich DPRs Are Not Aggregates 
(A) Representative images from FRAP analysis of subcellular localized DPR proteins 
expressed in muscle.  The dashed outline indicates the site of photobleaching and post-
bleaching quantification.  Recovery images are 150 seconds post-bleach.  Scale bar=2 
μm.  (B) Quantification of FRAP imaging.  Data shown are mean ± S.E.M.  from 9 to 10 
datasets per genotype.  (C) Average equilibrium fluorescence recovery after 60 seconds.  
Data shown are mean ± S.D.  from 9 to 10 datasets per genotype.  ‘n.s.’ - versus FIB-1-
GFP (one-way ANOVA with a post hoc Dunn’s multiple comparison test).  
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2.2.4   Nuclear Localization is Required for PR and GR Toxicity 
Given that the toxic dipeptides, (PR)50 and (GR)50, were primarily localized to the 
nucleus in muscle, we asked if nuclear localization was necessary for their toxicity.  To 
test this, we tethered each of the arginine-rich DPRs to a signal sequence-
transmembrane domain (SS-TM) tag that restricts the DPR to cellular membranes with 
the DPR oriented on the cytosolic side of the membrane.  In this context, the membrane-
localized (PR)50 and (GR)50 were excluded from the nucleus (Figure 2.7 A).  In contrast 
to soluble (PR)50 and (GR)50, membrane-localized (PR)50 and (GR)50 were viable in the 
absence of gfp(RNAi) and showed no age-dependent paralysis (Figure 2.7 B).  We further 
tested whether nuclear localization was sufficient for toxicity by fusing the (PR)50 DPR to 
the coding sequence for the his-58 gene, which encodes a DNA-binding histone only 
found in the nucleus.  GFP-HIS-58 expressing animals were viable and motile and 
exhibited strong nuclear GFP expression (Figure 2.7 C, D).  However, GFP-HIS-58-(PR)50 
expressing animals were not viable unless they were cultured under gfp(RNAi) conditions 
[number of viable transgenic progeny (>L4)/total progeny in the absence of GFP after 
72h—GFP-HIS-58–348/406; GFP-HIS-58-(PR)50–9/56; P<0.0001, Fisher’s exact test].  
Upon removal from gfp(RNAi), HIS-58-(PR)50 animals exhibited age-dependent paralysis 
(Figure 2.7 D), and this paralysis occurred with more rapid onset than in (PR)50 animals 
(Figure 2.7 E).  Thus, nuclear localization further enhances (PR)50 toxicity.  GFP 
fluorescence levels of HIS-58-(PR)50 were not higher than GFP fluorescence levels of  
(PR)50 (Figure 2.7 F).  Thus, the enhanced HIS-58-(PR)50 toxicity was not due to higher 
expression levels of the transgene.  Overall, these data show that nuclear localization is 
necessary and sufficient for (PR)50 toxicity in C. elegans.  
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Figure 2.7 Nuclear Localization of PR/GR is Necessary and Sufficent for Toxicity 
(A) Representative images of the indicated soluble or membrane-anchored DPR (green), 
the HIS-58-mCherry nuclear marker (red), and a merged image.  Arrows point to nuclear 
regions defined by the HIS-58 mCherry signal.  Coincident green and red signals in the 
TM-(PR)50 image is intestinal autofluorescence.  Scale bar=10 μm.  (B) Paralysis assay 
comparing animals expressing soluble or transmembrane localized (GR)50 (top) or (PR)50 
(bottom).  N=48–50 animals per genotype, ***P<0.001, **P<0.01, *P<0.05 (Log-rank test 
with Bonferroni adjusted P-value).  (C) Representative images of HIS-58 anchored (PR)50 
(green; top) or unanchored (PR)50 (green; bottom), HIS-58-mCherry nuclear marker (red) 
and a merged image.  Scale bar=5 μm.  (D) Paralysis assay comparing animals 
expressing nuclear-localized GFP or (PR)50.  N=30 animals per genotype, **P<0.01 (Log-
rank test with Bonferroni adjusted P-value).  (E) Paralysis assay comparing soluble (PR)50 
with HIS-58-(PR)50.  N=50 animals [(PR)50] or 80 animals [HIS-58-(PR)50], ***P<0.001 
(Log-rank test with Bonferroni adjusted P-value).  (F) Quantification of the GFP levels 
from the indicated genotype animals.  Each point shows the measured value for a single 
nucleus, horizontal line indicates population median with interquartile range.  
****P<0.0001 versus (PR)50-GFP (student’s t-test with non-parametric Mann-Whitney U 
test). 
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2.2.5   Age-Associated Toxicity of PR and GR Are Due to Different Mechanisms 
The toxicity of (PR)50 in an aged cellular environment could be due to the stochastic 
accumulation of toxic protein levels or toxic protein conformations over long periods of 
time.  Alternatively, the physiological process of aging could lead to a decline in cellular 
processes that oppose (PR)50 toxicity.  To differentiate between these two hypotheses, 
we tested the role of the aging process in the toxicity of (PR)50.  If (PR)50 toxicity is due to 
the accumulation of toxic protein levels/conformation over time, lifespan-extending 
conditions should have no effect on the rate of toxicity.  However, if the aging process 
actively regulates (PR)50 toxicity, alterations in the rate of aging should enhance (if 
lifespan shortening) or delay (if lifespan extending) the toxicity of (PR)50.  The insulin 
signaling pathway is the most well-characterized pathway that regulates lifespan and 
youthfulness from worms to humans [111].  Mutations in this pathway are thought to 
extend lifespan by promoting a youthful cellular physiological state.  Therefore, mutations 
in the insulin signaling pathway can be used to separate chronological and physiological 
states of aging.  In C. elegans, the daf-2 gene encodes the homolog of the insulin/IGF 
receptor.  Loss-of-function mutations in daf-2 exert their effects via signaling-dependent 
activation of the FOXO transcription factor DAF-16, as well as the heat shock transcription 
factor HSF-1 [112].  Mutations in daf-16 and hsf-1 suppress phenotypes associated with 
daf-2 mutations and accelerate the rate of aging [111]. 
To determine whether the toxicity of (PR)50 is dependent on the chronological age 
of the cell or the physiological age of the cell, we crossed the (PR)50 transgene into the 
daf-2(e1370); daf-16(mu86) double mutant and segregated all possible (PR)50 genotypes.  
If (PR)50 toxicity is due to the stochastic accumulation of toxic (PR)50 molecules or 
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conformations over time, then reduced insulin signaling should not alter the age-related 
phenotypes.  However, if (PR)50 toxicity is due to aging-induced changes in cellular 
physiology, then alterations in the rate of aging should slow the initiation and progression 
of toxicity.  We found that in the daf-2 mutant background, age-dependent declines in 
(PR)50 motility were significantly reduced (Figure 2.8 A).  These daf-2-dependent 
phenotypes were suppressed in a daf-2; daf-16 double mutant and were accelerated in 
the daf-16 mutant (Figure 2.8 B).  Likewise, a mutation in the heat shock transcription 
factor hsf-1, which accelerates the rate of aging [254], enhanced the toxicity of (PR)50 
(Figure 2.8 C).  Interestingly, the protective effects of the daf-2 mutant were not observed 
in (GR)50 expressing animals (Figure 2.8 A).  The protective effects of insulin signaling 
appear to act downstream from DPR accumulation and nuclear localization, as DPR 
abundance and subcellular distribution did not appear to be altered in any of these genetic 
backgrounds (Figure 2.8 D-F).  We also found that in motor neurons expressing (PR)50, 
daf-2 reduced the levels of neurodegeneration-associated membrane blebbing (Figure 
2.8 G).  These data demonstrate that alterations in the rate of aging impact (PR)50 toxicity 
in both C. elegans muscle cells and motor neurons.  It also suggests that (PR)50 toxicity 
is dependent on the cellular aging process and is not due to the buildup of toxic protein 
levels/conformations over time.  Additionally, these data imply that (PR)50 and (GR)50 are 
toxic through partially distinct mechanisms as enhanced DAF-16/FOXO activation 
protects (PR)50 animals but has no protective effects on (GR)50 animals.  
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Figure 2.8 Altering the Biological Rate of Aging Affects (PR)50 Toxicity 
(A) Paralysis assay of animals expressing GFP, (GR)50 or (PR)50 under the control of the 
myo-3 promoter in the wild-type or daf-2(e1370) background.  ‘Day 0’ animals were 
isolated as L4 stage animals.  N=48–50 animals per genotype.  n.s., ‘not significant’; 
**P<0.01 versus GFP control (Log-rank test with Bonferroni adjusted P-value).  (B) 
Paralysis assay of animals expressing (PR)50 under the control of the myo-3 promoter in 
the wild-type, daf-16(mu86), or daf-2(e1370); daf-16(mu86) background.  N=48–50 
animals per genotype.  n.s., ‘not significant’; ***P<0.001 versus (PR)50 (Log-rank test with 
Bonferroni adjusted P-value).  (C) Paralysis assay of animals expressing (PR)50 under 
the control of the myo-3 promoter in the wild-type or hsf-1(sy441) mutant background.  
N=48–50 animals per genotype.  ***P<0.001 versus wild-type (Log-rank test with 
Bonferroni adjusted P-value).  (D) Fluorescent microscopy images of day 1 adult worms 
expressing either (GR)50 or (PR)50 (green) and soluble muscle mCherry (red) in the wild-
type or daf-2(e1370) mutant background.  Arrow points to sites of nuclear DPR 
accumulation.  Scale bar=10 μm.  (E) Fluorescent microscopy images of Day 1 adult 
worms expressing (PR)50 (green) and soluble muscle mCherry (red) in the daf-16(mu86) 
or daf-2(e1370); daf-16(mu86) mutant background.  Arrow points to sites of nuclear DPR 
accumulation.  Scale bar=10 μm.  (F) Fluorescent microscopy images of day 1 adult 
worms expressing (PR)50 (green) and soluble muscle mCherry (red) in the wild-type or 
hsf-1(sy441) mutant background.  Arrow points to sites of nuclear DPR accumulation.  
Scale bar=10 μm.  (G) Quantification of membrane blebbing in each of the indicated 
strains.  For each animal, we counted the total number of commissures with blebbing and 
divided by the total number of detectable commissures.  N=20 animals per genotype.  
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Each symbol represents quantification for one animal expressed as a percentage.  The 
horizontal line indicates population median with interquartile range.  **P<0.01; 
****P<0.0001 versus GFP control (one-way non-parametric ANOVA with a post hoc 
Dunn’s multiple comparison test).  N=20 animals per genotype. 
2.2.6   Conserved Genes Suppress (PR)50 Toxicity  
To identify genes required for (PR)50 toxicity, we performed two unbiased screens 
using muscle-expressed PR.  In both screens, we initially selected animals that exhibited 
enhanced growth, since muscle expression of (PR)50 causes larval arrest (Figure 2.9 A).  
In the first screen, we used an unbiased chemical mutagenesis approach to identify gene 
mutations that allowed (PR)50 growth over a two-week period.  While this approach may 
identify mutations that subtly enhance growth, one major caveat is that we are unable to 
recover mutations in essential genes that may be required for wild-type growth or 
reproduction.  To address this limitation, we also performed an unbiased whole-genome 
RNAi screen for suppressors of (PR)50 growth arrest over a shorter one-week period.  
RNAi screens have several advantages over chemical mutagenesis screens.  First, the 
RNAi approach knocks down mRNA levels, versus complete knockout or gain-of-function 
alleles that can be produced by ENU mutagenesis.  Second, RNAi knockdown can be 
initiated post-developmentally, while gene knockout from an ENU-induced mutation 
causes alterations in gene function throughout the entirety of life.  Finally, the gene 
knockdown effect from RNAi is enhanced over time, in contrast to animals carrying ENU 
induced mutations that exhibit the same alterations of gene function between animals.  
This variable knockdown effect from RNAi is particularly useful when screening 
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populations of animals since it leads to the generation of animals expressing a range of 
loss-of-function phenotypes (from partial loss-of-function to complete null).  Because of 
these differences, RNAi screens allow for the identification of genes whose null 
phenotypes may be lethal or sterile.  
 The forward mutagenesis screen was performed by treating young animals with 
N-ethyl-N-nitrosourea (ENU), a DNA mutagen that primarily introduces point mutations 
[255].  Animals were allowed to self-fertilize for three generations on gfp(RNAi) bacteria 
and were then moved onto E. coli OP50 bacteria, a common food source for lab-grown 
C. elegans, which does not repress expression of (PR)50.  Animals that grew while 
expressing (PR)50 were identified as suppressors.  Fifteen suppressors were individually 
isolated in this manner.  However, all fifteen suppressors exhibited strongly reduced 
transgene expression, based on the expression a myo-3::RFP reporter located on the 
same transgene as the myo-3p::(PR)50-GFP reporter.  Transgene suppression is a 
commonly observed phenotype in C. elegans [256].  To ensure that these mutants caused 
transgene suppression, we measured the RFP signal using a COPAS BIOSORT, as well 
as the (PR)50-GFP mRNA levels using qPCR.  The suppressors had a five-fold reduction 
in RFP fluorescent signal (Figure 2.9 B).  The level of (PR)50 mRNA was further reduced, 
with five of the six tested suppressors having no detectable (PR)50 mRNA and one 
suppressor having a five-fold reduction in levels of (PR)50 mRNA (Figure 2.9 C).  These 
data show that all the suppressors identified in our ENU mutagenesis screen were likely 
transgene suppressors.  Therefore, the mechanism of suppression of ENU-isolated 
suppressors is indirect and not likely to inform us as to specific and conserved 
mechanisms of toxicity of (PR)50. 
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As an alternative to the ENU suppressor screen, we also performed a genome-
wide RNAi screen to identify suppressors of muscle expressed (PR)50 toxicity.  We 
employed a commercially available RNAi library to screen 15,865 genes.  Eggs were 
placed on plates seeded with bacteria expressing double-stranded RNA (dsRNA) against 
the gene of interest.  After one week of growth, RNAi suppressors were identified by 
whether their respective plates contained mobile animals in multiple stages of 
development.  While this screen did identify some transgene suppressors, it also 
identified several suppressors that did not appear to affect transgene expression levels.  
We identified 391 initial ‘hits’ that allowed some growth of (PR)50 expressing animals.  
After six independent rescreens, we identified 12 genes that caused suppression of 
(PR)50 toxicity in at least 4/6 rescreens but did not have strong effects on transgene 
expression levels (Table 2.1).  Seven of the twelve (PR)50 suppressors have been 
previously reported to have loss-of-function phenotypes of ‘lethal’ or ‘sterile’, suggesting 
they would not be isolated in a chemical mutagenesis screen.  Remarkably, all of the PR 
suppressors have strong sequence homology to human genes, and four of the twelve 
genes were previously identified in PR or GR modifier screens performed in yeast, 
Drosophila, or mammalian cells [98-100], suggesting that mechanisms of (PR)50 are 
evolutionarily conserved.  Based on sequence homology, our PR suppressors fell into 
three distinct functional categories: nuclear transport/RNA binding, ubiquitin-mediated 
protein degradation, and chromatin regulation.  While the lab has pursued these genes 
further, including demonstrating that the human homologs of these genes also protect 
against PR toxicity in mammalian cells, I have not been involved in that phase of the 
project and will not discuss it further.  However, this screen illustrates the power of C. 
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elegans genetic approaches for the discovery of new and conserved mechanisms of RAN 
protein toxicity. 
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Figure 2.9 Transgene Suppressors Identified in Forward Mutagenesis Screen 
(A) Example images of myo-3p::(PR)50-GFP being expressed and on GFP RNAi to mimic 
suppression of PR toxicity.  (B) Average fluorescence of RFP and (C) GFP in a worm, as 
measured by the COPAS Biosorter through measuring the total fluorescence of the worm 
and dividing it by the time of flight of the worm.  N=500 animals. 
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Table 2.1 RNAi Gene Knockdowns that Suppress myo-3p::(PR)50-GFP Toxicity  
 
 
NLS=Nuclear Localization Signal 
1 – Interacts with both PR and GR in human cells; [195] 
2 – Enhanced the toxicity of GR50 in Drosophila model; [195] 
3 – Enhanced the toxicity of PR25 in Drosophila model; [99] 
4 – Suppresses the toxicity of PR50 when overexpressed in yeast; [98] 
2.3  Discussion 
The study of RAN peptides is still in its infancy, with the discovery of RAN 
translation less than a decade old [4].  Intensive study of the C9orf72 dipeptides has 
established that the arginine-rich dipeptides, GR and PR, are consistently toxic in a 
Table 1.1.  RNAi gene knockdowns that suppress myo-3p::(PR)50-GFP toxicity 
C. elegans Yeast Fly Human Description Predicted NLS 
Nuclear transport / RNA binding 
Rsp-6/C33H5.12 MRD1 X162 SRSF31 RNA binding protein; nuclear localized; homologous to yeast NSR1 No 
Ztf-4/T10B11.3 NGR1 CG424582 NCOA5/hnRNPC1 contains RRM domain Yes 
C18H9.3 SYH1 Gigyf GIGYF1 yeast homolog SYH1 binds proline-rich sequences and influences nuclear pore distribution Yes 
ima-3/F32E10.4 KAP1224 Kap-α32,3 KPNA31 1 of 3 nuclear importin alpha subunits No 
Ergo-1 None AGO1T1 AGO3 Production of endo-siRNAs Yes 
Ubiquitin-mediated protein degradation 
Bath-43/T16H12.5 None roadkill SPOP Speckle-type POZ protein; may interact with histones Yes 
Ufd-2/T05H10.5 Ufd2 UBE4B/ CG9934 UBE4a E3 and/or E4 ubiquitin ligase  No 
Rpn-12/ZK20.5 RPN12 RPN12 PSMD8 nonATPase regulatory subunit of the 26S proteasome No 
Rpn-9/T06D8.8 RPN9 RPN9 PSMD13 nonATPase regulatory subunit of the 26S proteasome No 
Chromatin regulation 
Met-2 /R05D3.11 MET2 eggless SETDB1 Histone methyltransferase Yes 
Utx-1/D2021.1 CYC8 Utx UTX/UTY Histone demethylase Yes 
Pis-1/T13F2.3 None PTIP PAXIP1 Pax transcription factor interacting protein Yes 
1 – Interacts with both PR and GR in human cells; Lee et al 2016 
2 – Enhanced the toxicity of GR50 in Drosophila model in Lee et al 2016 
3 – Enhanced the toxicity of PR25 in Drosophila model in Boeynaems et al 2016 
4 – Suppresses the toxicity of PR50 when overexpressed in yeast in Jovicic et al 2015 
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variety of systems [98, 99, 183], a finding replicated in our C. elegans model.  Previously 
studied systems lack the genetic tools available in C. elegans to separate chronological 
aging from biological aging.  We discovered modifying rates of aging had differential 
effects on (PR)50 compared to (GR)50.  Unbiased screens for genetic suppressors of PR 
toxicity have been performed in yeast [98] and mammalian cells [100], but these unbiased 
screens lacked the context of a multicellular organism and may have missed relevant 
pathways essential for cellular viability or growth.  Using our new C. elegans model, we 
bypassed this requirement using a post-developmental RNAi-based approach to screen 
for suppressors of (PR)50 toxicity in a multicellular organism and identified several 
essential genes involved in previously identified PR toxicity pathways, as well as a novel 
nuclear ubiquitination pathway that regulates PR toxicity [98-100].  
2.3.1   Cellular Localization of Dipeptides Is Linked with Toxicity 
The C9orf72 DPRs exhibit similar toxic and cellular characteristics in C. elegans 
to those observed in other models [98, 195].  In C. elegans, (PR)50 and (GR)50 are toxic 
in multiple tissues, while (PA)50 and (GA)50 are not toxic in any tissues.  Both PA and GA 
localize in the cytoplasm, while PR and GR localize in the nucleus.  PA is diffuse while 
GA forms aggregates.  Neurodegenerative proteins typically aggregate [251, 257, 258].  
Therefore, it was surprising that GA formed aggregates but did not cause toxicity.  In other 
systems, GA dipeptides exhibit mild toxicity at repeat lengths ≥100 [96, 182, 183], and 
exhibit length-dependent toxicity in human cells [183]. Because we only examined GA at 
50 repeats, our studies do not preclude the possibility that GA may also be toxic in C. 
elegans at higher repeat lengths.   
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We observed that both PR and GR are toxic in multiple tissues and localize to the 
nucleolus.  Nuclear localization appears to be necessary and sufficient for toxicity.  PR 
and GR are not toxic when sequestered from the nucleus and driving PR localization to 
the nucleus significantly increases PR toxicity.  We were unable to generate nuclear 
enriched GR expressing animals, possible because animals are unable to grow under 
such toxic conditions.  Arginine-rich DPRs are known to localize to the nucleolus [94, 184, 
195, 196] and cause nucleolar stress [195, 196].  However, we are the first to establish 
that PR toxicity requires its localization to the nucleus.  The arginine repeats seen in PR 
and GR mimic the serine-arginine (SR) repeats present in the SR domains of many RNA 
binding proteins involved in pre-mRNA splicing.  One common property of these RNA 
binding proteins is that the SR domain is highly disordered and promotes de-mixing from 
the surrounding solution.  This process is called phase separation and is a biophysical 
property of many membraneless organelles, such as the nuclear pore, nucleolus, and 
nuclear speckles.  One of the first discovered characteristics of PR/GR was their ability 
to phase separate with RNA regulatory proteins in the nucleus [175].  While our studies 
suggest that such nuclear interactions are critical for PR toxicity, a caveat of these studies 
is the membrane anchors used to restrain DPRs from the nucleus could disrupt other 
important properties of PR and GR, such as phase separation or other ordered 
interactions that require a 3-dimensional space.  Previous research found that the toxicity 
of the arginine-rich dipeptides is correlated with their ability to phase separate [184].  
Therefore, in restricting PR and GR to a 2-D membrane, we may have also inhibited the 
ability of PR and GR to phase separate.  To complement this membrane anchoring 
approach, we attempted to sequester PR and GR away from the nucleus using an nuclear 
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export signal (NES).  However, PR-NES and GR-NES still localized to the nucleus (data 
not shown).   
In mammalian cells, PR and GR also localize to other phase-separated 
compartments such as nuclear pores, spliceosomes, and stress granules [195, 242].  We 
did not observe PR and GR localization to any other phase-separated component besides 
the nucleolus.  This could be due to signal intensity, as the GFP signal of (PR)50 and 
(GR)50 in worms is extremely low.  Another possibility is that high expression of PR and 
GR in other systems may drive DPR localization to additional phase-separated 
compartments.  However, the extremely low levels of (PR)50 and (GR)50 expression in our 
C. elegans model may not be sufficient to drive DPR localization to these other 
membraneless compartments.  Localization to phase-separated compartments, such as 
the nuclear pore, are sometimes inferred from a DPR-induced impairment in 
nucleocytoplasmic transport or stress granule formation/disaggregation [195, 196].  We 
did not directly test either of these cellular processes.  However, multiple genes involved 
in nucleocytoplasmic transport are suppressors of PR toxicity in our C. elegans model.  
Therefore, it is likely that PR disrupts nuclear pore function in our model as has been 
observed in other systems.   
Toxic GR and PR DPRs are unique among proteins associated with ALS and other 
neurodegenerative diseases in that GR/PR do not primarily form protein aggregates.  
However, they do concentrate within phase separated cellular compartments.  Other 
aggregating mutant proteins associated with different neurodegenerative diseases also 
impair phase separation, such as tau in Alzheimer’s [193], mHTT in HD [194], and FUS 
[192] and TDP-43 [259] in ALS and FTD.  These proteins were initially thought to be toxic 
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due to the pathological aggregates they formed in their respective neurodegenerative 
disease.  However, aggregation of misfolded proteins can be separated from toxicity of 
the proteins, suggesting protein aggregates may not be the main cause of toxicity [131].  
Instead, low molecular weight homopolymers, known as oligomers [231], are now thought 
to be a driving cause of toxicity [260].  One way oligomers may be toxic is by disrupting 
normal phase separation properties [188, 259].  Such a mechanism could link C9orf72-
associated ALS/FTD to other neurodegenerative conditions typically categorized as 
protein aggregation diseases. 
2.3.2   Repeat-Associated Toxicity of PR 
 Repeat length is strongly correlated with toxicity in several repeat expansion 
diseases, such as the polyQ diseases [11].  There have been conflicting reports as to 
whether the length of the G4C2 repeat in C9orf72 affects the age of onset of the disease 
[26, 29, 261, 262].  Patients with a family history of ALS or FTD have been identified with 
a C9orf72 repeat expansion of only 30 G4C2 repeats [9].  However, the diseases may not 
be solely caused by the C9orf72 repeat expansion.  Other ALS-associated mutations 
sometimes occur with shorter repeat lengths of G4C2 and may act synergistically with the 
G4C2 repeats to enhance their toxicity, thus, masking decreases in toxicity due to a lower 
repeat length [28].  Another confounding variable is that blood samples are used to 
determine the number of G4C2 repeats in patients.  However, the number of G4C2 repeats 
in a blood sample may not match the number of G4C2 repeats in the neurons of patients.  
This is because the repeats can undergo dramatic somatic expansion in the brain [30].  
However, some studies suggest this not likely to be common [263].  Somatic expansions 
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of repeats are common in other diseases [30].  However, the frequency and extent of both 
somatic and germline expansions appears to be more drastic and variable in C9orf72 
[264, 265].   
As our C. elegans models contain the dipeptide repeat but not the nucleotide 
repeat, we solely studied toxicity of repeat length due to the dipeptides.  In patients, the 
length of dipeptides may not be reflective of the length of the G4C2 repeat expansion.  
Since RAN translation does not use a canonical start codon, it is unclear where RAN 
translation initiates in patient neurons.  It is also unknown where RAN translation 
terminates, as repetitive RNA can cause stalling of translation machinery [266].  
Therefore, the entire G4C2 repeat may not be translated.  Understanding whether 
dipeptides cause length-dependent toxicity aids in interpreting various disease models as 
well as determining the pathogenic mechanisms of the dipeptides.  The arginine-rich 
dipeptides exhibit increased toxicity with increased repeat length [94, 183].  A minimum 
repeat length for GR has been observed in multiple systems [94, 183, 240], but a repeat 
length where PR is nontoxic had not been identified before our work.   
We found that PR is toxic at 25 repeats and 50 repeats, but PR was not toxic at 5 
repeats and 15 repeats.  At all repeat lengths, the PR protein localized to the nucleolus.  
The decrease in toxicity was not due to an increase in the amount of PR dipeptide, as the 
GFP signal was significantly brighter in animals with PR5 than animals with PR50, 
suggesting more PR5-GFP dipeptides were present in the nucleus.  While there are more 
dipeptides, it would take five times more PR5 dipeptides to have the same molar amount 
of PR repeats in the nucleus as PR25, so the total molar concentration of PR repeats in 
the nucleus could determine toxicity.  In addition to concentration, the repeat length may 
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also directly contribute to toxicity.  For example, a minimum length of PR repeats might 
be required for PR to bind to a protein and disrupt its function.  Determining if there are 
structural or organizational differences between nucleoli with PR5 and nucleoli with PR50 
could give clues as to how PR50 is causing cellular toxicity.  In other systems, PR impairs 
nucleolar structure and overall translation [195, 196, 267].  It would be informative to 
determine if the minimum PR repeat length required for nucleolar structural impairment 
and translational inhibition is similar to the minimum PR repeat length required for toxicity.   
2.3.3  Age-Associated Toxicity of PR and GR 
 Another common theme in neurodegenerative diseases is age-associated toxicity.  
Disease-associated repeat expansions are present from birth; but patients do not develop 
neurodegeneration until middle to late age.  This delay could be due to pathogenesis 
associated with biological aging.  For example, the repeat-derived DPRs may only be 
toxic when cells are senescent and protein homeostasis pathways are functioning at 
reduced levels.  Another possibility is that the age-dependent toxicity is due to 
chronological aging, and repeat products slowly accumulate over time until they reach a 
toxic threshold.  Yet another possibility is that RAN translation and subsequent DPR 
production does not occur until late age.  RAN translation is increased by activation of the 
integrated stress response [86, 89, 90], which is upregulated with age [268].  However, 
the age requirements for RAN translation have not been studied and will require the 
production of new tools and reagents that are beyond the scope of my research.  
Therefore, I focused on determining if DPR toxicity was due to biological or chronological 
aging.   
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C. elegans are uniquely situated for studying age-dependent DPR toxicity, as 
aging has been extensively studied in C. elegans.  Mutations in the C. elegans daf-
2/insulin pathway double the lifespan and extend the healthspan of the worms [110, 112].  
One of the major effects of activating the daf-2/insulin signaling pathway is to delay the 
proteotoxic consequences of aging, thus making mutants in the daf-2/insulin pathway 
ideal for separating physiological aging from chronological aging [112, 269].  The daf-
2/insulin pathway has been used to distinguish between toxicity due to chronological 
aging and toxicity due to biological aging in other worm models of genetic forms of ALS, 
such as those associated with mutant forms of proteins such as SOD1 [130, 245, 257, 
270-272], TDP-43 [143, 273], and FUS [143].  In each of these cases, the worm models 
express a mutant protein that forms protein aggregates.  The toxicity associated with the 
SOD1 and TDP-43 models is suppressed by delaying biological aging through activation 
of the daf-2/insulin signaling pathway [273, 274].  One way the daf-2/insulin signaling 
pathway is thought to oppose the toxicity of these disease models is via the upregulation 
of genes that maintain protein folding (i.e. chaperones) or enhance the clearance of 
misfolded/aggregated proteins (i.e. proteases) [248].   
Like SOD1 and TDP-43, we found that (PR)50 toxicity can also be suppressed by 
activating insulin signaling.  However, unlike SOD1 and TDP-43, (PR)50 did not form 
detectable protein aggregates.  Given that mutations in genes comprising the daf-2/insulin 
signaling pathway can modify all three disease models, this suggests that (PR)50 may 
share common toxic mechanisms with SOD1 and TDP-43, for example, via disruptions in 
protein homeostasis.  Interestingly, insulin signaling did not appear to alter PR abundance 
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or subcellular localization in our model, suggesting that this pathway may act downstream 
from PR nuclear functions to provide toxicity protection.   
In contrast to (PR)50, we found that activation of the daf-2/insulin signaling pathway 
did not delay the toxicity of (GR)50.  While GR and PR toxicity are usually thought to occur 
through the same mechanisms, our results are among the first to suggest that there may 
be some important differences.  Such differences could be due to daf-2 induced changes 
in DPR expression levels, such as a reduction in (PR)50 levels but not (GR)50 levels.  
However, in vivo imaging suggests that DPR levels were not significantly altered in the 
daf-2 background.  Therefore, the precise nature of such differences remains unknown.  
To date, with the exception of daf-2, all of the genes we have identified whose knockdown 
suppresses (PR)50 toxicity also suppress (GR)50 toxicity.  In the future, genetic screens 
utilizing animals expressing (GR)50 may allow us to identify GR suppressors and define 
DPR-specific toxicity mechanisms. 
2.3.4  Suppressors of PR Toxicity 
Through a genome-wide RNAi screen, we identified several pathways required for 
PR toxicity.  These pathways included nucleocytoplasmic transport, mRNA processing, 
chromatin regulation, and proteasomal protein degradation (Table 2.1).  Some of these 
pathways have been previously linked to PR and GR toxicity by screens in other systems 
[93, 98-100, 243].  Components of nucleocytoplasmic transport have been identified as 
modifiers of PR and GR toxicity in yeast, flies, human cells, and now C. elegans.  Notably, 
hnRNPC/ztf-4, mGIGYF2/C18H8.3, KPNA3/ima-3, and SRSF3/rsp-6 were identified as 
modifiers of PR toxicity in our screen as well as in other systems [98, 99, 195, 243].  The 
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fact that in our blinded genome-wide screen, we discovered modifiers of PR toxicity also 
identified in other screens reflects both the conserved nature of PR toxicity and the power 
of the C. elegans system to identify conserved modifiers.   
We identified the nucleocytoplasmic trafficking pathway as being important for PR 
toxicity.  GR and PR induced nucleocytoplasmic trafficking defects have been reported in 
multiple systems [99, 242].  Given that the phase-separation properties of nuclear pores 
allows them selective permeability [189], it is logical dipeptides that localize to phase-
separated structures may change the chemical properties of these structures and disrupt 
nuclear transport [195].  Defects in nucleocytoplasmic transport also occur in other 
neurodegenerative diseases caused by phase-separating proteins, such as Alzheimer’s 
Disease [275] and HD [214]. Therefore, disrupted nucleocytoplasmic transport could be 
a general trait of neurodegenerative diseases.  However, disrupted nucleocytoplasmic 
traffic is unlikely to be the only way that PR and GR cause toxicity, as proteins not involved 
in nucleocytoplasmic transport have also been identified as involved in PR and GR 
toxicity.   
Other cellular pathways required for PR toxicity in our screen and several other 
screens are chromatin regulation and mRNA processing [98-100, 195, 243].  mRNA 
processing has been previously implicated in ALS as mutations in the mRNA transport 
proteins TDP-43 and FUS can cause ALS [276-278].  Aggregates of TDP-43 and FUS 
are also prominent pathological features of ALS [162, 279].  In general, RNA binding 
proteins (RBPs) have a higher likelihood of containing disordered regions, which are 
required for phase separating into stress granules or nuclear speckles [280, 281].  It is 
currently unclear if either disruption of RBP phase separation or disruption of the role of 
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RBPs in mRNA processing is a stronger contributor to ALS [282].  Epigenetic 
modifications such as altered chromatin methylations also occurs in types of ALS not 
caused by the C9orf72 repeat expansion [283, 284].  Overall, the effect of chromatin 
regulation in ALS has received limited attention.  However, our identification of chromatin 
regulators as being critical components of PR toxicity suggests that future studies in this 
area are warranted. 
 The fourth pathway that suppressed PR toxicity in our screen was the proteasomal 
degradation pathway.  Accumulation of misfolded proteins is a common theme associated 
with several neurodegenerative diseases [46, 285].  Previous screens in yeast and human 
cells have also identified the proteasomal degradation pathway as a suppressor of PR 
toxicity [98, 100] .  Of note, genes that code for two regulatory non-ATPase subunits of 
the 26S proteasome [100]  were identified in our screen, PSMD8/rpn-12 and 
PSMD13/rpn-9.  While there are 11 additional proteasome regulatory genes and 14 
additional core proteasome catalytic subunit genes in C. elegans, our screen did not 
identify any others as being required for PR toxicity.  Deletion of PSMD8 also suppressed 
PR toxicity in an unbiased CRISPR screen performed in human cells [100].  PR can bind 
to the proteasome and inhibit proteasomal degradation [286].  Therefore, PR may interact 
with the proteasome via interaction with RPN9 and/or RPN12.  Loss of these proteins 
may eliminate the ability of PR to interact with the proteasome, likely in the nucleus.  Along 
these lines, we also identified a nuclear E3 ligase adaptor (SPOP/BATH-43), which had 
not been previously found in a suppressor screen of PR.  Interestingly, an interactor of 
SPOP, RBX1, is a modifier of PR toxicity [100].  SPOP is a substrate adaptor for the 
CUL3-RING ubiquitin ligase and undergoes phase separation when it interacts with its 
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substrates [287], which may facilitate SPOP and PR interactions.  The fourth gene we 
found that is involved in proteasomal degradation is ufd-2/UBE4B, an E3/E4 ubiquitin 
ligase [288].  ufd-2/UBE4B was one of the strongest suppressors identified in the screen 
and, like bath-43/SPOP, localizes to the nucleus, suggesting that the E3 ligase adaptor 
SPOP and the E3 ligase UBE4B may interact physically and/or functionally.  Interestingly, 
SPOP is a well-established genetic cause for many prostate, endometrial, and renal 
cancers [289-291].  Recently, a small molecule inhibitor of SPOP was reported that 
effectively blocks the growth of SPOP mutant renal cancer cells [292].  In the future, it 
may be interesting to determine if this drug can also be utilized to inhibit SPOP in a 
neuronal context and protect against PR toxicity. 
2.3.5   Study Limitations 
 Our model had three main limitations.  First, like most other DPR models, our C. 
elegans model utilizes ectopic expression of DPR at levels that are unlikely to mimic 
physiological DPR levels.  However, DPR expression levels in patients have only been 
determined in postmortem samples, where they are rarely observed in motor neurons and 
when they are observed, they are present at extremely low levels [179, 180].  However, 
the rare nature of PR/GR positive motor neurons in postmortem tissue could be due to 
the death of cells containing the arginine-rich dipeptides.  This theory was supported by 
a recent rodent model where a high concentration of cells contained PR at the onset of 
disease, but very few cells contained PR near the end of the disease progression and 
many of the cells in the previously PR-rich region had died [10].  Overcoming this limitation 
is challenging since low level PR expression does not produce detectable phenotypes in 
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C. elegans (data not shown).  Even in patients, physiological expression levels of DPRs 
take 30-40 years to cause toxicity.  Therefore, overexpression may be a necessary 
compromise in model systems, including mammalian cell lines, in order to facilitate 
phenotypes required for discovery of disease mechanisms. 
A second limitation of our model is that each dipeptide was expressed individually, 
whereas dipeptides can be co-expressed in patient cells [34].  A study that co-expressed 
different dipeptides with GA found that GR or PR could sequester GA into the nucleus 
[96]. Therefore, co-expressed dipeptides are likely to have reciprocal effects on 
localization and toxicity.  The effects of the G4C2 RNA and reduction of the C9ORF72 
protein, both of which occur in C9orf72 repeat expansion patients [8], were also not 
addressed in our model, both of which could strongly affect the cellular environment and 
the toxicity of the different dipeptides.  C9ORF72 is involved in the autophagosome-
lysosome pathway and decreased levels of C9ORF72 cause impaired proteostasis and 
increase the toxicity of the RAN dipeptides [293].  In the future, examining the toxicity of 
DPRs in animals carrying a loss-of-function mutation in the C. elegans C9orf72 homolog 
alfa-1 [294] or in the presence of a G4C2 transgene [91, 295] may help to address these 
limitations. 
2.3.6   Future Directions 
 The limitations of our model, in combination with our findings so far, provide a 
roadmap for future research.  There are three future projects that would add to our 
understanding of C9orf72 DPR toxicity.  The first project is to co-express the dipeptides, 
most importantly PR and GR, to determine if the dipeptides act synergistically.  The only 
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previous co-expression model co-expressed GA with the other dipeptides [96]. As GA is 
not toxic in most models, we would instead focus on the commonly toxic dipeptides, PR 
and GR.  We could examine how co-expression of different dipeptides affects cellular 
localization and the relative toxicity of the dipeptides.  Such studies may reveal synergistic 
interactions between DPRs, which may engage completely distinct toxicity pathways than 
those identified with our individual PR toxicity model. 
The second project would be creating a more accurate C. elegans model of 
C9orf72 toxicity that incorporates DPR toxicity, RNA toxicity and loss of C9orf72 function.  
Such a model may allow us to determine the significance of DPR toxicity in the presence 
of these additional factors.  To create such a model, we could insert a G4C2 repeat 
expansion in the first intron of the C. elegans C9orf72 homolog alfa-1 to mimic the G4C2 
repeat expansion in patients.  In patients, the G4C2 repeat expansion causes a reduction 
of C9ORF72 protein levels because the repeat reduces C9orf72 mRNA levels.  Thus, a 
G4C2 repeat expansion in the intron of alfa-1 may cause a reduction of ALFA-1 protein 
levels, making it a model for loss of C9ORF72 as well as a model for RNA toxicity.  Our 
lab has previously generated a C. elegans (G4C2)120 overexpression model, which 
undergoes RAN translation (data not shown).  However, the repeat is not in the context 
of either C9orf72 or alfa-1.  Placing this repeat within alfa-1 could create a more holistic 
perspective to understand the complicated relationship between loss of C9ORF72 
function, accumulation of repetitive RNA, and DPRs.  
 The third possible project is determining how PR impacts proteasome toxicity, 
which is currently being pursued by other members of the lab.  The ubiquitin-proteasome 
degradation pathway was previously implicated in ALS as knockdown of proteasomes in 
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murine motor neurons causes symptoms and pathology similar to ALS [49].  Several ALS-
causative mutations cause defects in the ubiquitin-proteasome pathway [296, 297].  In 
our model, RNAi knockdown of either bath-43/SPOP or ufd-2/UBE4B suppressed PR 
toxicity in C. elegans.  Whether knockdown of bath-43/SPOP or ufd-2/UBE4B also 
suppresses PR toxicity in human neurons needs to be determined.  Given that SPOP is 
an E3 ligase adaptor and UBE4B is an E3 ligase, on hypothesis is that SPOP and UBE4B 
interact to mediate PR toxicity.  Consistent with this hypothesis, both SPOP and UBE4B 
are localized to the nucleus [298, 299].  However, SPOP typically acts as an adaptor for 
cullin-type E3 ligases, and UBE4B is not a cullin-type E3 ligase.  This suggests either that 
SPOP and UBE4B exhibit a novel functional interaction or that other E3 ligases may 
mediate the role of SPOP in mediating PR toxicity.  Whatever the case, the observation 
that loss of ubiquitin proteasome components prevents PR toxicity is unusual and 
suggests that the stabilization of one or more pro-survival substrate may mediate 
protection against PR toxicity.  Interestingly, several known SPOP substrates are 
chromatin regulators, which were also identified in our genetic screen.  Testing whether 
chromatin regulators or other proteins are relevant targets of SPOP and/or UBE4B will be 
a major goal for future work. 
2.3.7   Summary 
Our C. elegans model of C9orf72-derived RAN dipeptides replicated previous 
findings in other systems and identified novel requirements for PR and GR toxicity.  We 
established that while PR and GR localize to the nucleus, PR and GR do not entirely 
share their mechanisms of toxicity.  PR toxicity requires an aging cellular environment, 
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while GR toxicity depends on the chronological age of the cell.  An RNAi suppressor 
screen found twelve conserved suppressors of PR toxicity.  Four of the twelve genes had 
been previously identified as interactors or modifiers of PR and GR toxicity in other 
systems.  All twelve of the PR suppressor genes have human homologues, suggesting 
that PR toxicity engages highly conserved pathways.  Therefore, our C9orf72 RAN C. 
elegans model established that RAN products can be characterized in C. elegans and 
that C. elegans models of RAN products can be used to screen for conserved 
suppressors of RAN product toxicity.   
2.4 Methods  
Caenorhabditis elegans strains and culture 
Strains were cultured on standard NGM media with E. coli OP50 bacteria.  Strains 
expressing (PR)50 and (GR)50 DPRs were cultured on gfp(RNAi) bacteria at 20°C until the 
experiment, when they were shifted to E. coli OP50.  The following strains were used; 
daf-2(e1370), daf-16(mu86), hsf-1(sy441).  Standard genetic approaches were utilized to 
cross mutants into the DPR backgrounds.  The homozygous genotype of every strain was 
confirmed by DNA sequencing of the mutant lesion.  Wild-type animals were reisolated in 
every cross and utilized as the DPR only control in resulting experiments.  DPR toxicity 
studies were carried out using animals grown at 25°C, unless otherwise noted. 
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Molecular Biology and Transgenics 
Codon-varied dipeptide sequences were isolated from previously described 
plasmids [94] (nucleotide sequences can be found in the Appendix D-Table 4.2).  (PR)5, 
(PR)15 and (PR)25 codon-varied plasmids were synthesized (GeneArt, ThermoFisher 
Scientific, Waltham, MA, USA).  Dipeptide sequences were isolated as a HindIII/BamHI 
fragment and subcloned into the C. elegans expression vector pPD95.79 to generate 
dipeptide with a C-terminal GFP tag.  Promoters were PCR amplified, incorporating both 
a 3XFLAG epitope immediately downstream from the start ATG and HindIII sites flanking 
the fragment.  Promoters were subcloned into the DPR-pPD95.79 vectors as HindIII 
fragments.  To make N-terminal GFP–(PR)50 and GFP–(GR)50 fusions, GFP was PCR 
amplified and cloned in frame with the start codon of the myo-3 promoter.  The dipeptide 
sequences were subcloned as a HindIII/BamHI fragment into the pPD49.26 expression 
vector.  The myo-3-GFP fragment was then subcloned into the DPR-pPD49.26 as a 
HindIII fragment.   
The membrane-bound DPRs were generated by a PCR fusion method.  We first 
amplified the signal sequence and transmembrane domain from the pat-3 gene as 
supplied in vector pPD122.39.  The membrane domain was then fused to the myo-3 
promoter in-frame with the start ATG and then subcloned as a HindIII fragment into the 
DPR-pPD95.79 vectors.  The resulting clones produce a membrane-localized DPR with 
the DPR facing the cytoplasm.   
To make the his-58–DPR fusions, the his-58 genomic sequence was PCR 
amplified and Gibson cloned (New England Biolabs, Ipswich, MA, USA) into the myo-
3p::GFP sequence downstream of and in-frame with the GFP sequence.  The resulting 
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myo-3p::GFP-his-58 fragment was subcloned as a HindIII fragment into the DPR-
pPD49.26 vectors.  A list of nucleotide sequences for promoters used can be found in 
Appendix D-Table 4.4. 
Transgenic worms were generated by injecting the DPR construct (20ng/ml) and 
the myo-3p::mCherry pCFJ104 or myo-3p::dsRed2 marker plasmid (100ng/ml) into the 
gonad of wild-type animals.  Transgenes were integrated using a standard gamma ray 
(Cs137) mutagenesis, followed by selection of animals exhibiting 100% transmission of 
the mCherry marker.  Integrated strains were outcrossed six times to wild-type animals.  
In the case of (PR)50 and (GR)50, injected animals were maintained on gfp(RNAi) plates 
until the experimental assay was performed.  All procedures involving recombinant or 
synthetic nucleic acid molecules and materials were approved by the University of 
Pittsburgh Institutional Biosafety Committee. 
 
Thrashing Assay 
To measure thrashing, animals were maintained at 25°C on E. coli OP50, and 
transgenic animals for each strain were picked as L4s the day before the experiment.  
The following day, worms were placed on clean NGM plates and allowed to move freely 
for 10 min so that most of the bacteria came off the animal before the experiment.  Worms 
were then placed individually into 3 cm-petri dishes containing M9 buffer and allowed to 
adjust to the new environment for 5 min.  The worms were then observed for 30 s and the 
number of thrashes (reversal of body bend that crosses the midline) was counted.  We 
were unable to score thrashing in daf-2(e1370) animals as daf-2 animals have severely 
impaired thrashing. 
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Microscopy 
Worms were anesthetized (10mM levamisole) and mounted on agar pads for 
fluorescence microscopy.  Images were collected on either a Leica MZ16FA stereo 
dissecting scope or a Leica DMI4000 inverted microscope and a Leica DFC 340Fx digital 
camera (Leica Microsystems, Wetzlar, Germany).  Z-stack images were deconvolved 
using Leica AF6000 software.  Unless noted, images within an experiment were collected 
using the same exposure settings and processed with identical deconvolution 
parameters. 
 
Commissure Assay 
L4 animals of the indicated genotype were isolated at 25°C and imaged 24 hours 
later as ‘Day 1 adults’.  All of the strains contained an unc-47p::GFP marker to reveal 
GABA motor neuron morphology.  Animals were anesthetized in 10 mM levamisole and 
Z-series images of GABAergic commissures were collected.  Commissure breaks were 
identified as interruptions in the GFP signal surrounded by dorsal and ventral GFP in the 
commissures.  Blebbing was scored only in the commissures and was identified by the 
presence of one or more GFP varicosities.  For assays involving daf-2, we were unable 
to score either membrane blebbing or commissure breakage in (GR)50 expressing 
animals because the neuronal GFP marker used to score such events was undetectable, 
likely due to significant neurodegeneration that continued to occur in (GR)50; daf-2 
animals.  
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Brood Size Assay 
For brood size assays, at least 10 L4 stage animals were individually picked to E. 
coli OP50-containing NGM plates at 25°C and transferred to a new plate every 24 hour 
until cessation of egg laying.  Each plate was allowed to age for 48–72 hour and the 
number of animals ≥L4 stage of development was counted.  Brood sizes were normalized 
within each strain to the mean brood size of animals grown on gfp(RNAi) bacteria. 
 
Paralysis Assay 
For all assays except for that shown in Figure 2.7, gravid DPR expressing 
transgenic animals were moved from gfp(RNAi) to E. coli OP50 and allowed to lay eggs 
for 24 hours.  The resulting progeny were allowed to grow up on E. coli OP50, permitting 
DPR accumulation.  Ten L4 animals were placed on each of three to five plates (N=30–
50 per assay).  Each day, animals that failed to move at least half a body length in 
response to manual stimulation with a platinum wire but were still alive (pharyngeal 
pumping, movement of less than half a body length) were scored as paralyzed.  Animals 
that died, desiccated, or exhibited internal hatching of progeny were censored from the 
assay.  Each day, mobile animals were transferred to a new plate and paralyzed, dead, 
and censored animals were removed from the assay.   
For the assay in Figure 2.7 D and E, HIS-58-(PR)50 progeny from animals moved 
from gfp(RNAi) to E. coli OP50 were not viable, presumably owing to the enhanced 
toxicity of the nuclear localized (PR)50 protein.  Therefore, for these assays, animals were 
removed from gfp(RNAi) as L4 stage animals, placed on E. coli OP50 at 25°C, and motility 
in the animals moved from gfp(RNA) was monitored as described above.  Since animals 
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are removed from the assay once they are scored as paralyzed, it is not appropriate to 
utilize statistical approaches that compare means and errors between time points (i.e. T-
tests, ANOVA tests).  Instead, we utilized the Log-rank statistical method, a cumulative 
statistical approach that compares changes in population sizes over time for a specified 
endpoint (53).  Because this end-point assay is cumulative and not replicative, data points 
do not contain error bars.  For each assay, 2–3 independent trials with 45–50 animals per 
assay were performed and the results from one representative trial are shown. 
 
Lifespan Assays  
For lifespan assays, worms grow at 20°C were picked as L4 and allowed to grow 
at 20°C until the next day, when 10 young adults were placed on five 3 cm plates.  
Lifespan assays were performed with E. coli OP50 spotted on NGM plates at 25°C.  
Worms were classified as alive, dead (no movement in response to touch with a wire), or 
censored (lost or bagged worms) once a day for lifespan assays.   
 
COPAS Fluorescence Quantification 
Day 1 adult animals expressing each DPR-GFP transgene under the control of the 
myo-3 promoter were washed off plates and analyzed using a COPAS Biosorter.  
Fluorescent detection settings were identical for all samples.  Only animals with time-of-
flight measurements from 400-600 (young adults) were used for the analysis of 
fluorescence. 
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Quantitative PCR  
L1 animals from each of the indicated genotypes were synchronized using the 
hypochlorite method.  Animals were plated on E. coli OP50 and allowed to grow at 20°C 
for ~48 hours.  500 young adult animals were sorted into 1.5 ml tubes using a COPAS 
BIOSORT.  3 biological replicates were performed for each genotype.  Purified total RNA 
was converted to cDNA and quantitative PCR against GFP was carried out on an ABI7500 
qPCR system (Applied Biosystems, Fisher Scientific, Foster City, CA) using the SYBR 
green method.  Samples were normalized against expression for the actin gene act-2.  
Each sample was then normalized against the expression of the GFP only control. 
 
FRAP 
FRAP studies were carried out on levamisole anesthetized day 1 adult 
hermaphrodites using a Leica DMI8 confocal microscope at the University of Pittsburgh 
Center for Biologic Imaging.  Images were captured at 20–30 Hz.  Following imaging of 
baseline fluorescence, a region of interest corresponding to a portion of the nuclear or 
cytoplasmic foci was photobleached and fluorescence recovery within the photobleached 
area was monitored over at least 60 seconds.  Data were normalized so that the image 
preceding the photobleach was set to 100% and the first image following the photobleach 
was set to zero percent. 
 
ENU Forward Mutagenesis Screen 
C. elegans L4s were placed in 2.4mM ENU and then gently shaken for 4 hours at 
room temperature.  The worms are then washed 5x with M9 and allowed to recover for 
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24 hours on NGM plates.  After 24 hours, gravid P0s were picked and allowed to lay 
progeny on (gfp)RNAi plates for 6 hours.  The P0s were then removed and the plates with 
the eggs were placed at 20°C.  After a week, the starved progeny were washed onto E. 
coli OP50 and placed at 25°C.  After a week, the worms still growing at 25°C were picked 
as possible candidates.  To ensure the independence of alleles, only one candidate was 
picked per plate. 
 
COPAS Sorting of Suppressors 
Bleach synchronized adult day 1 adult animals were sorted through the COPAS 
Biosorter (Union Biometrica, Holliston, MA, USA).  The overall RFP signal of the worm 
and the worm time of flight of were measured.  Relative RFP signal was measured as 
(Overall RFP signal / Time of flight) and used to test for transgene suppression. 
 
RNAi Screen 
Genome-wide RNAi screening was performed using a commercially available 
RNAi feeding library (MRC Geneservice, Cambridge, U.K.).  Single colonies were 
inoculated into 1 ml of LB media containing 25μg/ml carbenicillin and grown overnight 
with shaking at 37°C.  10 microliters of each culture were spotted on each well of a 24-
well plate containing NGM with 20mM NaCl, 1mM IPTG, and 25μg/ml carbenicillin.  15-
20 eggs were seeded in each well and the plates were incubated for a week at 20°C.  
They were then scored on their ability to move and have progeny.  The clones were 
rescreened 2 times and those that are picked up 4/6 times were counted as suppressors 
of (PR)50 toxicity. 
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Statistical Analysis 
Paralysis assays were analyzed using the Kaplan–Meier log-rank function 
(OASIS) [300, 301].  Comparisons of means were analyzed with either a two-tailed 
Student’s t-test (two groups) or ANOVA (three or more groups) using the Tukey’s or 
Dunn’s post-test analysis as indicated in GraphPad Prism7 (GraphPad Software, Inc., La 
Jolla, CA, USA).  P-values of<0.05 were considered significant. 
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3.0  HD RAN Polypeptides Exhibit PolyQ-Independent Toxicity 
3.1  Introduction 
Repeat-Associated non-AUG (RAN) translation occurs in four different disease 
caused by a CAG/CTG repeat expansion: Huntington’s disease (HD) [12], spinocerebellar 
ataxia type 8 (SCA8) [4], Huntington disease-like 2 (HDL2) [4], and Fuchs endothelial 
corneal dystrophy (FECD) [85].  All four CAG repeat expansions encode identical 
homopolymeric RAN peptides, although the flanking sequences differ between genes.  
There are 10 other neurodegenerative diseases caused by a CAG or CTG repeat 
expansions that are likely to undergo RAN translation, although experimental evidence is 
currently lacking.  Altogether, fourteen distinct diseases could produce RAN translation 
products from a CAG/CTG repeat.  Determining which of the CAG/CTG RAN 
polypeptides are pathogenic and defining their mechanism(s) of toxicity could expand our 
understanding of CAG/CTG repeat expansion diseases.  
HD is the most common CAG/CTG repeat expansion disease [302, 303].  Patients 
suffer from this incurable neurodegenerative disease for decades before passing due to 
secondary complications.  HD patients commonly exhibit psychological, cognitive, and 
motor problems such as depression, rigid thinking, and chorea, respectively [202].  The 
CAG repeat expansion in the Huntingtin gene, HTT, causes all cases of HD [205].  
Patients with a CAG repeat expansion ≥40 repeats in HTT (also referred to as mutant 
HTT (mHTT) in HD patients) begin to exhibit HD-associated motor defects at ~40 years 
of age [55, 203].  However, the age of onset of HD is inversely correlated with the length 
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of the CAG repeat [205].  In other words, patients with long CAG repeats develop the 
disease earlier in life than patients with shorter CAG repeats.  Large increases in the 
length of the CAG repeat arise through impaired replication of the G/C-rich repeats during 
germline division [304].  Impaired repeat replication leads to intergenerational increases 
in CAG repeat lengths, or genetic anticipation, which causes an earlier age-of-onset of 
HD in the offspring relative to the parent [304].  Despite the clear genetic basis for HD, 
the molecular mechanisms that drive disease severity and outcomes are still poorly 
understood.  Currently, HD and other CAG repeat expansion disease are incurable.   
HD is an autosomal dominant monogenic disease.  Therefore, most patients have 
a family history of HD [305] and are aware at an early age that they are at risk of 
developing HD [306].  These patients can undergo pre-symptomatic genetic testing for 
HD, but they are not diagnosed as having HD until they develop motor defects [307].  The 
average post-diagnosis lifespan for HD patients is ~20 years [203].  Prior to diagnosis, 
HD patients have an increased risk of psychological problems up to ~15 years before 
motor symptoms appear [207, 208].  Patients typically discover their risk for HD as 
juveniles, when their parents develop HD.  The patients can confirm their HD status at 
age 18, when they can undergo genetic testing.  Patients can display cognitive [208] and 
psychiatric [207] defects due to HD up to 15 years before diagnosis (~30 years of age). 
Motility defects normally begin ~40 years of age [203], with patients living 10-20 years 
after motor problems arise.  Since there are no corrective treatments for HD, this disease 
has a lifelong impact on patients.   
Therapeutic strategies for treating HD have focused on the polyglutamine (polyQ) 
tract within the first exon of the HTT gene, which is encoded by the CAG repeat 
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expansion.  The ability of polyQ to aggregate correlates with the length of the polyQ 
polypeptide.  Levels of polyQ aggregation also increase with age [75].  Because of these 
characteristics, the polyQ aggregates were initially thought to be the cause of toxicity.  
However, the ability of polyQ to aggregate can be separated from polyQ toxicity [131].  
Current studies suggest that polyQ oligomers (low abundance, low molecular weight 
homopolymers [231]) are stronger contributors to HD then polyQ aggregates (abundant 
high molecular weight polymers [231]) [308].  However, brain regions such as the caudate 
white matter lack detectable polyQ aggregates but still undergo apoptosis in HD [12].  In 
addition, juvenile HD patients have ≥60 CAG repeats and minimal detectable polyQ 
aggregates in their brains, even though there is widespread loss of neurons [12].  These 
data clearly suggest that polyQ-independent disease mechanisms also contribute to HD 
pathology. 
 One potential polyQ-independent disease mechanism is the production of 
homopolymeric RAN peptides, which was discovered to occur in HD in a landmark 2015 
study [12].  In both adult and juvenile patients, HD RAN products are present in brain 
regions lacking polyQ that are still undergoing apoptosis.  Interestingly, some of these 
polyQ deficient brain regions have high levels of other RAN peptides [12].  Thus, RAN 
products appear to contribute to HD in both adults and juvenile patients.  HD CAG repeat 
expansions produce four RAN products: polySerine (polySer), polyLeucine (polyLeu), 
polyAlanine (polyAla), and polyCysteine (polyCys).  Canonical translation produces 
polyQ.  All four RAN peptides and polyQ are weakly toxic at 90 repeats when 
overexpressed in neuronal cells [12]. Whether or not these peptides are also toxic at more 
disease-relevant lengths found in the majority of HD patients is not known.  Both polySer 
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and polyGln form protein aggregates in cell culture [12]. Protein aggregates sequester 
cellular protein folding and degradation resources [310]. Therefore, aggregation of RAN 
peptides other than polyQ could disrupt protein folding molecular pathways required for 
HD models.  Whether protein folding pathways or other molecular pathways influence the 
toxicity of RAN peptides is not known.   
To address these questions, I created codon-varied GFP-tagged HD RAN 
homopolymers at both disease-relevant lengths (38 repeats) and highly expanded lengths 
(90 repeats).  I expressed these peptides in multiple cellular settings in C. elegans.  I 
found that all RAN peptides, except for polyLeu, formed highly compact aggregates.  The 
only RAN peptide that was toxic in all cellular settings was polyLeu.  I found that polyLeu 
displayed length-associated toxicity and caused significant neurodegeneration in vivo.  
Notably, neurodegeneration was not observed with codon-varied polyGln, suggesting that 
these two polypeptides cause toxicity through distinct pathways.  To better understand 
the pathways of polyLeu toxicity, I performed an unbiased forward genetic ENU 
mutagenesis and identified suppressors that ameliorate the toxicity of polyLeu.  Whole-
genome resequencing and RNAi phenocopy identified several candidate genes required 
for polyLeu toxicity.  The molecular nature of these genes suggests that polyLeu causes 
toxicity through mechanisms involving the secretory pathway.  Identifying the cellular 
processes involved in polyLeu toxicity gives direction to future research for treatments for 
HD patients, as well as patients suffering from other diseases caused by CAG repeat 
expansions. 
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3.2  Results 
3.2.1  HD RAN Model 
The CAG repeat expansion in HD could be toxic through the G/C-rich RNA, the 
polyGln peptide produced through canonical translation, or through one or more of the 
homopolymeric peptides produced through RAN translation.  To focus on the individual 
toxicity of the RAN peptides, I created C. elegans models for each of the five possible 
CAG RAN products.  To individually model the RAN peptides, a previously described 
codon-variation strategy [95] was employed for each homopolymeric peptide to maintain 
the amino acid repeats but remove the nucleotide repeats.  The codon-varied constructs 
were also designed to minimize computationally predicted RNA hairpin structures in the 
resulting RNA, as hairpin structures are thought to be required for RAN translation and 
could lead to the production of non-relevant RAN products [311].  The individual RAN 
peptides were instead expressed through canonical AUG-initiated translation and studied 
at either 38 repeats or 90 repeats (Figure 3.1 A).  The 38 repeat peptides are similar to 
the minimum length of 40 CAG repeats that ensures a patient will develop HD.  The 90 
repeat peptides mimic the length investigated in a previous paper [12].  The 
homopolymeric peptides were also tagged at the C-terminus with GFP for in vivo 
visualization of the RAN peptides (Figure 3.1 A).  The modeled RAN peptides lacked 
genetic context (i.e. no flanking human HTT sequence) as each RAN peptide is in a 
different reading frame leading to a unique genetic context for each RAN peptide.  
Including the genetic contexts of the RAN peptides would limit our ability to assign 
phenotypes to specific homopolymeric peptides rather than flanking sequences.  To 
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compare the characteristics of the individual RAN peptides to the characteristics of the 
mHTT CAG repeat expansion, I created an expanded CAG repeat with polyGlutamine in-
frame with the start codon.  Throughout my thesis, I will refer to the CAG-encoded 
polyGlutamine as “polyQ” and the codon-varied polyGlutamine as “polyGln”.  Unlike the 
codon-varied polyGln, the CAG-encoded polyQ may exhibit either RNA toxicity, toxicity 
from RAN products besides polyglutamine, or both.  To study the functional 
consequences, I expressed each codon-varied construct in both GABAergic neurons and 
muscle cells using cell type specific promoters.  
3.2.2  GABAergic Neuron Model of HD RAN Polypeptides 
 Neurodegeneration due to HD starts in the striatum and most strongly degrades 
the GABAergic neuronal population in the striatum [312].  HD RAN polypeptides are found 
in degenerating regions of the striatum that lack polyQ, suggesting they contribute to 
neurodegeneration [12].  We expressed RAN polypeptides specifically in the GABAergic 
neurons of C. elegans using the unc-47 promoter, which controls the expression of the 
vesicular GABA transporter.  There are 26 GABAergic neurons in C. elegans and 19 of 
the 26 GABAergic neurons are motor neurons [146].  GABAergic neuron somas are 
located along the ventral nerve cord and extend single axons, known as commissures, 
across the dorsal-ventral midline to the dorsal muscle cells.  Commissures are commonly 
used to measure neurodegeneration since they provide single axon resolution [247, 313].  
The function of GABAergic neurons can also be assessed using a reversal assay, since 
loss of GABAergic neurons causes a significant deficit in the ability of C. elegans to 
reverse direction [146].  Quantifying the number, morphology, and function of GABAergic 
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neuron commissures is a useful measure of the neurotoxic potential of proteins expressed 
in C. elegans [95, 143, 144, 247].   
We characterized the effect of the CAG-derived RAN polypeptides on these 
GABAergic neuron parameters.  (Q)38-GFP worms, which expressed CAG-encoded 
polyglutamine (and possibly other RAN peptides), strongly inhibited the ability of the 
worms to reverse when expressed in GABAergic neurons.  Surprisingly, (Gln)38-GFP 
worms expressing polyglutamine encoded by a codon-varied sequence were comparable 
to control animals expressing GFP alone.  In contrast, (Leu)38-GFP worms exhibited 
highly significant movement defects.  (Ala)38-GFP and (Ser)38-GFP also caused reversal 
defects (Figure 3.1 B).  No defects were observed for (Cys)37-GFP. 
To test if the functional defects were caused by cellular damage, the neuronal 
commissure structures were examined.  Neurodegeneration of commissures causes 
blebbing (swelling of the cellular membrane), breaks in the commissures, or branching of 
the commissures [95, 247, 314, 315].  The formation of the commissures was assessed 
by co-expressing unc-47p::RFP, which fills the GABAergic neurons.  Commissure 
morphology was assessed by measuring the percentage of total detectable commissures 
in the animal that were blebbing, broken, or failed to reach the dorsal side.  Consistent 
with our functional data, animals expressing (Gln)38-GFP exhibited no defects in 
commissure structure (Figure 3.1 C, D).  Animals expressing (Leu)38-GFP exhibited highly 
penetrant commissure defects, although the neuron somas were intact.  The GABAergic 
neurons in (Leu)38-GFP worms traversed the length of the animals instead of the width, 
suggesting defects in neuron stability and/or axon guidance (Figure 3.1 C, D).  (Q)38-GFP 
worms also had abnormal commissures, with roughly half of the commissures in each 
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worm being abnormal or incomplete.  (Cys)37-GFP did not cause a significant functional 
defect.  However, 19% of the commissures in (Cys)37-GFP worms were abnormal.  
(Ser)38-GFP caused a slight functional defect but did not cause a significant defect in the 
form of the commissures (Figure 3.1 C).  These data show that the expression of (Leu)38-
GFP, but not other RAN peptides, is sufficient to cause both structural and functional 
defects in GABAergic neurons.  They also suggest that factors other than polyglutamine 
contribute to the toxicity of (Q)38-GFP, as a codon-varied (Gln)38-GFP did not exhibit 
toxicity. 
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Figure 3.1 PolyLeucine Is the Most Toxic HD RAN Peptide in Neurons 
(A) Molecular strategy for expression of codon-varied polypeptide repeats in C. elegans.  
(B) Quantification of the reversal ability of transgenic animals expressing the indicated 
polypeptide under the GABAergic neuron specific unc-47 promoter.  N=15 
animals/genotype.  Each symbol represents one animal, the horizontal line is the mean 
and the bars define the standard deviation.  *P<0.05, **P<0.01, ***P<0.001 versus GFP 
control (one-way non-parametric ANOVA with a post hoc Dunn’s multiple comparison 
test).  (C) Quantification of incomplete or abnormal commissures.  For each animal we 
counted the number of commissures with blebbing, breakage, or that failed to reach the 
dorsal side, and divided that number by the total number of commissures.  N=11-20 
animals/genotype.  The data is expressed in a box and whisker plot where the whiskers 
go from min to max.  Statistics done by one-way non-parametric ANOVA with a post hoc 
Dunn’s multiple comparison test against the GFP control.  (D) Representative images of 
unc-47+ motor neurons in animals expressing the described polypeptide.  V points to 
blebs, arrowhead points to branching, and the asterisk is at commissures that fail to reach 
the dorsal side.  Scale bar=10 μm.   
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3.2.3  Muscle Model of HD RAN Polypeptides 
 C. elegans GABAergic neurons are anatomically small (cell bodies 1-2 micron) and 
inaccessible to some genetic approaches, such as RNAi-mediated gene knockdown 
[316].  To gain more insights into RAN peptide cell biology, as well as to generate a 
platform for RNAi and forward-mutagenesis based genetic suppressor screening, we 
expressed the HD RAN polypeptides in muscle cells using the myo-3 promoter, which 
encodes a muscle-specific myosin heavy chain A.  Toxicity in muscle cells can cause 
larval arrest and/or motility defects [75, 95].  We found that muscle expression of (Leu)38-
GFP caused highly penetrant larval arrest phenotype (Figure 3.2 A).  Muscle expression 
of (Ala)38-GFP, (Gln)38-GFP, (Cys)37-GFP, and (Q)38-GFP caused a weakly penetrant 
larval arrest phenotype.  However, (Ser)38-GFP did not induce larval arrest.  To facilitate 
post-developmental expression of each peptide, we initially grew animals on gfp(RNAi) 
and then switched them to empty vector(RNAi) to prevent peptide expression during 
development and permit expression during adulthood [95].  (Q)38-GFP caused a 
significant increase in paralysis of animals as they aged.  However, (Ala)38-GFP, (Gln)38-
GFP, and (Leu)38-GFP caused no significant enhancement in paralysis (Figure 3.2 B).   
Paralysis assays measure strong defects in muscle function.  However, the binary 
nature of this assay is not a sensitive measure of motility.  To more quantitatively measure 
changes in motility, we performed thrashing assays.  While only (Q)38-GFP caused age-
dependent paralysis, (Q)38-GFP, (Cys)37-GFP, (Leu)38-GFP, and (Ala)38-GFP all caused 
a decrease in thrashing rates.  (Ala)38-GFP motility defects were highly penetrant, 
whereas (Q)38-GFP, (Cys)37-GFP, and (Leu)38-GFP defects were more variable.  Similar 
to motor neuron expression, muscle expression of (Q)38-GFP caused a strong motility 
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defect, but (Gln)38-GFP did not cause a motility defect (Figure 3.2 C).  As in GABAergic 
neurons, this suggests that factors other than polyGln contribute to the toxicity of polyQ.   
To test if increased repeat length would cause an increase in toxicity, we 
expressed 90 repeats of codon-varied polyGln, polySer, polyCys, and polyLeu.  We were 
unable to synthesize 90 repeats of polyQ or codon-varied polyAla for unknown technical 
reasons.  Only (Gln)90-GFP and (Leu)90-GFP caused significant thrashing defects (Figure 
3.2 D).  Only polyGln had a strong increase in toxicity with increased repeat length, which 
had been previously observed in C. elegans polyQ models [75].  None of the HD 
polypeptides caused a shortening of lifespan when expressed at 38 repeats (Figure 3.2 
E).  
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Figure 3.2 The Majority of HD RAN Polypeptides Are Toxic in Muscle 
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(A) Larval arrest measured by sorting a synchronized population 48 hours after eggs were 
laid on a plate.  The worms were sorted through the COPAS Biosorter and animals with 
a time of flight ≥ 300 were categorized as adults, animals with a time of flight <300 were 
categorized as larvae.  (N=188-269 worms), *P<0.05, ****P<0.0001, (Kruskal Wallis test 
of multiple comparisons with a post hoc Dunn’s multiple comparison test).  (B) Paralysis 
assay for adult animals raised in the absence of gfp(RNAi).  **P<0.01, (Log Rank Test 
with Bonferroni-adjusted p-value).  (C) Liquid thrashing quantification of transgenic 
animals raised in the absence of gfp(RNAi), expressing the indicating polypeptides under 
the muscle-specific myo-3 promoter.  N=20 animals/genotype.  Each symbol represents 
one animal, the horizontal line is the mean and the bars represent the standard deviation.  
*P<0.05, ***P<0.001, ****P<0.0001 versus GFP control (one-way non-parametric ANOVA 
with a post hoc Dunn’s multiple comparison test).  (D) Liquid thrashing quantification of 
transgenic animals expressing the indicated polypeptides under the muscle-specific myo-
3 promoter (one-way non-parametric ANOVA with a post hoc Dunn’s multiple comparison 
test).  (E) Lifespan measured in transgenic animals raised in the absence of gfp(RNAi), 
expressing the indicating polypeptides under the muscle-specific myo-3 promoter.  N=50 
(Log Rank Test with Bonferroni-adjusted P-value). 
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3.2.4  Localization Patterns of HD RAN Polypeptides 
 To gain insights into the cell biological properties of the GFP-tagged HD RAN 
polypeptides, we took advantage of the transparent nature of C. elegans and performed 
live animal fluorescent imaging.  Previous studies found that polyQ and polySer form 
puncta at disease-relevant repeat lengths [12, 75].  However, there is nothing known with 
regards to the localization properties of the other codon-varied RAN peptides.  Both (Q)38-
GFP and (Gln)38-GFP had both diffuse signal and puncta, consistent with previous polyQ 
models (Figure 3.3 A).  (Ser)38-GFP formed puncta but did not have diffuse signal (Figure 
3.3 A), consistent with other polySer models [12].  (Ala)38-GFP and (Cys)37-GFP also 
formed puncta.  PolyCys and polySer localization patterns appeared similar.  (Cys)90-RFP 
and (Ser)90-GFP exhibited strong colocalization, suggesting they are forming on similar 
structures (Appendix C- Figure 4.1).  Unlike the other RAN peptides, the GFP signal for 
(Leu)38-GFP was extremely low and only detectable in a subset of adult muscle cells 
(vulval muscle cells) (Figure 3.3 A).  The low polyLeu signal could be due to localization 
within a cellular compartment that impairs GFP fluorescence.  GFP has impaired folding 
in oxidizing environments such as the lumen of the endoplasmic reticulum (ER) [317]. 
Additionally, leucine repeats commonly insert into membranes [318, 319].  Therefore, one 
possibility is that (Leu)38-GFP is in a membrane and the GFP tag is oriented within an 
oxidizing environment.  To test this possibility, I replaced GFP with a more stable version 
of GFP called superfolded GFP (sfGFP).  sfGFP has several point mutations that enhance 
folding and fluorescence in non-optimal environments, such as the ER [320, 321].  Unlike 
(Leu)38-GFP, (Leu)38-sfGFP was observed in adult muscle cell, in addition to the vulval 
cells, and localized to the periphery of large spherical bodies of unknown origin (Figure 
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3.3 B).  This suggests (Leu)38 is membrane-bound and localized to an environment that 
impairs folding of GFP.    
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Figure 3.3 Every HD Polypeptide Forms Puncta at 38 Repeats 
(A) Representative images of the indicated polypeptide in muscle expressed under myo-
3 promoter.  Asterisks mark intestinal autofluorescence.  Scale Bar=10 μm.
(B) Representative image of myo-3p::(Leu)38-sfGFP.  Scale Bar=10 μm.
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3.2.5  All HD RAN Peptides Form Aggregates 
All HD RAN products form puncta in vivo, which may be aggregates.  PolyGln and 
polySer are known to form aggregates [12, 127].  However, the structure of the puncta 
containing the other HD RAN products is unknown.  The pathogenicity of the HD RAN 
peptides may be related to type of structures they form in cells.  PolyQ aggregates are a 
common feature of HD patient tissue, and certain modifiers of polyQ aggregation also 
modify the toxicity of polyQ [310]. To better understand the cellular properties and 
potential toxic mechanisms of the HD RAN polypeptides, we tested if the HD RAN puncta 
exhibited restricted diffusion properties, a characteristic of protein aggregates [252].  The 
standard in vivo test for aggregation is Fluorescence Recovery After Photobleaching 
(FRAP), which measures the rate of diffusion of GFP-labeled molecules within a structure 
[252].  Soluble GFP molecules rapidly recover most of their fluorescence following FRAP, 
whereas protein aggregates exhibit slow and limited fluorescent recovery.  Previous 
polyQ models have established that polyQ forms aggregates, so polyQ was used as a 
positive control for aggregation.  We found that polyGln, polySer, polyCys, and polyAla 
exhibited limited FRAP recovery similar to aggregated polyQ (Figure 3.4).  However, 
polyLeu FRAP recovery was more rapid and extensive, suggesting that polyLeu 
structures have more freely diffusible molecules within the aggregate and/or more 
exchange of molecules with the surrounding cytosol.  The total recovery of (Leu)38 was 
only 20%, so the majority of polyLeu peptides are immobile in the aggregate (Figure 3.4 
C).  Every HD polypeptide except for polyLeu formed aggregates with a fluorescent 
recovery comparable to a polyGln aggregate, including the nontoxic polySer, 
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emphasizing that polyLeu may be toxic by affecting different cellular pathways then 
polyglutamine. 
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Figure 3.4 PolyLeu Forms Protein Aggregates With Limited Mobility 
(A) Representative images from FRAP analysis of subcellular localized polypeptide
proteins expressed in muscle.  Dashed outline indicates the site of photobleaching and 
post-bleaching quantification.  Recovery images are 60 seconds post-bleach.  Scale 
bar=1 μm.  (B) Quantification of FRAP imaging.  Data shown are mean ± standard error 
of the mean (SEM), N=5-17 datasets/genotype).  (C) Average equilibrium fluorescence 
recovery after 60 seconds.  Data shown are mean ± SEM for 5-17 datasets.  **P<0.01, 
(one-way ANOVA with a post hoc Dunn’s multiple comparison test). 
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3.2.6  PolyLeu Toxicity is Length Dependent  
Like aggregation, length-dependent toxicity is a classic characteristic of CAG 
repeats.  PolyGln is well established to exhibit length-dependent toxicity, which we 
confirmed using our codon-varied constructs (Figure 3.2 C, D).  To determine if polyLeu 
also exhibits length-dependent toxicity, I expressed polyLeu at 11 repeats, 20 repeats, 29 
repeats, and 38 repeats in GABAergic neurons and muscle cells.  (Leu)11-GFP, (Leu)20-
GFP and (Leu)29-GFP caused no functional defects in GABAergic neurons (Figure 3.5 A). 
Only (Leu)38-GFP caused functional defects (Figure 3.5 A).  Therefore, polyLeu exhibits 
length-dependent toxicity in GABAergic neurons and requires more than 29 repeats to 
cause toxicity.  The change in toxicity could be due to altered localization patterns of 
polyLeu depending on the length of leucine repeats.  We consequently expressed the 
various lengths of polyLeu in muscle cells to determine whether the different lengths of 
polyLeu had similar localization patterns.  (Leu)11-GFP and (Leu)20-GFP had distinct 
localization patterns that appeared localized to membranes, since they outlined but did 
not fill structures within the cell.  However, (Leu)11-GFP localizes to a reticular structure 
that fills the muscle cell and small spherical structures ~1 µm in diameter, while (Leu)20-
GFP localizes to the periphery of the muscle cell, potentially the plasma membrane, as 
well as various structures inside the cell that exhibit no consistent shape (Figure 3.5 C). 
Cellular localization of (Leu)29-GFP and (Leu)38-GFP was challenging to determine since 
both lengths of polyLeu appeared to inhibit the fluorescence of the GFP attached to the 
repeats (Figure 3.5 B).  The length-dependent decrease in fluorescence was specific to 
the polyLeu-bound GFP, as free RFP expressed in the same tissues did not have a 
length-dependent decrease in fluorescence (Figure 3.5 C).  A version of GFP with 
110 
enhanced folding (sfGFP) allowed the detection of (Leu)38 localization.  (Leu)38-sfGFP 
formed hollow spherical bodies that were ~1 µm in diameter, similar in size to the bodies 
seen with (Leu)11-GFP.  (Leu)38-sfGFP also had a weak signal in the body of the muscle 
cell, the structure of which was not determined.  Therefore, (Leu)11-GFP and (Leu)38-
sfGFP localized to similar hollow, spherical bodies ~1 µm in diameter.  (Leu)20-GFP had 
a distinct localization pattern outlining multiple structures in the cell.  (Leu)11-GFP, (Leu)20-
GFP, and (Leu)29-GFP did not exhibit the larval arrest observed in both (Leu)38-GFP and 
(Leu)38-sfGFP.  Together, these data suggest that the strong toxicity of (Leu)38-GFP is 
length-dependent, with more than 29 leucine repeats required to cause larval arrest when 
expressed in muscle, or reversal defects when expressed in motor neurons.  The increase 
in toxicity does not appear to be due to a change in the localization pattern of polyLeu, 
since non-toxic (Leu)11-GFP and (Leu)29-GFP exhibited many of the same localization 
properties as toxic (Leu)38-GFP.  The length-dependent toxicity of polyLeu, in addition to 
polyLeu being toxic in multiple tissues, suggests that polyLeu could be a strong 
contributor to CAG repeat toxicity. 
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Figure 3.5 Toxicity of PolyLeu Is Length Dependent 
(A) Quantification of the reversal ability of transgenic animals expressing the indicated 
length of polyLeu under the GABAergic neuron specific unc-47 promoter.  N=15 
animals/genotype.  Each symbol represents one animal, the horizontal line is the medan 
and the bars represent the standard deviation.  *P<0.05 versus GFP control (one-way 
non-parametric ANOVA with a post hoc Dunn’s multiple comparison test) (B) Average 
fluorescence of GFP and (C) RFP in single animals, as measured by the COPAS 
Biosorter through measuring the total fluorescence of the worm and dividing it by the time 
of flight of the worm.  N=149-611.  **P<0.01, ***P<0.001, ****P< 0.0001 versus myo-
3p::(Leu)11-GFP control (one-way non-parametric ANOVA with a post hoc Dunn’s multiple 
comparison test) (D) Representative images of the indicated length of polyLeu in muscle 
expressed under the myo-3 promoter.  The animals are day 1 adults.  Scale Bars=20 μm.    
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3.2.7  Forward Mutagenesis Screen to Identify Suppressors of PolyLeu Toxicity 
 To identify the molecular pathways required for polyLeu toxicity, we performed a 
forward mutagenesis screen for suppressors of polyLeu-induced larval arrest.  Animals 
were treated with N-Ethyl-N-Nitrosourea (ENU), which is widely used to induce mutations 
in forward mutagenesis screens [322-324].  ENU causes alkylation of nucleic acids 
leading to missense mutations and, unlike other mutagens like ethyl methanesulfonate 
(EMS), produces a broad spectrum of nucleotide changes [325].  After ENU treatment, 
animals self-fertilized while growing on (gfp)RNAi, which suppressed (Leu)38-GFP 
expression and toxicity.  Second generation animals were examined to determine if they 
carried homozygous recessive mutations that suppressed the toxicity of polyLeu.  The 
animals were removed from (gfp)RNAi and placed on E. coli OP50, a commonly used 
laboratory food source for C. elegans that allows expression of (Leu)38-GFP.  Any animals 
that grew and reproduced over multiple generations carried a genetic suppressor of 
(Leu)38-GFP toxicity (Figure 3.6 A).  To identify any suppressors that caused a general 
decrease in transgene expression, the expression level of another component of the 
same transgene, myo-3p::RFP, was quantified based on RFP fluorescence (Figure 3.6 
C).  myo-3p::RFP is located in the same transgene that expresses (Leu)38-GFP, as the 
two plasmids were co-injected and then integrated into the genome [326].  After selecting 
for suppressors that did not decrease transgene expression, 25 independent suppressors 
were isolated (Figure 3.6 B).  To determine if similar pathways were likely affected in the 
different suppressors, the localization of (Leu)38-GFP was examined in ten of the identified 
suppressors.  Three distinct localization patterns for (Leu)38-GFP were observed in the 
suppressors (Figure 3.6 D).  Two of the suppressors had wild-type expression patterns 
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of (Leu)38-GFP.  Six suppressors had increased diffuse signal in the muscle and two 
suppressors had diffuse signal in the gonads.  The variety of localization patterns 
suggests the screen identified several genes and/or pathways mediating (Leu)38-GFP 
toxicity. 
To identify the phenotype causing mutations, we used whole-genome sequencing 
(WGS) and subsequent RNAi phenocopying.  WGS was used to identify nonsynonymous 
single nucleotide polymorphisms (SNPs) and insertions/deletions (indels) in exons of the 
suppressors.  Several assumptions were made to simplify identification of the relevant 
mutations: the suppression is due to a single gene, the mutation causes loss of function, 
and the mutation is homozygous.  Homozygous mutations not found in the starting 
(Leu)38-GFP strain were identified in 914 genes (Figure 3.7).  Each suppressor had an 
average of 45.3 ± 12.6 genes containing polymorphisms.  While several genes were 
overrepresented in the screen (alh-2 (polymorphisms present in 10/25 suppressors), 
H03A11.2 (13/25 suppressors), tag-80 (23/25 suppressors), ttn-1 (25/25 suppressors), 
ZC247.1 (19/25 suppressors)), the same genes were also identified as containing 
polymorphisms in an unrelated forward mutagenesis screen performed in our lab and 
appear to be mutated frequently due to their large size.  Therefore, we chose to exclude 
these genes from further analysis.  For the remaining genes, we used the Enrichment 
Analysis Tool on WormBase (www.wormbase.org) to identify protein families 
overrepresented in our screen.  Overrepresented protein families included proteins with 
ATPase activity, active transmembrane transport, or ATP or GTP binding ability.  To test 
if any of these genes were necessary for larval arrest, I performed a candidate-gene RNAi 
screen (Figure 3.7).  I screened genes from the suppressor screen that were: mutated in 
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multiple suppressors, had a stop-codon-inducing mutation, or were part of an over-
represented protein family.  Of the 165 genes that fit these requirements, 108 genes had 
available RNAi clones for the gene knockdown.  These 108 genes were screened by 
RNAi in two separate screens using three replicates per screen.  Five gene knockdowns 
consistently suppressed (Leu)38-GFP induced larval arrest in at least 3 of 5 plates during 
the two screens (Table 3.1).  Many of the candidate genes caused larval arrest when 
knocked down with RNAi, which is likely why only 5 gene knockdowns phenocopied the 
suppression of larval arrest.  One of the candidates, F35A5.1, has the same SNP mutation 
in 17 suppressors, with no other mutations in F35A5.1 present in suppressors.  The 17 
suppressors have different localization patterns of (Leu)38-GFP and different levels of 
suppression of larval arrest, making it unlikely that the mutation in F35A5.1 is the 
causative mutation.  Another gene, T28A11.17, is part of a gene family in C. elegans with 
at least eight other genes, some of which contain an L-domain, a protein domain also 
found in cell-surface receptors such as the insulin receptor (IR) or the epidermal growth 
factor receptor (EGFR).  T28A11.17 is predicted to have two transmembrane domains, 
suggesting this protein is found in the secretory pathway.  However, T28A11.17 does not 
have a human homologue and its function is unknown, making its disease relevance 
unclear.  Therefore, we focused on the three remaining genes, each of which were part 
of a common protein family.  SRI-62 is a G-protein coupled receptor (GPCR), PMP-2 is 
an ATP-binding cassette transporter (ABC transporter), and UBH-4 is a deubiquitinating 
enzyme (Table 3.2).  To determine if loss of these genes caused similar effects, I studied 
the suppressors thought to have causative mutations in one of the genes. 
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I characterized the mutations in the identified polyLeu suppressors to determine 
how the mutations in sri-62, pmp-2, and ubh-4 could suppress toxicity.  The four 
suppressors all strongly suppress larval arrest (Figure 3.6 B and Table 3.2).  sri-62 (dr57) 
affects a G-protein-coupled receptor (GPCR) of the serpentine chemoreceptor class.  
dr57 converts a glutamine to an early stop-codon mutation (Q85*), which causes sri-62 
truncation or mRNA degradation through nonsense-mediated mRNA decay.  The sri-62 
mutant had diffuse (Leu)38-GFP in the gonad of animals, which is never observed in wild-
type animals.  pmp-2(dr59) affects a predicted ortholog of the human ABC transporter 
ABCD3, which is involved in peroxisomal import of fatty acids and is associated with some 
forms of a peroxisome assembly disorder called Zellweger syndrome.  dr59 generates a 
missense mutation (L457F) within the P-loop domain of pmp-2 that hydrolyzes ATP.  The 
mutated leucine is also conserved between C. elegans and humans, suggesting that loss 
of PMP-2 ATP hydrolysis and substrate transport may form the basis for (Leu)38-GFP 
suppression.  The pmp-2 mutant altered the (Leu)38-GFP expression by causing strong 
diffuse localization of (Leu)38-GFP within muscle.  ubh-4 (dr58) and ubh-4 (dr60) both 
contain the same molecular missense mutation (S6R), although both suppressors were 
isolated independently (Table 3.1).  The mutated serine is not conserved between C. 
elegans and humans and is not within a known catalytic domain, so it is unclear how the 
mutation impacts UBH-4 function.  Both ubh-4 alleles exhibit a wild-type pattern of (Leu)38-
GFP localization.  Taken together, these data suggest that loss of multiple genes 
suppress (Leu)38-GFP toxicity and the mechanisms of suppression are likely to differ due 
to the diverse effects of each mutant on (Leu)38-GFP localization.   
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To determine whether sri-62, pmp-2 and ubh-4 were general or cell-type specific 
suppressors of polyLeu toxicity, I tested whether these mutants also suppressed (Leu)38-
GFP toxicity in GABAergic neurons.  (Leu)90-GFP and GFP were co-expressed in the 
GABAergic neurons of each suppressor, which causes the loss of normal commissures 
in wild-type animals (Figure 3.8).  We asked whether or not commissure morphology was 
restored in each of the suppressor mutants.  In ubh-4 (dr60), animals had wild-type 
commissures, suggesting suppression of (Leu)90-GFP toxicity in GABAergic neurons 
(Figure 3.8).  Both pmp-2 (dr59) and sri-62 (dr57) had commissure defects similar or 
worse to the wild-type control, suggesting they were unable to suppress commissure 
defects (Figure 3.8).  These data suggest that sri-62 and pmp-2 are only required for 
polyLeu toxicity in muscle, while ubh-4 is required for polyLeu toxicity in multiple tissues.  
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Figure 3.6 Multiple Types of PolyLeu Suppressors Identified in Mutagenesis 
Screen 
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(A) Diagram of ENU mutagenesis screen for suppressors of larval arrest caused by myo-
3p::(Leu)38-GFP toxicity.  myo-3p::(Leu)38-GFP animals were treated with ENU 
mutagenesis  and the F2 generation was raised on gfp(RNAi) at 20°C to suppress 
polyLeu toxicity.  Plates with the F2 population were allowed to starve and a subset of the 
starved larvae (F2-F4) were washed onto a new OP50 plate and placed at 25°C.  Animals 
that were able to propagate for several generations had suppressed polyLeu toxicity and 
one suppressor was isolated from each plate.  (B) The worms were sorted through the 
COPAS Biosorter and animals with a time of flight ≥ 300 were categorized as adults, 
animals with a time of flight <300 were categorized as larvae.  (C) The average RFP 
levels of the worm were measured by dividing the total RFP signal of a worm by its time 
of flight (N=211-523).  (D) Representative images of the different localization patterns 
observed in suppressors.  V points to vulval muscles.  Scale Bar=10 μm. 
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Figure 3.7 Diagram of Workflow to Identify Genes Required for PolyLeu Toxicity 
Twenty-five suppressors were isolated from a forward mutagenesis screen.  Whole-
genome sequencing of suppressors identified 914 genes containing a nonsynonymous 
substitution or insertion/deletion in at least one isolated suppressor.  A subset of genes 
were identified that: were mutated in multiple suppressors, had at least one nonsense 
mutation, or were part of an overrepresented protein family.  The Ahringer RNAi library 
or the ORFeome RNAi library were then checked to determine if they contained RNAi 
clones for the subset of genes.  Genes with RNAi clones in the Ahringer/Orfeome 
libraries were used in a candidate RNAi screen.  Growth was the selection criteria.  
Starvation-synchronized L1’s were seeded onto RNAi plates (2 plates/RNAi strain) and 
grown at 25°C.  After 1 week, the plates were scored blindly for growing and moving 
larvae.  The hits from the first RNAi screen were tested again in a second RNAi screen 
(3 plates/RNAi strain).  RNAi targets that suppressed polyLeu toxicity in 3/5 plates were 
counted as suppressors.  The ENU-induced mutations in the RNAi-confirmed candidate 
genes were reexamined to determine if duplicated mutations caused similar 
characteristics (strength of polyLeu suppression and localization of polyLeu-GFP).  
Genes were considered strong candidates if the ENU mutants had similar phenotypes 
and RNAi against the gene suppressed polyLeu toxicity.   
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Table 3.1 RNAi Phenocopied Genes Identified from the Candidate RNAi Screen 
Gene Human Homologue Group Suppressors with Mutations Mutation 
F35A5.1 NEFH Neurofilament 
dr57, dr60, dr61, dr62, dr59, dr63, 
dr64, dr65, dr67, dr68, dr69, dr71, 
dr73, dr74, dr75 
E1257K 
T28A11.17 None Unknown dr59, dr61, dr64  V87M 
sri-62 None Receptor dr57 Q85* 
ubh-4 UCHL5 Ubiquitin dr58, dr60 S6R 
pmp-2 ABCD3 ABC transporter dr59 L457F 
 
 
 
Table 3.2 (Leu)38-GFP Suppressors with Mutations in RNAi Phenocopied Genes 
Suppressor Suppression  Potential Gene             (Allele Effect) Gene Family myo-3p::(Leu)38-GFP Localization 
dr57 Strong  sri-62 (Q85*) Receptor Whole Animal 
dr59 Strong pmp-2 (L457F) ABC Transporter Strong Diffuse Signal in Muscle 
dr60 Strong ubh-4 (S6R) Ubiquitin Ligase Unchanged 
dr58 Strong ubh-4 (S6R) Ubiquitin Ligase Unchanged 
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Figure 3.8 dr60 Suppresses PolyLeu Toxicity in GABAergic Neurons 
Representative images of the indicated suppressors with the starting line as a control.  V 
points to the commissures in the image.  The green punctate signal in control/dr55/dr53 
is autofluorescence.  Animals had extrachromosomal expression of unc-47p::(Leu)90-
GFP and unc-47p::(GFP) and had myo-3p::(Leu)38-GFP and myo-3p::RFP integrated.  
The animals are day 1 adults maintained on (gfp)RNAi.  Scale Bars=20 μm. 
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3.3 Discussion 
In this study, I investigated the cell biological and pathophysiological properties of 
the newly discovered HD RAN polypeptides.  I found that all of the HD RAN peptides 
formed biophysically defined protein aggregates.  However, only a single HD RAN 
peptide, polyLeu, caused both neuropathological changes and functional defects in the 
tissues that I studied.  Since polyLeu has never before been associated with a disease, 
polyLeu effector mechanisms are unknown.  To identify these mechanisms, I performed 
an unbiased forward genetic screen for suppressors of polyLeu phenotypes.  I identified 
three candidate genes whose inhibition blocks polyLeu toxicity in muscle.  The molecular 
identity of these genes may provide insight into how polyLeu contributes to CAG diseases 
like HD.  Given that my studies represent the first in vivo dissection of CAG-associated 
RAN peptide properties, I will discuss my findings for each RAN peptide individually, with 
a particular focus on how my findings integrate with previous reports of the structure and 
function of each homopolymeric peptide.  
3.3.1  PolyCys and PolySer: Weakly Toxic RAN Products 
 Both polyCys and polySer exhibited similar cell biological and phenotypic effects 
when expressed in C. elegans.  PolyCys and polySer formed aggregates at 38 and 90 
repeats.  They also colocalized when expressed together.  The colocalization of polySer 
and polyCys is not solely due to their polar charge.  Glutamine is also a polar amino acid, 
but polyQ does not colocalize with either polySer or polyCys (Appendix C-Figure 4.2).  A 
possible explanation of the distinct aggregation patterns of polyQ, polySer, and polyCys 
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could be that polySer and polyCys may localize to a different subcellular environment 
than polyQ.  For example, both Cys and Ser [327], but not Gln, are known targets for 
post-translational protein palmitoylation, which anchors proteins to cellular membranes 
[328].  The palmitoylation of Cys residues in another protein, cysteine string protein α, is 
essential for protein aggregation and is associated with the neurodegenerative disease 
adult-onset neuronal ceroid lipofuscinosis [329].  Therefore, post-translational 
modification of polySer and polyCys, but not polyGln, may lead to protein interactions that 
drive protein aggregation in ways that are distinct from polyGln.  Future studies examining 
the post-translational modification state of the polySer and polyCys protein could provide 
insights into these and other potential aggregation mechanisms. 
Another common property of polyCys and polySer is that expression of either 
polypeptide caused weak and inconsistently toxic effects.  GABAergic expression of 
(Cys)37 caused minor structural but not functional defects, whereas GABAergic 
expression of (Ser)38 caused functional defects, but not structural defects.  Muscle 
expression of (Cys)37 caused weak motility defects and larval arrest.  However, muscle 
expression of polySer never caused motility defects or larval arrest.  When expressed on 
their own, polyCys and polySer exhibit little to no phenotypic consequences in C. elegans.  
This was surprising considering a recent study that suggested polySer has significant 
toxicity in a SCA8 murine model, another CAG repeat expansion disease [330].  However, 
this model did not express a pure polySer protein.  Rather, it expressed the CAG 
expanded ATXN8 gene, which is the genetic cause of SCA8.  polySer is one of several 
RAN products translated from the SCA8 CAG repeat.  However, the other possible RAN 
products were not studied.  In the murine model of SCA8, polySer was thought to be toxic 
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because RAN translated polySer colocalized with degenerating brain regions that lacked 
the ATXN8 protein.  However, RAN translation products from different reading frames 
typically occur in the same tissue [12] and can occur in the same cells [6]. Therefore, 
polySer may be acting as a biomarker for RAN translation, and one or more of the other 
CAG RAN products are toxic in neurons.  My studies strongly suggest that polySer alone 
does not cause neurodegeneration in the SCA8 murine model.  However, polySer may 
have synergistic interactions with other RAN peptides that enhance toxicity.  In the future, 
it will be important to test this possibility by co-expressing polySer with each of the other 
RAN products and determining if there is any change in toxicity. 
3.3.2  PolyQ and PolyGln: PolyQ Has Polyglutamine-Independent Toxicity 
The CAG-encoded polyglutamine (polyQ) model and the CAG/CAA-encoded 
polyglutamine (polyGln) models exhibit radically different levels of toxicity.  GABAergic 
expression of (Q)38 caused substantial structural and functional neuronal defects, but 
GABAergic expression of (Gln)38 caused no detectable changes.  Similarly, muscle 
expression of (Q)38 caused extensive motility defects, while muscle expression of (Gln)38 
caused no motility defects.  PolyGln did display length-dependent toxicity, as muscle 
expression of (Gln)90 produced motility defects.  However, disease-relevant lengths of 
polyGln did not cause toxicity, while disease-relevant lengths of polyQ did cause toxicity. 
The disparity between the toxicity of these two models of polyglutamine is 
antithetical to the widely-held belief that polyglutamine is the driving cause of the toxicity 
in HD.  If polyglutamine is the main toxic effect of the CAG repeat, the observed 
differences between the polyQ model and the polyGln model must be due to 
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dissimilarities in the biological properties of the polyglutamine expressed in each model.  
However, the amino acid sequence produced from both models is identical, although both 
lack surrounding genetic context that could significantly enhance or suppress toxicity 
levels.  In addition, the polyglutamine expressed by both polyQ-GFP and polyGln-GFP 
formed aggregates.  Therefore, the difference in toxicity between polyQ and polyGln is 
likely due to the different nucleotide sequences encoding the homopolymer.  The CAG 
repeat in the polyQ model could be toxic through its RNA repeats [331] or possible RAN 
products [12].  Conversely, the mixed CAG/CAA repeat is not toxic through either its RNA 
repeats or possible RAN products.  The CAG/CAA sequence was designed to minimize 
the formation of RNA secondary structures, which are required for RNA toxicity [332] and 
may be required for RAN translation [4].  Therefore, differences in toxicity between polyQ 
and polyGln animals are likely due to the glutamine-independent causes of toxicity in 
polyQ, such as the repetitive CAG RNA or RAN products.  To determine if RAN products 
may be contributing to the toxicity of polyQ, RAN translation could be measured by placing 
GFP in the +1 reading frame or the +2 reading frame of the CAG repeat to detect RAN 
expression of polySer or polyAla, respectively.  In the future, it will be important to re-
examine whether or not existing C. elegans CAG models are producing RAN peptides in 
addition to polyGln.  The presence of such peptides may dramatically alter the use and 
interpretation of studies based on these models. 
Previous studies have found the nucleotide sequence encoding polyglutamine 
affects the toxicity of a ‘polyQ’ model.  In both Drosophila [333] and cell culture [334], a 
CAG-encoded polyglutamine was significantly more toxicity than a CAA-encoded 
polyglutamine.  The difference in toxicity between the CAG repeats and CAA repeats was 
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ascribed to CAG RNA being toxic, as CAG repeats in untranslated regions also cause 
toxicity [331, 333].  CAA repeats do not undergo RAN translation [4] or cause RNA toxicity 
[333], so, the CAA-encoded polyglutamine is comparable to the CAG/CAA-encoded 
polyglutamine used in this study.  However, none of the “untranslated” CAG models have 
been tested for RAN translation.  RAN products may be produced in the RNA toxicity 
models and contribute to their observed phenotypes.   
Widely-used models of ‘polyQ’ diseases, such as the murine R6/2 strain and the 
C. elegans AM141 strain, could also be undergoing RAN translation.  Therefore, these 
‘polyQ’ models may express both polySer and polyAla from the CAG sense RNA strand.  
If the antisense CUG RNA is also transcribed in these models, RAN translation would 
additionally produce polyLeu and polyCys, as well as polyAla in a different genetic 
context.  The possibility of glutamine-independent toxicity occurring in common HD 
models is made clear by the drastic differences in toxicity between my polyQ model and 
polyGln model.  Given the widespread and experimentally proven prevalence of RAN 
translation in several CAG repeat expansion disorders, referring to these diseases as 
‘PolyQ diseases’ may no longer be accurate and our descriptions of these diseases 
should be modified to include our evolving understanding of the role of the RAN peptides 
besides PolyQ.   
3.3.3  PolyAla: A Possible Contributor to CAG Toxicity 
PolyAla may be a strong contributor to CAG repeat toxicity.  In C. elegans, polyAla 
was toxic in both muscle and GABAergic neurons.  Muscle expression of polyAla caused 
strong motility defects, and GABAergic expression of polyAla caused functional, but not 
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structural, defects.  (Ala)38-GFP also formed aggregates when expressed in muscle cells 
of C. elegans.  In humans, expanded polyAla repeats cause aggregation in multiple 
diseases [335].  The aggregation of the polyAla repeats caused the mislocalization of the 
polyAla containing proteins and a concordant loss-of-function phenotype [335].  Since 
polyAla toxicity is mediated by the loss of protein function containing the expanded Ala 
tract, polyAla toxicity has mainly been studied within its native genetic context.  The 
toxicity of a polyAla peptide without genetic context, as was modeled in our study, has 
not been thoroughly studied.  In addition, because the expanded alanine repeats in the 
polyAla diseases are on average shorter than 30 repeats, a pure polyAla peptide had not 
been modeled at an HD relevant length until our work. 
A homopolymeric alanine peptide may be toxic through similar mechanisms as the 
alanine repeat-expansion diseases.  A yeast-two hybrid model found that homopolymeric 
disease-relevant lengths of polyAla self-interact ((Ala)29 and (Ala)28) [336].  It is unknown 
if alanine repeat lengths that normally appear in proteins (5-21 repeats) [337] also interact 
with disease-relevant lengths of alanine repeats.  This could be tested by co-expressing 
(Ala)11 and (Ala)38.  Based on previous research, (Ala)11 should be diffuse in our model, 
while (Ala)38 is known to aggregate in our model.  If the (Ala)11 only aggregates when co-
expressed with (Ala)38, then (Ala)38 may be binding proteins containing similar lengths of 
polyAla repeats.  PolyAla repeats are enriched in transcription factors [337, 338], which 
need to be localized to the nucleus to perform their function.  Therefore, the interaction of 
the transcription factors containing polyAla repeats with the polyAla aggregates could 
deplete the cell of available transcription factors.  PolyAla aggregates sequestering 
transcription factors could also explain the difference in toxicity observed between muscle 
 130 
cells and GABAergic neurons, as the depleted transcription factors may be less important 
in GABAergic neurons.   
3.3.4  PolyLeu Is the Most Toxic HD RAN Product 
 The most toxic HD RAN product across tissues was polyLeu.  Like polyAla, 
polySer, and polyCys, polyLeu caused functional defects when expressed in GABAergic 
neurons and motility defects when expressed in muscle.  However, polyLeu expression 
caused highly penetrant phenotypes in both muscle and neurons, which were only weakly 
observed in the other RAN models.  GABAergic expression of polyLeu induced significant 
morphological defects where every commissure had some sort of structural impairment.  
Muscle expression of (Leu)38-GFP caused larval arrest of ~90% of the population.   
The strong toxicity of polyLeu was unexpected, as polyLeu repeat expansions 
have not been previously linked to a genetic disease.  This is in spite of polyLeu repeats 
being one of the most common single amino acid repeats in the human proteome, with 
~1,500 proteins containing polyLeu repeats longer than four leucines [337]. However, all 
the naturally occurring polyLeu repeats are 11 leucines or shorter, suggesting there is an 
evolutionary selection against longer polyLeu repeats.  The lack of polyLeu repeat 
expansion diseases could be due to polyLeu repeat expansions disrupting development 
in humans as it does in C. elegans.  In mammalian cells, RAN translation, which produce 
polyLeu, increases activity with activation of the integrated stress response pathway [86, 
89, 90], and the integrated stress response pathway is activated with age [268], so RAN 
translation rates could increase with age.  Another possible reason why polyLeu repeat 
expansions do not typically occur is because polyLeu repeats are not encoded by a 
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nucleotide repeat.  Unlike glutamine, which is encoded by only two codons, leucine is 
encoded by six codons.  However, single amino acid repeats of leucine have an average 
codon homogeneity of 55%, which is more homogenous than the single amino acid 
repeats of alanine (37%) [339]. As polyAlanine can undergo pathogenic repeat 
expansions, it seems likely polyLeu can as well.  Previous work has found that polyLeu 
repeats longer than 30 repeats cause toxicity in cells [340, 341] and in Drosophila [342], 
but all models were created with a CTG repeat that could be undergoing RAN translation. 
My work is the first evidence that a codon-varied pure polyLeu peptide causes significant 
cellular toxicity. 
The toxicity of polyLeu could be due to the apparent membrane-localization of 
polyLeu.  While the expression pattern of polyLeu changes based on the length of the 
leucine repeat, every length of polyLeu appears to be membrane-localized.  This is 
consistent with previous findings that polyLeu peptides as short as nine repeats can 
spontaneously incorporate into lipid membranes [318, 343, 344].  Single amino acid 
repeats of polyLeu occur in many signal peptides or transmembrane proteins [338]. For 
this reason, leucine is the most common amino acid in proteins that localize to the 
Endoplasmic Reticulum (ER), Golgi Apparatus, or vacuoles [345].  Consistent with this, 
(Leu)11-GFP localizes to a tubular network in C. elegans, which resembles previous 
reports of ER [346], and spherical bodies that are ~1.2 µm in diameter, which cluster at 
the distal regions of the muscle cells.  Eleven leucine repeats can act as an anchor signal 
sequence to target proteins to a membrane [344], so the spherical structures may be part 
of the endocytic pathway.  (Leu)20-GFP appears to localize to the plasma membrane and 
smaller membrane-bound compartments, as (Leu)20-GFP marks various structures, some 
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structures similar to the peripheral shape of a C. elegans muscle cell, and other spherical 
and non-spherical structures.  To confirm whether (Leu)20-GFP marks the plasma 
membrane, (Leu)20-GFP should be co-localized with a plasma membrane marker, such 
as glycosylphosphatidylinositol (GPI) [346].  The disease-relevant length of polyLeu, 
(Leu)38-sfGFP, localizes to the boundaries of unidentified spherical structures that are 
distributed throughout the length of the muscle cell and are similar in size to those seen 
with (Leu)11.  The spherical structures containing (Leu)38-sfGFP may also be part of the 
endocytic pathway.  (Leu)38-sfGFP has a diffuse background signal that may be the ER, 
based on the localization pattern of (Leu)11 and the fact that this signal is only detected 
with sfGFP-tagged (Leu)38, as opposed to GFP-tagged (Leu)38.  The oxidizing 
environment of the ER inhibits the folding of GFP, but not the folding of sfGFP, which 
could explain why (Leu)38-GFP had impaired fluorescence.  If the spheres are derived 
directly from the ER, the (Leu)38-sfGFP marked spheres should contain ER-resident 
proteins such as the phosphatidylinositol synthase PISY-1 [347].  
 Longer repeat lengths of polyLeu disrupt the ability of GFP to fold properly.  
(Leu)29-GFP and (Leu)38-GFP have impaired fluorescence due to misfolding of GFP, as 
a variant of GFP with a higher rate of folding [320], sfGFP, did not have impaired 
fluorescence when attached to (Leu)29/38.  There are three possible hypotheses for why 
longer repeat lengths of polyLeu have impaired fluorescence (Figure 3.9), which make 
easily testable predictions.  The first hypothesis for the impaired folding of (Leu)29/38-GFP 
is that longer leucine repeats such as (Leu)29/38 cause a switch in the orientation of 
polyLeu-GFP compared to shorter leucine repeats such as (Leu)11/20.  This orientation 
change causes the C-terminal GFP of (Leu)29/38-GFP to be inside the lumen of the 
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membrane-bound structure, which could be an unfavorable environment for GFP folding.  
Varying the length of a polyLeu repeat in the signal-anchor sequence of a transmembrane 
protein can affect the orientation of the protein in the membrane [348].  In addition, 
membrane-bound organelles such as the ER [321] can suppress GFP fluorescence.  The 
orientation of transmembrane proteins can be studied using glycosylation, which occurs 
in the ER lumen.  Glycosylatable GFP (gGFP) has an N-linked glycosylation site and can 
be used to determine if the GFP is localized in the ER lumen or the cytoplasm [349, 350].  
Cytosol-oriented gGFP will be not be glycosylated and will fluoresce strongly.  However, 
lumen-oriented gGFP will be glycosylated and, thus, will fluoresce weakly [349].  This 
experiment could identify the orientation of (Leu)38-GFP in the membrane. 
The second hypothesis for why (Leu)29/38-GFP displays impaired folding is that 
longer repeats of polyLeu, (Leu)29/38, localize to structures that disrupt GFP folding, while 
shorter repeats of polyLeu, (Leu)11/20, localize to structures that do not disrupt GFP 
folding.  The localization of a protein can be affected by the length of the transmembrane 
domain, as seen with the yeast protein UBC6 localizes to the ER, Golgi, or plasma 
membrane depending on the length of its transmembrane domain [351].  PolyLeu 
exhibited length-dependent localization patterns with (Leu)11 and (Leu)20, so (Leu)29/38 
could also be localized to different cellular regions.  If (Leu)38 does colocalize with the 
shorter lengths of polyLeu, (Leu)38 is most likely to colocalize with (Leu)11 as both (Leu)38-
sfGFP and (Leu)11-GFP localize to spherical cellular structures.  The two lengths of 
polyLeu can be expressed together with different fluorescent tags to determine if they 
colocalize.  Any structures that have (Leu)38 but lack (Leu)11 can be identified using 
fluorescent markers for the different endosomal compartments in C. elegans [346, 347].  
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There are established markers for the ER (KDEL [352]), the Golgi (AMAN-2 [353]), the 
peroxisome (DAF-22 [347]), and other compartments. The identified organelle can be 
studied to determine if its lumen impairs GFP folding. 
The third hypothesis for impaired folding of (Leu)29/38-GFP is that higher repeat 
lengths of polyLeu disrupt the folding environment of the cell, causing a decrease in 
overall protein folding rates including the folding of GFP.  Impaired protein folding occurs 
in other neurodegenerative models, such as a C. elegans (CAG)40-YFP model [130] 
where the (CAG)40-YFP sensitizes the worms to other misfolding mutations.  Like the 
(CAG)40-YFP model, (Leu)38 polypeptides may sequester molecular chaperones away 
from their normal client proteins.  This would deplete the available chaperone levels in 
either the ER or the cytoplasm, depending on the localization of the misfolded proteins, 
and increase the misfolding rate of other proteins in that compartment, such as GFP.  
Impaired folding in the ER causes activation of binding immunoglobin protein (BiP)/hsp-
4 [354, 355].  Therefore, one test of this hypothesis would be to determine if hsp-4 levels 
are increased in cells expressing (Leu)38-GFP.  Similar tests could be used to measure 
impaired protein folding in other compartments, such as the cytoplasm (hsp-16) and the 
mitochondria (hsp-6).  
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Figure 3.9 Possible Models of PolyLeu Length-Dependent Variation in GFP 
Folding 
Model 1: The shorter polyLeu repeats, such (Leu)11, cause the GFP to be oriented in the 
cytosol where it folds properly and fluoresces, while the longer polyLeu repeats, such as 
(Leu)38, cause the GFP to be oriented in the ER lumen where it is unable to fold properly.  
Model 2: The length of the polyLeu repeats varies where polyLeu is targeted.  (Leu)11 is 
targeted to membrane-bound structures where GFP can fold properly and fluoresce, while 
(Leu)38 is localized in different membrane-bound structures that disrupt the folding and 
fluorescence of GFP.  Model 3: both (Leu)11 and (Leu)38 have GFP oriented inside the 
lumen, but GFP folding is impaired in (Leu)38 due to an increase in misfolded proteins 
with (Leu)38.  
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3.3.5  PolyLeu Screen Hits 
A forward mutagenesis screen and subsequent RNAi screen for genes required 
for (Leu)38-GFP-induced larval arrest identified three candidates: sri-62, pmp-2, and ubh-
4.  sri-62 encodes a serpentine seven-transmembrane GPCR, pmp-2 encodes an ABC 
(ATP-binding cassette) transporter, and ubh-4 encodes a deubiquitinating enzyme.   
sri-62 is a nematode-specific gene and is poorly studied.  It encodes a 334 amino 
acid long protein with seven transmembrane domains.  As a serpentine receptor, SRI-62 
is likely a chemoreceptor and is localized to the plasma membrane.  However, both its 
specific function and its cellular localization is unknown.  A study of the expression pattern 
of C. elegans chemoreceptors found sri-62 expression in the PVT interneuron [356].  The 
PVT interneuron is important for the spatial arrangement of neurons and secretes netrin 
to aide neurons in pathfinding [357].  While SRI-62 was not observed in the muscle [356], 
part of the sri-62 promoter may have been excluded in the construct used to study sri-62.  
To develop a more accurate understanding of the expression pattern of sri-62, it will be 
important to determine the native expression pattern using methods such as 
CRISPR/Cas9 tagging of the endogenous sri-62 gene.  SRI-62 is also not likely to be a 
broad suppressor of neurodegenerative proteins, as reduction in levels of sri-62 was 
identified in a previous RNAi screen as an enhancer of tau-induced toxicity in C. elegans 
[358]. In contrast, we identified sri-62(RNAi) as a suppressor of polyLeu toxicity.  
Therefore, how sri-62 is required for toxicity is likely specific to polyLeu. 
Another identified suppressor of polyLeu toxicity, pmp-2, also encodes a 
transmembrane protein.  Also, like sri-62, pmp-2 is not well characterized in C. elegans.  
However, it has a strong human homologue, ABCD3, that has been extensively studied.  
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Both C. elegans PMP-2 and ABCD3 have four transmembrane domains.  PMP-2 likely 
localizes to the peroxisome [359], as ABCD3 is a peroxisomal protein that imports long 
fatty acids and branched acyl-CoA into peroxisomes [360].  It is unclear if ABCD3 is 
primarily translated on cytoplasmic ribosomes or inserted into the ER as ABCD3 has been 
observed in the ER [361], but ABCD3 can also escape targeting to the ER and instead 
be translated by free ribosomes [362]. Mutations in ABCD3 are associated with a 
heterogenous group of peroxisome assembly disorders called Zellweger syndrome [363].  
Peroxisome dysfunction has not been previously linked to HD, so it is unclear how the 
function of PMP-2 is required for polyLeu toxicity.  
Other than the fact that they both encode multi-pass transmembrane proteins and 
are required for polyLeu toxicity, sri-62 and pmp-2 have little in common.  However, 
previous studies on polyLeu provides some suggestions as to how these seemingly 
unrelated proteins may be required for (Leu)38 toxicity.  For example, a (Leu)24 polypeptide 
capped by two lysines on either end is sufficient to inhibit the function of the sarcoplasmic 
reticulum calcium pump (SERCA).  This peptide was based on the SERCA inhibitor, 
phospholambin, which contains a leucine-rich transmembrane domain.  A similarly 
constructed polypeptide with only 18 leucines failed to inhibit SERCA [364].  Other 
research on phospholambin found that the leucine-rich transmembrane domain of 
phospholambin inhibits SERCA by locking SERCA in an unbound confirmation [365].  
Therefore, polyLeu may be toxic in a similar manner as phospholambin by interacting with 
the hydrophobic transmembrane domains of SRI-62 and PMP-2 and disrupting their 
ability to function (Figure 3.8).  Another possibility is that polyLeu is disrupting the folding 
of SRI-62 and PMP-2 in the ER, thereby activating the ER unfolded protein response 
 138 
(UPRER) and potentially driving ER-associated protein degradation (ERAD) of these and 
other substrates (Figure 3.10).  PolyLeu is more likely to be toxic by disrupting protein 
folding than to be toxic by disrupting protein function.  This is because polyLeu would 
need to have precise interactions with proteins to disrupt their function, but not their 
folding.  If polyLeu is toxic through disrupting folding of proteins in the ER, (Leu)38 
expression should cause an increase in misfolded proteins in the ER leading to activation 
of the UPRER.  UPRER activation would upregulate the reporter hsp-4p::GFP [366], as 
hsp-4 is the C. elegans homologue of BiP and is activated by the UPRER [367].   
The final gene identified in the screen, ubh-4, encodes a deubiquitinating enzyme 
that has a human homologue, uchl5.  Reducing protein levels of UBH-4 increases the 
rate of proteasomal degradation [368].  The ubh-4 homologue in humans, uchl5, has been 
previously linked to CAG repeat expansion diseases.  Reducing protein levels of UCHL5 
suppresses the aggregation of an ataxin3-polyQ (CAG) model in mammalian cells, which 
likely also produced polyLeu via RAN translation [368]. Therefore, ubh-4/uchl5 may have 
conserved effects on polyLeu toxicity.  Decreased levels of UBH-4 may suppress polyLeu 
toxicity through enhanced proteasomal degradation of the misfolded transmembrane 
proteins, if polyLeu causes toxicity by increasing misfolding of transmembrane proteins 
(Figure 3.10).  Additional studies will be needed to test this model.   
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Figure 3.10 Model of PolyLeu Toxicity Through Causing Misfolding in ER 
PolyLeu may be toxic by disrupting the folding of transmembrane-domain containing 
proteins such as PMP-2 and SRI-62.  This increase in misfolded proteins would deplete 
the ER of chaperones and make GFP more likely to misfold, as the ER is already an 
unfavorable folding environment for GFP.  The deletion mutant of sri-62 would decrease 
the amount of misfolded proteins in the ER, as SRI-62 no longer needs to fold correctly.  
The pmp-2 mutation may stabilize PMP-2 folding or cause degradation of PMP-2, either 
way causing a decrease in the total amount of misfolded proteins in the ER.  Knockdown 
of ubh-4 causes activation of the proteasome, so mutations in ubh-4 may disrupt UBH-4 
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activity so that the activity of the proteasome is increased.  This would increase the 
degradation of proteins and prevent UPR activation. 
3.3.6  Limitations of Model  
 Our C. elegans HD RAN model offers a simplified view of the various HD RAN 
products, which is advantageous for developing a basic understanding of how each HD 
RAN product may contribute to HD.  However, our model lacks several key pieces of 
information required for a more nuanced understanding of HD RAN toxicity.  In our 
system, each of the HD RAN products are modeled individually without genetic context.  
Therefore, we cannot comment on how the HD RAN products interact with each other.  It 
is likely that RAN products are co-expressed in HD since RAN translation occurs in 
multiple reading frames in the same cell in other RAN diseases [96].  The RAN products 
may act synergistically when co-expressed.  Given that polyAla, polySer, polyCys, and 
polyGln all formed aggregates, it is reasonable to predict that co-expression of two or 
more polypeptides may overwhelm the chaperone capacity of the cell and activate 
relevant unfolded protein response pathways in the cytoplasm and/or the ER.  Since 
polyLeu may cause activation of UPRER, it is easy to see how the HD RAN polypeptides 
could act synergistically.  To test these models, the individual HD RAN polypeptides need 
to be co-expressed to determine how the RAN polypeptides are toxic together, not just 
on their own.   
 Another limitation of our model is that the HD RAN peptides lack the surrounding 
genetic context that is present in the HTT gene.  Previous work modeling CAG repeats in 
various forms of HTT found that certain genetic contexts could greatly increase the CAG 
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repeat toxicity in mice [369].  With regards to HD RAN translation, the precise translation 
initiation and termination sites for the various peptides have not yet been described.  Work 
modeling RAN translation of the Fragile X CGG repeat expansion suggests that RAN 
translation can initiate using near-cognate start codons, which only have one nucleotide 
different from a start codon [87].  Therefore, new HD RAN models initiating from near-
cognate start codons in-frame with the repeat expansions and extending to stop codons 
downstream of the repeat could prove informative.  This would be particularly interesting 
for polyLeu, as the amino acids on either side of a polyLeu repeat affect the orientation 
of the polyLeu within a plasma membrane.  
 The main limitation of our model is also the main advantage; C. elegans are not 
mammals.  C. elegans allow for rapid discovery of genetic pathways required for toxicity.  
However, the evolutionary conservation of these pathways needs to be confirmed in 
either mammalian cells or mice.  Therefore, a key experiment that needs to be performed 
is confirming that the HD polypeptides exhibit similar toxicity in both C. elegans and 
mammalian cells.  Previous work by our lab has shown that pathways regulating the 
toxicity of C9orf72 RAN peptides are highly conserved from C. elegans to mammals.  
Therefore, it seems likely that the pathways regulating the toxicity of HD RAN peptides 
will also be conserved.  Experimental testing of this prediction should be a high future 
priority. 
3.3.7  Conclusion 
 RAN translation has been confirmed to occur in four different CAG/CTG repeat 
expansion neurodegenerative diseases, but this is the first work to examine the individual 
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RAN polypeptides at a disease-relevant length.  It has been 26 years since the discovery 
of the genetic cause of HD in 1993, and soon people with an HD CAG repeat expansion 
born in the same year of the discovery of the HTT CAG repeat expansion could be 
exhibiting HD symptoms.  Treatments need to be found for these patients.  Developing a 
more complete picture of the mechanisms underlying mHTT CAG toxicity is a vital part of 
that goal.  Current treatment methods are focusing on knocking down levels of the sense 
strand of HTT RNA.  However, polyLeu is produced from the antisense strand of mHTT.  
Therefore, suppression of only the sense strand and sense strand RAN peptides, 
including polyQ, may not be sufficient to protect these patients from developing HD. 
 Every HD RAN polypeptide, except for polyGln, exhibited toxicity in the C. elegans 
RAN model when expressed at a disease-relevant repeat length.  PolySer, polyCys, 
polyAla, and polyGln all formed aggregates.  PolyLeu caused strong toxicity in both motor 
neurons and in muscle cells where it caused larval arrest.  A forward mutagenesis screen 
and RNAi screen, along with impaired GFP fluorescence data, suggest that polyLeu may 
be toxic through disrupting folding of transmembrane proteins in the ER and activating 
ERAD and the UPRER.  This is consistent with previous “polyQ” models where activation 
of ERAD was the first stress response detected [370-372].  It was proposed that the 
activation of ERAD was due to ERAD proteins which were detected in polyQ aggregates.  
As HTT is produced in the cytoplasm, it has puzzled researchers why it would cause a 
strong activation of ERAD.  One possible explanation is that another RAN peptide, 
polyLeu, leads to ERAD activation.  Additional studies will help to unravel the potential 
significance of polyLeu and other previously unknown HD RAN peptides. 
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3.4 Methods 
Caenorhabditis elegans strains and culture 
Strains were grown on standard NGM media with gfp(RNAi) bacteria at 20°C until 
the generation before the experiment.  Animals were picked at the L4 staged and shifted 
to E.  coli OP50 and allowed to have progeny at 20°C.  The progeny were picked as L4s, 
kept on E.  coli OP50 and grown at 25°C.  All experiments were performed at 25°C.   
 
Molecular Biology and Transgenics 
Codon-varied sequences were synthesized for the 90 repeat polypeptides 
(Integrated DNA Technologies, Coralville, Iowa, USA).  38 repeat polypeptides were 
made using “building blocks” which were nucleotide codon-varied sequences for 11 
repeats that were synthesized (GeneWiz, South Plainfield, NJ, USA).  The “building 
blocks” could be added to each other by digesting the vector containing a building block 
with BsmbI and an insert containing a building block with BsaI as previously described 
[373].  The nucleotide sequences used for the HD polypeptides are listed in Appendix D 
(Table 4.3) Promoters were produced and cloned in as previously described [95].   
Transgenic worms were generated by injecting the DPR construct (20 ng/µl) and 
the myo-3p::mCherry pCFJ104 marker plasmid (100 ng/µl) into the gonad of wild-type 
animals.  Transgenes were integrated using a standard gamma ray (Cs137) mutagenesis, 
followed by selection of animals exhibiting 100% transmission of the mCherry marker.  
Integrated strains were outcrossed six times to wild-type animals.  Injected animals were 
maintained on gfp(RNAi) plates until the experimental assay was performed.  All 
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procedures involving recombinant or synthetic nucleic acid molecules and materials were 
approved by the University of Pittsburgh Institutional Biosafety Committee.   
 
Reversal Assays 
Animals were maintained on gfp(RNAi) at 20°C, until the generation before the 
experiment.  Animals were selected as L4s and placed on E. coli OP50 at 20°C to have 
progeny.  30-40 progeny were picked as L4 animals and moved to 25°C on E. coli OP50 
bacteria.  24 hours later, the progeny were tested for their ability to reverse (N=20 
worms/assay).  All assays were done blinded.  Animals were lightly tapped on the head 
with a platinum pick.  They were scored from 1-4 on their ability to reverse as previously 
described [374].  Each worm was scored 5 consecutive times, as wild-type worms began 
to acclimate to the head tapping at 7 consecutive times.   
 
Commissure Assays 
L4 animals of the indicated genotype were isolated at 25°C and imaged 24 hours 
later as ‘Day 1 adults’.  All of the strains contained an unc-47p::RFP marker to reveal 
GABAergic motor neuron morphology.  Animals were anesthetized in 10 mM levamisole 
and Z-series images of GABAergic commissures were collected.  Commissure breaks 
were identified as interruptions in the RFP signal surrounded by dorsal and ventral RFP 
in the commissures.  Blebbing was scored only in the commissures and was identified by 
the presence of one or more RFP varicosities.  Abnormal commissures were identified as 
those exhibiting branching and/or failing to reach the dorsal side of the animal. 
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Microscopy 
C. elegans were anesthetized in 10 mM levamisole for 10 minutes.  The animals 
were then picked onto 3% agarose pads for fluorescence microscopy.  Widefield images 
were collected on a Leica DMi4000 inverted microscope and a Leica DFC 340x digital 
camera (Leica Microsystems, Wetzlar, Germany).  Z-stack images were deconvolved 
using Leica AF6000 software. 
 
COPAS Experiments 
Animals grown at 20°C on (gfp)RNAi were placed on E. coli OP50 for 6 hours to 
collect a synchronized brood.  The adults were then removed and the plates were placed 
at 25°C.  48 hours later, the progeny were sorted through a COPAS Biosorter (Union 
Biometrica, Holliston, MA, USA).  Worm time of flight (TOF) was measured.  Animals with 
a TOF≥300 were counted as adults, based on previous experiments.  Animals with a TOF 
below 300 were counted as larvae.  For fluorescent measurements (GFP or RFP) 
fluorescent detection settings were identical for all samples.  Average fluorescence was 
measured as total fluorescence divided by the time of flight.  
 
Paralysis Assays  
Gravid animals were moved from gfp(RNAi) to E. coli OP50 and allowed to lay 
eggs for 24 hours at 20°C.  The resulting progeny were allowed to grow up on E. coli 
OP50, permitting RAN peptide accumulation.  Animals were picked as L4s and ten 
animals were placed on each of five plates (N=50 worms per assay).  Each day, animals 
that failed to move at least half a body length in response to manual stimulation with a 
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platinum wire but were still alive (pharyngeal pumping, movement of less than half a body 
length) were scored as paralyzed.  Animals that died, desiccated on the plate edges, or 
exhibited internal hatching of progeny were censored from the assay.  Each day, mobile 
animals were transferred to a new plate and paralyzed, dead, and censored animals were 
removed from the assay.   
 
Thrashing Assays 
Gravid animals were moved from gfp(RNAi) to E. coli OP50 and allowed to lay 
eggs for 24 hours at 20°C.  The resulting progeny were allowed to grow up on E. coli 
OP50, permitting polypeptide accumulation.  40 transgenic animals for each strain were 
picked as L4s and moved to an E. coli OP50 plate and placed at 25°C.  The following 
day, worms were placed on clean NGM plates and allowed to move freely for 10 minutes 
so that most of the bacteria came off the animal before the experiment.  Worms were 
placed individually into 3 cm petri dishes containing M9 buffer and allowed to adjust to 
the new environment for 5 minutes.  The worms were observed for 30 seconds and the 
number of thrashes (reversal of body bend that crosses the midline) was counted. 
 
Lifespan Assays  
Worms grown at 20°C were picked as L4 and allowed to grow at 20°C until the 
next day, when 10 young adults were placed on five 3 cm plates.  Lifespan assays were 
performed with E. coli OP50 spotted on NGM plates at 25°C.  Worms were classified as 
alive, dead (no movement in response to touch with a wire), or censored (lost or bagged 
worms) once per day for lifespan assays.   
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FRAP Microscopy 
Confocal fluorescence images were captured on a Nikon A1plus confocal 
microscope through an Apo 60x/ 1.4NA Oil objective lens.  The microscope was operated 
on the NIS-Elements AR version 5.02 software platform.  GFP or RFP were excited at 
488 or 561, respectively.  Images were captured every 11 seconds to avoid bleaching 
over the course of imaging.  Following imaging of baseline fluorescence, a region of 
interest corresponding to a portion of the puncta was photobleached and fluorescence 
recovery within the photobleached area was monitored over at least 60 seconds.  Data 
were normalized so that the image preceding the photobleach was set to 100% and the 
first image following the photobleach was set to zero percent.  Imaging conditions over 
the time course of the experiment caused minimal loss of signal, suggesting an absence 
of photobleaching during the monitoring period.  FRAP analysis was performed using Fiji 
software [375].  X-y drift was corrected using the “Correct 3d Drift” plugin [376]. 
 
ENU Suppressor Screen 
myo-3p::(Leu)38-GFP L4s were placed in 2.4mM ENU and then gently shaken for 
4 hours at room temperature.  The worms are then washed 5x with M9 and allowed to 
recover for 24 hours on NGM plates.  After 24 hours, gravid P0s were picked and allowed 
to lay progeny on (gfp)RNAi plates for 6 hours.  The P0s were then removed and the 
plates with the eggs were placed at 20°C.  After a week, the starved progeny were washed 
onto E. coli OP50 and placed at 25°C.  After a week, the worms still growing at 25°C were 
picked as possible candidates.  To ensure independence of alleles, only one candidate 
 148 
was selected per plate.  The picked worms were allowed to propagate at 25°C.  Worms 
that continued to propagate and had detectable RFP under the microscope were picked 
as suppressors. 
 
Whole-Genome Sequencing 
Genomic DNA was isolated from each of the suppressor lines using the PureGene 
Core Kit A according to the manufacturer’s instructions.  Genomic DNA libraries were 
prepared by BGI Genomics (Cambridge, MA USA) using Next-Generation Sequencing 
(HiSeq Xten).  Deep sequencing reads were analyzed using Galaxy (usegalaxy.org).  
Both snps and indels were isolated as described in Appendix E.  Only homozygous 
snps/indel which did not occur in the starting strain and were within genes were 
considered as possible causative mutations.   
 
RNAi Screen 
Bacteria were grown from the Ahringer or Orfeome library for the screen.  Bacteria 
were seeded on (RNAi) NGM in 10cm petri dishes and allowed to grow for 3 days at room 
temperature.  myo-3p::(Leu)38-GFP animals were bleached as previously described [377], 
onto a clean NGM plate and left for 18 hours at 20°C so the progeny would synchronize 
by arresting as L1s.  The progeny were washed off the plate with M9 media, and rinsed 
2-3 times with M9 media to remove dauer pheromones.  ~30 L1 animals were seeded 
onto each plate.  The plates were placed at 25°C and left for 1 week and then blindly 
scored based on the presence or absence of moving larvae. 
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Statistical Analysis 
Comparison of means were analyzed with ANOVA using Dunn’s post-test analysis 
in GraphPadPrism 7 (Graphpad Software, Inc., LaJolla, CA, USA).  The plateau was 
measured using one phase association in GraphPadPrism 7. 
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4.0 HD/ALS RAN Models Summary 
We have created and characterized two different RAN peptide models, one for 
ALS-associated GGGGCC repeat expansion, and one for HD-associated CAG repeat 
expansions.  The most toxic ALS associated dipeptides are PR and GR which localize to 
phase-separated compartments such as the nucleolus.  The most toxic HD polypeptide 
is polyLeu, which interacts with membranes.  While initially the mechanism of toxicity for 
these two different RAN products appears distinct, there may be similarities.  An RNAi 
screen for genetic suppressors of PR toxicity identified multiple genes whose products 
likely phase separate, based on the prevalence of low complexity domains.  However, 
proteins in the ubiquitin-proteasome pathway were also identified.  PR appears to be toxic 
through its localization to phase-separated compartments and its interactions with the 
proteins localized there.  Similarly, polyLeu may be toxic by localizing to lipid membranes 
and either inhibiting folding of proteins with transmembrane domains, or inhibiting the 
function of the transmembrane domains.  An unbiased screen in polyLeu identified a 
regulator of ubiquitin-mediated protein degradation (ubh-4) as required for polyLeu 
toxicity.  ubh-4 expression can modify proteasome activity, suggesting that the 
proteasome may be important for suppressing polyLeu toxicity.  Therefore, the cellular 
dysfunction caused by PR/GR and polyLeu may be due to their disruption of cellular 
compartments.  The unbiased screens performed in the C. elegans ALS RAN model and 
the C. elegans HD RAN model have yielded molecular regulations of toxicity in both 
diseases. 
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Appendix A - Abbreviations Table 
ABC transporter ATP-binding cassette transporter 
ALS Amyotrophic Lateral Sclerosis 
C cytosine 
C9 Chromosome 9 open reading frame 72 
C9orf72 Chromosome 9 open reading frame 72 
C. elegans Caenorhabditis elegans 
CCD Cleidocranial dysplasia 
CCHS Congenital central hypoventilation 
Cftr cystic fibrosis transmembrane conductance regulator 
DM1 myotonic dystrophy type 1 
DM myotonic dystrophy type 2 
DMPK DM1 protein kinase 
DRPLA dentatorubral-pallidoluysian atrophy 
DPR dipeptide repeat 
E. coli Escherichia coli 
EGFR epidermal growth-factor receptor 
EMS ethyl methanesulfonate 
ENU N-ethyl-N-nitrosourea 
EPM1 Myoclonus progressive epilepsy of Unverricht and Lundborg 
ER endoplasmic reticulum 
FECD Fuchs endothelial corneal dystrophy 
FMR1 fragile X mental retardation 1 
FMR2 Fragile XE syndrome mental retardation 
FRAP  fluorescent recovery after photobleaching 
FTDA Friedreich ataxia 
FTD  frontotemporal dementia 
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FXS  fragile X syndrome 
FXTAS  fragile X-associated tremor/ataxia syndrome 
G guanine 
G4C2 GGGGCC 
GABA γ-aminobutryic acid 
gGFP glycosylatable GFP 
GP glycine-proline 
GPCR G-protein-coupled receptor 
GPI glycosylphosphatidylinositol 
GR glycine-arginine 
HD Huntington’s disease 
HDAC  histone deacetylase 
HDL2 Huntington disease-like 2 
HFG Hand-foot-genital syndrome 
HPE5 Holoprosencephaly 5 
HTT huntingtin 
IR Insulin receptor 
JHD Juvenile Huntington’s disease 
mHTT mutant huntingtin 
MRGH mental retardation, growth hormone deficiency 
N.S. not significant 
NES nuclear exit signal 
NLS nuclear localizaiton signal 
NDD neurodegenerative disease 
OPMD oculopharyngeal muscular dystrophy 
PA proline-alanine 
polyQ  polyGlutamine (encoded by CAG repeats) 
polyAla polyAlanine 
polyCys polyCysteine 
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polyGln polyGlutamine (encoded by codon-varied repeats) 
polyLeu polyLeucine 
polySer polySerine 
PR proline-arginine 
pre-mRNA precursor messenger RNA 
RAN  Repeat-Associated non-AUG Translation 
ROS reactive oxygen species 
SBMA spinal-bulbar muscular atrophy 
SCA8 spinocerebellar ataxia type 8 
SCA17 spinocerebellar ataxia type 17 
sfGFP superfolded GFP 
SOD1 superoxide dismutase 1 
SPD syndactyly 
UTR untranslated region 
VNC ventral nerve cord 
WGS Whole-Genome Sequencing 
XLMR X-linked mental retardation 
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Appendix B – Repeat Expansion Diseases   
Table 4.1 List of All Known Repeat Expansion Diseases  
Disease Repeat Repeat Location Encode 
Suspected 
Mechanism of 
Toxicity 
RAN 
Translation 
Age 
Onset NDD? 
ALS/FTD GGGGCC Intron -- RAN/RNA GOF Yes Yes Yes 
SBMA CAG Exon PolyQ Protein GOF ? Yes Yes 
SCA1 CAG Exon PolyQ Protein GOF ? Yes Yes 
SCA2 CAG Exon PolyQ Protein GOF ? Yes Yes 
SCA3 CAG Exon PolyQ Protein GOF ? Yes Yes 
SCA6 CAG Exon PolyQ Protein GOF ? Yes Yes 
SCA7 CAG Exon PolyQ Protein GOF ? Yes Yes 
SCA8 CTG/CAG UTR/Exon PolyQ 
RNA 
GOF/Protein 
GOF 
Yes Yes Yes 
HD CAG Exon PolyQ Protein GOF Yes Yes Yes 
HDL2 CTG UTR -- RNA GOF ? Yes Yes 
SCA12 CAG UTR -- Unk. ? Yes Yes 
SCA17 CAG Exon PolyQ Protein GOF ? Yes Yes 
DRPLA CAG Exon PolyQ Protein GOF ? Yes Yes 
DM1 CTG UTR -- RNA GOF Yes Yes Yes 
DM2 CTG/CCTG Intron -- RNA GOF Yes Yes Yes 
FXTAS CGG UTR -- RAN GOF Yes Yes Yes 
SCA31 TGGAA Intron -- RAN GOF/RNA GOF Yes Yes Yes 
FRDA GAA Intron -- LOF ? Yes Yes 
SCA10 ATTCT Intron -- RNA GOF ? Yes Yes 
EPM1 CCCCGCCCCGCG Promoter -- LOF ? Yes Yes 
OPMD GCG Exon polyAla Protein GOF* ? Yes No 
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Table 4.1 (continued) 
FECD CTG Intron -- RNA GOF Yes Yes No 
FMR1 CGG UTR -- LOF ? No No 
FMR1 CGG UTR -- LOF ? No No 
XLMR GCG Exon polyAla LOF* ? No No 
SPD GCG Exon polyAla protein GOF* ? No No 
CCD GCG Exon polyAla LOF* ? No No 
HPE5 GCG Exon polyAla LOF* ? No No 
HFG GCG Exon polyAla LOF* ? No No 
FOXL2 
(BPES) GCG Exon polyAla LOF* ? No No 
Multiple 
Skeletal 
Dysplasia 
GAC Exon polyAla LOF ? No No 
FRAXA CGG UTR -- LOF ? No No 
FRAXE CCG UTR  LOF ? No No 
FRA11b 
Jacobsen 
syndrome 
CCG UTR -- DNA GOF ? No No 
CCHS GCN Exon polyAla Unk.* ? No No 
MRGH GCN Exon polyAla LOF, polyAla ? No No 
 
*=Other mutations in the same gene cause the same disease. 
-- = Does not undergo canonical translation.   
GOF=gain of function.  LOF=loss of function.  NDD=Neurodegenerative Disease 
Unk.= Unknown 
ALS=amyotrophic lateral sclerosis.  CCD=Cleidocranial dysplasia.  CCHS=Congenital 
Central Hypoventilation.  FTD=frontotemporal dementia.  HD=Huntington’s disease.  
HDL2=Huntington disease-like 2.  DM1=Myotonic Dystrophy Type 1.  DM2=Myotonic 
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Dystrophy Type 2.  DRPLA=Dentatorubral-Pallidoluysian Atrophy.  EPM1=Myoclonus 
Progressive Epilepsy of Unverricht and Lundborg.  FECD=Fuchs endothelial corneal 
dystrophy.  FMR1=Fragile X Syndrome of mental retardation.  FMR2=Fragile XE 
syndrome Mental retardation.  FRDA=Friedreich Ataxia.  FXTAS=Fragile X-Associated 
Tremor/Ataxia Syndrome.  HFG=Hand-foot-genital syndrome.  
HPE5=Holoprosencephaly 5.  MRGH=Mental retardation, growth hormone deficiency.  
OPMD=Oculopharyngeal Muscular Dystrophy.  SBMA=spinal-bulbar muscular atrophy.  
SCA=spinocerebellar ataxia.  SPD=Syndactyly.  XLMR=X-linked mental retardation. 
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Appendix C – Colocalization Data 
 
 
Figure 4.1 PolySer and PolyCys Colocalize 
Day 1 adult animals grown at 20°C.  Animals express myo-3p::(Ser)90-RFP and myo-
3p::(Cys)90-GFP.  PolySer and PolyCys exhibited strong colocalization.  Immobilized in 
levamisole and imaged using a Leica DMI8 confocal microscope at the University of 
Pittsburgh Center for Biologic Imaging.  Size bar is 20 µm. 
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Figure 4.2 PolySer and PolyCys Do Not Colocalize with PolyQ 
Day 1 adult animals grown at 20°C.  AM141 animals (integrated with unc-54p::(Q)40-YFP) 
express extrachromosomal myo-3p::(Ser)90-RFP, myo-3p::(Cys)90-RFP, or myo-
3p::(Gln)90-RFP.  Codon-varied (Gln)90 colocalizes with the CAG-repeat derived (Q)40.  
Both (Ser)90 and (Cys)90 fail to colocalize with (Q)40.  The animals were immobilized in 
levamisole and imaged using a Leica DMI4000 inverted microscope and a Leica DFC 
340Fx digital camera (Leica Microsystems, Wetzlar, Germany).  The arrow points to 
colocalized signal.  Size bar is 30 µm. 
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Appendix D - Plasmid Sequences 
Table 4.2. Nucleotide Sequences of Codon-Varied DPRs 
 
Red-HindIII and BamHI cloning sites 
  
 Table S3. Nucleotide sequenc s of codon-varied dipeptide sequences used in this study 
(PA)50 
aagcttgggccggccccggctccggcacctgcgcccgctccagcaccggcgcctgctcccgcaccagctcctgcacccgcgcca 
gcacccgctccagcgcctgctcctgcaccggctcccgcgccagcacctgctccggcgcccgcaccagctcctgccccggccccg
gctccggcacctgcgcccgctccagcaccggcgcctgctcccgcaccagctcctgcacccgcgccagcacccgctccagcgcct
gctcctgcaccggctcccgcgccagcacctgctccggcgcccgcaccagctcctgccccgggttggtaccgagctcggatcc 
(GA)50 
aagcttcccggggccggtgccggagcaggcgctggtgcgggcgccggagctggtgcaggcgcgggagccggtgctggcgcag
gagcgggtgcaggcgcgggtgccggagctggcgcaggagcgggtgctggcgccggagcaggtgcgggcgctggggccgggg
ccggtgccggagcaggcgctggtgcgggcgccggagctggtgcaggcgcgggagccggtgctggcgcaggagcgggtgcag
gcgcgggtgccggagctggcgcaggagcgggtgctggcgccggagcaggtgcgggcgctggggccggctggtaccgagctcg
gatcc 
(PR)50 
aagcttggccggccccggccgcgtcctcgcccacgaccgagacctcgtccacgcccgcgacctagaccacggccgcgccctcg
accaagacctcgcccgagaccacgacctcgtccgcgcccaagacctcgaccgcgtccacgccctagaccgcgaccccggccc
cggccgcgtcctcgcccacgaccgagacctcgtccacgcccgcgacctagaccacggccgcgccctcgaccaagacctcgccc
gagaccacgacctcgtccgcgcccaagacctcgaccgcgtccacgccctagaccgcgaccccgggggtaccgagctcggatc
c 
(PR)25 
aagcttccccggccgcgtcctcgcccacgaccgagacctcgtccacgcccgcgacctagaccacggccgcgccctcgaccaag
acctcgcccgagaccacgacctcgtccgcgcccaagacctcgaccgcgtccacgccctagaccgcgaccccgggggtaccgag
ctcggatcc 
(PR)15 
aagcttccgcgccctcgaccaagacctcgcccgagaccacgacctcgtccgcgcccaagacctcgaccgcgtccacgccctag
accgcgaccccgggggtaccgagctcggatcc 
(PR)5 
aagcttccgcgtccacgccctagaccgcgaccccgggggtaccgagctcggatcc 
(GR)50 
aagcttgcccggggccggggccgtggtcgcggacgaggcagaggtcgtggacgcggccgaggtagaggacgtggccgcggt
cgaggaagaggtcgcggcagaggacgaggtcgtggccgcggaagaggtcgaggccgtggacgcggtagaggccgaggccg
gggccggggccgtggtcgcggacgaggcagaggtcgtggacgcggccgaggtagaggacgtggccgcggtcgaggaagag
gtcgcggcagaggacgaggtcgtggccgcggaagaggtcgaggccgtggacgcggtagaggccgaggccggcggtaccgag
ctcggatcc 
 
Red – HindIII and BamHI cloning sites 
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Table 4.3 Nucleotide Sequences of Codon-Varied HD RAN Polypeptides 
(Ala)38 
aagcttcgggtctcagcagccgcagcggccgcagcagccgcggcagccgcagcggccgcagcagccgcggca
gccgcagcggccgcagcagccgcggcagccgcagcggccgcagcagccgcggcagcgagacggatcc 
(Cys)37 
aagcttcgggtctcatgttgctgttgctgctgttgctgttgttgttgctgttgctgctgttgctgttgttgttgctgttgctgctgttgct
gttgttgttgctgttgctgctgttgctgttgttgtttgagacggatcc 
(Ser)38 
aagcttcgggtctcatcttcctcatcgtcctcatcgtcttcctcttcctcatcgtcctcatcgtcttcctcttcctcatcgtcctcat
cgtcttcctcttcctcatcgtcctcatcgtcttcctctttgagacggatcc 
(Leu)38 
aagcttcgggtctcattattgcttctcctgttacttctcctattattgcttctcctgttacttctcctattattgcttctcctgttacttctc
ctattattgcttctcctgttacttctcctattattgagacggatc 
(Gln)38 
aagcttcgggtctcacagcaacaacagcagcaacagcagcaacagcaacaacagcagcaacagcagcaacag
caacaacagcagcaacagcagcaacagcaacaacagcagcaacagcagcaacagcagagacggatc 
(Q)38 
aagcttcgggtctcacagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcag
cagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagcagagacggatc 
(Leu)11 
aagcttcgggtctcattattgcttctcctgttacttctcctattattgagacggatc 
(Leu)20 
aagcttcgggtctcattattgcttctcctgttacttctcctattattgcttctcctgttacttctcctattattgagacggatc 
(Leu)29 
aagcttcgggtctcattattgcttctcctgttacttctcctattattgcttctcctgttacttctcctattattgcttctcctgttacttctc
ctattattgagacggatc 
(Leu)90 
aagcttttattgcttctcctactgttattgcttctcctactgttattgcttctcctactgttattgcttctcctactgttattgcttctccta
ctgttattgcttctcctactgttattgcttctcctactgttattgcttctcctactgttattgcttctcctactgttattgcttctcctactgtt
attgcttctcctactgttattgcttctcctactgttattgcttctcctactgttattgcttctcctactgttattgcttctcctactgcgga
tc 
(Cys)90 
aagctttgttgctgttgctgctgttgttgctgttgctgttgctgttgctgctgttgttgctgttgctgttgctgttgctgctgttgttgctg
ttgctgttgctgttgctgctgttgttgctgttgctgttgctgttgctgctgttgttgctgttgctgttgctgttgctgctgttgttgctgttg
ctgttgctgttgctgctgttgttgctgttgctgttgctgttgctgctgttgttgctgttgctgttgctgttgctgctgttgttgctgttgcc
ggatc 
(Ser)90 
aagctttcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcg
tcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcct
catcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgtcttcctcatcgt
cttcccggatc 
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Table 4.3 (continued) 
(Gln)90 
aagcttcaacagcagcaacaacagcaacagcagcaacagcaacaacagcaacagcagcaacagcaacaaca
gcagcaacaacagcaacagcagcaacagcaacaacagcaacagcagcaacagcaacaacagcagcaacaa
cagcaacagcagcaacagcaacaacagcaacagcagcaacagcaacaacagcagcaacaacagcaacagc
agcaacagcaacaacagcaacagcagcaacagcaacagcaacaacagcaacagcagcaacagcaacggat
c 
 
Red-HindIII and BamHI cloning sites 
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Table 4.4 Promoter Sequences and Targeting Sequences  
Myo-3p - FLAG 
aagcttgtttgatgaaaaccaatgaaacaagtgattatagtctctgttttcgttaattttgaattttgcttgataaggctgcaac
aaagatcaggttgacatatattttcagtaatttattttaacctgtactctatcactgccggctataataagttcttgaataaaat
aattttcccgacaaaacatgagtatttctttcgaaaataaaagtgcaggctaattagagattattctgtaattaactgcataa
tttgtcacgtgccatagttttacattccactacgtcatagttcttaaaatactaatctcctgaaaatagaagtaggtgaagaa
agtttaattatcagttctaaaatgacaattgatctttggaatatgttctgaaactaccgatcattgaacagatgctatttgaatg
atatagaattgtatatttgcaatttctgaaacgcgttcttaaaggcacacagattaattcaaaagggtctggccgcaaaaa
ggtttatggtggccgattttgagttttgtgtgtgattgctttttcacaatcagtgttttcaggattatgtgatgaactagatcttcaa
gtttcgttacatttcatatgttttcggaactcacgaagtacatattgggtattgtgctcaaaaaattcagcaatcagcttcgctc
cgctgactttagaacccaaaaaaatagtatggccaaactgactgtgttacgatcatttcaatttttcaatacatatttaagat
ttctaagagtaagaaggtcaaaaactgttctggaatacatatatatttttcaggttacaattagtcaaaaagtgcactgaa
atatacgttttaatttcacgaataacccaattagttcaatgtatttttggtcaaccaacgttaaagtttggcttccaaccaattat
catttctgatcaaccacaatgttttttctttatctgcaagttaattttttatttttatccagatgtttggcatatttttcaattcttcactag
cgcccacttcttgcacttccggcgccctgaatctaatgcatctgttgcaagaattgaaagaccaatcaacacattgttttctt
cacgagatactgaagaaaatgaataaaaacagagaaaaagagccatgtgattagtgacaactgttgctaacagata
ccatagcttggacttggtacgtgatggcaacgtatgggtcaacaaaaatgattgcagagggggtgcaaaacagtcaa
gtcgagaaaatatgaaaaacagaaaacaaagaacagaaaaatgggtttgagagtcagtataatttataaaagaaa
aattgtacatagaaattaaccatttttgtagaagaagttatttttcaagcatcgttaaaaattattcaaagcaccttatttcatat
ttaattttaaacatggttaaatgaacaacacggtgcgcaatcaggaaaacttgaaatctgaaactgttgttgtgatcttcttc
gcaactgttcagatagcactagtgtaatgttaagagtgcgcgaatataatggaatataatggatcacacctcctgccatc
aggtaaacgtctctgttatcacatatttccaactattaaatttttaccttttacagttttacatttttttgaaaaaagtaactttttgtc
ttcaaaatccctgacgaaaatatcaaatattttaatcgagactgcagaggaaccgattgatgatttggaaaatccagcttt
acctgtgtaagaactgaaaagtttcataaccctagggtattcccagttacattccccactggctaacaatagcacccagtt
tttcatcacctttcttcaaatttctcggcgatttgttaaaaacaaaatttgtgtcccttctctgatatctctatgtctctaaacacaa
gttcatcggaaaacgaaggagggtaggtgttggttgggctcccgaagtgaaaatagaagagcaagaatagaatatta
gagagagagtgcagagagggcgggatagctcccgggattccgttttcttcttctttatcttcaacgatgatgtgtgtgcgtg
ttgtatagattctgttgctcccccacaactcgctccgaaggctcaatacaattcaattgatattggaggagagcctaccgg
agtgggaggataagaagaaacataagaagaagaagaagaagaagcatgcttctggtttttgatgctatgaaaacgg
cacaaaaagatgattgaggtcccttttcaataccttctctcatctttcaaatcccattgaaacctaaaacttctcaccacgct
ttaccattgttctccaaaaacttatagcaatgtctataacttttttatctctgaaaagcagtgttccatttttctttttcctattttatttc
aattgtttctcacatttcgtttggattctttgcttgtcaaccagcttcttcttccacttttaccgtctaattttcagggcagggagcc
atcaaacccacgaccactagatccatctagaaATGgattacaaggatgacgacgataagaagctt 
Myo-3p-signal sequence-transmembrane-FLAG 
aagcttgtttgatgaaaaccaatgaaacaagtgattatagtctctgttttcgttaattttgaattttgcttgataaggctgcaac
aaagatcaggttgacatatattttcagtaatttattttaacctgtactctatcactgccggctataataagttcttgaataaaat
aattttcccgacaaaacatgagtatttctttcgaaaataaaagtgcaggctaattagagattattctgtaattaactgcataa
tttgtcacgtgccatagttttacattccactacgtcatagttcttaaaatactaatctcctgaaaatagaagtaggtgaagaa
agtttaattatcagttctaaaatgacaattgatctttggaatatgttctgaaactaccgatcattgaacagatgctatttgaatg
atatagaattgtatatttgcaatttctgaaacgcgttcttaaaggcacacagattaattcaaaagggtctggccgcaaaaa
ggtttatggtggccgattttgagttttgtgtgtgattgctttttcacaatcagtgttttcaggattatgtgatgaactagatcttcaa
gtttcgttacatttcatatgttttcggaactcacgaagtacatattgggtattgtgctcaaaaaattcagcaatcagcttcgctc 
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Table 4.4 (continued)  
cgctgactttagaacccaaaaaaatagtatggccaaactgactgtgttacgatcatttcaatttttcaatacatatttaagat
ttctaagagtaagaaggtcaaaaactgttctggaatacatatatatttttcaggttacaattagtcaaaaagtgcactgaa
atatacgttttaatttcacgaataacccaattagttcaatgtatttttggtcaaccaacgttaaagtttggcttccaaccaattat
catttctgatcaaccacaatgttttttctttatctgcaagttaattttttatttttatccagatgtttggcatatttttcaattcttcactag
cgcccacttcttgcacttccggcgccctgaatctaatgcatctgttgcaagaattgaaagaccaatcaacacattgttttctt
cacgagatactgaagaaaatgaataaaaacagagaaaaagagccatgtgattagtgacaactgttgctaacagata
ccatagcttggacttggtacgtgatggcaacgtatgggtcaacaaaaatgattgcagagggggtgcaaaacagtcaa
gtcgagaaaatatgaaaaacagaaaacaaagaacagaaaaatgggtttgagagtcagtataatttataaaagaaa
aattgtacatagaaattaaccatttttgtagaagaagttatttttcaagcatcgttaaaaattattcaaagcaccttatttcatat
ttaattttaaacatggttaaatgaacaacacggtgcgcaatcaggaaaacttgaaatctgaaactgttgttgtgatcttcttc
gcaactgttcagatagcactagtgtaatgttaagagtgcgcgaatataatggaatataatggatcacacctcctgccatc
aggtaaacgtctctgttatcacatatttccaactattaaatttttaccttttacagttttacatttttttgaaaaaagtaactttttgtc
ttcaaaatccctgacgaaaatatcaaatattttaatcgagactgcagaggaaccgattgatgatttggaaaatccagcttt
acctgtgtaagaactgaaaagtttcataaccctagggtattcccagttacattccccactggctaacaatagcacccagtt
tttcatcacctttcttcaaatttctcggcgatttgttaaaaacaaaatttgtgtcccttctctgatatctctatgtctctaaacacaa
gttcatcggaaaacgaaggagggtaggtgttggttgggctcccgaagtgaaaatagaagagcaagaatagaatatta
gagagagagtgcagagagggcgggatagctcccgggattccgttttcttcttctttatcttcaacgatgatgtgtgtgcgtg
ttgtatagattctgttgctcccccacaactcgctccgaaggctcaatacaattcaattgatattggaggagagcctaccgg
agtgggaggataagaagaaacataagaagaagaagaagaagaagcatgcttctggtttttgatgctatgaaaacgg
cacaaaaagatgattgaggtcccttttcaataccttctctcatctttcaaatcccattgaaacctaaaacttctcaccacgct
ttaccattgttctccaaaaacttatagcaatgtctataacttttttatctctgaaaagcagtgttccatttttctttttcctattttatttc
aattgtttctcacatttcgtttggattctttgcttgtcaaccagcttcttcttccacttttaccgtctaattttcagggcagggagcc
atcaaacccacgaccactagatccatctagaaATGccaccttcaacatcattgctgctcctcgcagcacttcttc
cattcgctttaccagcaagcgattggaagactggagaagtcactccggataatgcaacagtctgggtcagaa
aacataaagattgtcctccacctgtccctgtgctcgcaattgtgctcggagtcattgcgggtatcgtaatcctcg
gaattcttctcttgttgctctggaaattgctcacagtacttcatgatagatccgaggtaccggtagaaaaagatta
caaggatgacgacgataagaagctt 
Myo-3p-GFP-FLAG-his-58 
aagcttgtttgatgaaaaccaatgaaacaagtgattatagtctctgttttcgttaattttgaattttgcttgataaggctgcaac
aaagatcaggttgacatatattttcagtaatttattttaacctgtactctatcactgccggctataataagttcttgaataaaat
aattttcccgacaaaacatgagtatttctttcgaaaataaaagtgcaggctaattagagattattctgtaattaactgcataa
tttgtcacgtgccatagttttacattccactacgtcatagttcttaaaatactaatctcctgaaaatagaagtaggtgaagaa
agtttaattatcagttctaaaatgacaattgatctttggaatatgttctgaaactaccgatcattgaacagatgctatttgaatg
atatagaattgtatatttgcaatttctgaaacgcgttcttaaaggcacacagattaattcaaaagggtctggccgcaaaaa
ggtttatggtggccgattttgagttttgtgtgtgattgctttttcacaatcagtgttttcaggattatgtgatgaactagatcttcaa
gtttcgttacatttcatatgttttcggaactcacgaagtacatattgggtattgtgctcaaaaaattcagcaatcagcttcgctc
cgctgactttagaacccaaaaaaatagtatggccaaactgactgtgttacgatcatttcaatttttcaatacatatttaagat
ttctaagagtaagaaggtcaaaaactgttctggaatacatatatatttttcaggttacaattagtcaaaaagtgcactgaa
atatacgttttaatttcacgaataacccaattagttcaatgtatttttggtcaaccaacgttaaagtttggcttccaaccaattat
catttctgatcaaccacaatgttttttctttatctgcaagttaattttttatttttatccagatgtttggcatatttttcaattcttcactag
cgcccacttcttgcacttccggcgccctgaatctaatgcatctgttgcaagaattgaaagaccaatcaacacattgttttctt
cacgagatactgaagaaaatgaataaaaacagagaaaaagagccatgtgattagtgacaactgttgctaacagata
ccatagcttggacttggtacgtgatggcaacgtatgggtcaacaaaaatgattgcagagggggtgcaaaacagtcaa 
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Table 4.4 (continued) 
gtcgagaaaatatgaaaaacagaaaacaaagaacagaaaaatgggtttgagagtcagtataatttataaaagaaa
aattgtacatagaaattaaccatttttgtagaagaagttatttttcaagcatcgttaaaaattattcaaagcaccttatttcatat
ttaattttaaacatggttaaatgaacaacacggtgcgcaatcaggaaaacttgaaatctgaaactgttgttgtgatcttcttc
gcaactgttcagatagcactagtgtaatgttaagagtgcgcgaatataatggaatataatggatcacacctcctgccatc
aggtaaacgtctctgttatcacatatttccaactattaaatttttaccttttacagttttacatttttttgaaaaaagtaactttttgtc
ttcaaaatccctgacgaaaatatcaaatattttaatcgagactgcagaggaaccgattgatgatttggaaaatccagcttt
acctgtgtaagaactgaaaagtttcataaccctagggtattcccagttacattccccactggctaacaatagcacccagtt
tttcatcacctttcttcaaatttctcggcgatttgttaaaaacaaaatttgtgtcccttctctgatatctctatgtctctaaacacaa
gttcatcggaaaacgaaggagggtaggtgttggttgggctcccgaagtgaaaatagaagagcaagaatagaatatta
gagagagagtgcagagagggcgggatagctcccgggattccgttttcttcttctttatcttcaacgatgatgtgtgtgcgtg
ttgtatagattctgttgctcccccacaactcgctccgaaggctcaatacaattcaattgatattggaggagagcctaccgg
agtgggaggataagaagaaacataagaagaagaagaagaagaagcatgcttctggtttttgatgctatgaaaacgg
cacaaaaagatgattgaggtcccttttcaataccttctctcatctttcaaatcccattgaaacctaaaacttctcaccacgct
ttaccattgttctccaaaaacttatagcaatgtctataacttttttatctctgaaaagcagtgttccatttttctttttcctattttatttc
aattgtttctcacatttcgtttggattctttgcttgtcaaccagcttcttcttccacttttaccgtctaattttcagggcagggagcc
atcaaacccacgaccactagatccatctagaaATGagtaaaggagaagaacttttcactggagttgtcccaattcttgt
tgaattagatggtgatgttaatgggcacaaattttctgtcagtggagagggtgaaggtgatgcaacatacggaaaactta
cccttaaatttatttgcactactggaaaactacctgttccatgggtaagtttaaacatatatatactaactaaccctgattattt
aaattttcagccaacacttgtcactactttctgttatggtgttcaatgcttctcgagatacccagatcatatgaaacggcatg
actttttcaagagtgccatgcccgaaggttatgtacaggaaagaactatatttttcaaagatgacgggaactacaagac
acgtaagtttaaacagttcggtactaactaaccatacatatttaaattttcaggtgctgaagtcaagtttgaaggtgatacc
cttgttaatagaatcgagttaaaaggtattgattttaaagaagatggaaacattcttggacacaaattggaatacaactat
aactcacacaatgtatacatcatggcagacaaacaaaagaatggaatcaaagttgtaagtttaaacatgattttactaa
ctaactaatctgatttaaattttcagaacttcaaaattagacacaacattgaagatggaagcgttcaactagcagaccatt
atcaacaaaatactccaattggcgatggccctgtccttttaccagacaaccattacctgtccacacaatctgccctttcga
aagatcccaacgaaaagagagaccacatggtccttcttgagtttgtaacagctgctgggattacacatggcatggatga
actatacaaagattacaaggatgacgacgataagatgccaccaaagccatctgccaagggagccaagaaggc
cgccaagaccgtcgttgccaagccaaaggacggaaagaagagacgtcatgcccgcaaggaatcgtactc
cgtctacatctaccgtgttctcaagcaagttcacccagacaccggagtctcctccaaggccatgtctatcatga
actccttcgtcaacgatgtattcgaacgcatcgcttcggaagcttcccgtcttgctcattacaacaaacgctcaa
cgatctcatcccgcgaaattcaaaccgctgtccgtttgattctcccaggagaacttgccaagcacgccgtgtct
gagggaaccaaggccgtcaccaagtacacttccagcaagaagctt 
Unc-47p-FLAG 
aagcttcgtgcatcttcaaagatttggtataattatgtagagtgaaaaaatagtggaaaatagataaattttttgaaaatatt
tgggctccatccagagtccatttttccggagtccactcaaatagttttcagaaaaattggacttgaaagatgtagagctttgt
tgcatacagaattagaataattaaaaattgggtagaacattttcttcgtaaattttcagagttaatattggcaaagactgtttg
atttgcacttttgactggaaaaaaaggctatagtccacagaaaactattttccagaaagtttattttttccaaatttttaattgta
caataaagaattaacatgaagatggaaaatgctcaattttcagtaaaaaattacaaaaatatctataaacaagtaaact
actacaactaccaaaaagaatgaaaacaaacaaattggaagtaatgcgaaacaaaaaatgaatgagcgatctgct
gagctctctctctctctctctttccatctttctctctatatcttcatcttttgctagcagccacttttggtgtgaagggtgtagaaga
aagagaaagagagaccgaaacataaagacatagacaacacggtcttcctccacttctatacacactcttctgcttcttct
tctcctgctggctttcaagcaacggacacggccgaaagcagaagccgtgcagaaaaaaagaagaagaagaaaaa 
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Table 4.4 (continued) 
agaaaagagctgtggccacacaaacaaatggatgttgtctctgtagcaatggcggttggctccgcgagagcgccgga
ggggaaattgggagacaaaaagttaatgcacttgacaatacagcgatataattcagatttactgtgacgggaagattgt
tgacatggggaataggaagaatgaagatctcaacgttttcggaacagttgtacgatatgattttccagggtactaaaaca
ttaaaactgtcaaaggggtacagcatgttgtcatcacttcaaacttttcaatgcataaatttcttgtcagatctgatcctctata
cttgaagtttataccgataaaggttttcaacagattttgaagcatttgaatcaggggtgcctgggtaaacctatcatacgaa
actgccaatttgtcctgtgaatcgtatctattaaaacaagactgaaaataactaaacttctacgtcaaaaagttgacaaa
acaactttcttggaaaaaaagctgttgggatcccggaacagtcgaaagtcggtggcaagcgccgaactgctgacggt
ctaaccggggcacaaatcaggggtgagcggcaaacgatttttccggcaaatcggcaaatcggcaaattgccaatatt
gaaatacccggcaaatcggtaaatagccggaattgaaaatttccggcaaactggtaaaccgcaaattgctgatttgcc
gaatttgccgggaagacggcaattgccaaacatattcggcaaattgtggttttgcactttttggaaatttcagaatttcaatc
ggcaaattgtgcacatcctatgaattttcctacatctattttgaaaagtaagcaaattctatgaaaatatctaaagaaaaat
ggaaaaaattttcaaaaaggcacagttttaagtgtttccgtctaataaaaaaatccccctaaacacttccggcaaattgat
gttcggcaaatggcaaatcggaaacttgccgaaaattacagtttccggtaaatcggcaaaccggcaaactgcctgaat
tgaaaagttccgtcaaatcggcaaaccgacaacacccctggcacaaatgatggacatactgaggcaatttgccggttt
tccaattgcaggaaattttcaattccggcagtgtgccgatttgccggaaattttaattcaggcaaattgccgatttcccgattt
cccgatttgccggaaaaaatcgtttgccgcccacccctgggtctgaaccttgattgttacaaaacatttttagctctttggag
aaataaaatgaatctcgtaaaatttaattgacgaggacgatattagctgtctctttagaccaaattcagaaaaaaagaa
agaatacttcccaaatttccggtccctctctcgttttttttgccaataaactcactatagtcgctggttcccccctattcacattta
ttctaccaatccatcagtggaaccagaaaaaagaagagcctttcggtttggagagtagggtctaataatcccccgtgct
cttcaaatcattgtgccaacacacagacacactttatgtgtgctcacacacacacgctatttgaagagcgaagacgacg
acgacgcattcagagctcttttccacgaaatttgctccatctttccacaatctgtctttcctgtgagacgacagcgtcacattt
atttcattacagATGgattacaaggatgacgacgataagaagctt 
 
 
Red – HindIII cloning sites 
Underline – FLAG sequence 
ATG – start codon 
Green – GFP sequence 
Bold italics – Signal sequence-transmembrane domain 
Bold – his-58 sequence 
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Appendix E – Galaxy Workflow 
Workflow and restraints used to extract novel snps and indels from sequencing 
information on Galaxy (https://usegalaxy.org) 
  
1. Input datasets 
a. C. elegans FASTA reference genome 
b. FASTQ forward reads 
c. FASTQ reverse reads 
d. SnpEff database 
 
2. Map with BWA for Illumina 
a. Library is paired-end 
b. Maximum edit distance (aln -n)=0 
c. Fraction of missing alignments given 2% uniform base error rate (aln -
n)=0.04 
d. Maximum number of gap opens (aln -o)=0 
e. Maximum number of gap extensions (aln -e)=-1 
f. Disallow long deletion within 16 bp towards the 3’ end (aln -d) 
g. Disallow insertion/deletion within 5 bp towards the end (aln -i) 
h. Number of first subsequences to take as seed (aln -l)=-1  
i. Maximum edit distance in the seed (aln -k)= 2 
j. Mismatch penalty (aln -M)=3 
k. Gap open penalty (aln -O)=11 
l. Gap extension penalty (aln -E)=4 
m. Disable iterative search (aln -N)=False  
n. Maximum number of alignments to output in the XA tag for reads paired 
properly (samse/sampe-n)=3 
o. Maximum number of alignments to output in the XA tag for disconcordant 
read pairs (excluding singletons (sampe -N))=10 
p. Maximum insert size for a read pair to be considered as being properly 
(sampe-a)=500 
q. Maximum occurrences of a read for pairing (sampe -o)=100000 
 
3. Filter Sequence Alignment/Map (SAM) 
a. The read is unmapped  
b. Do not set the states for this flag 
 
4. SAM to Binary Alignment/MAP (BAM) 
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5. Add or Replace Read Groups 
 
6. Unified Genotyper 
a. Binding for reference-ordered datas 
i. Identify SNPs 
ii. Minimum phred-scaled confidence threshold at which variants not 
at ‘trigger’ track sites should be called=30.0 
iii. Minimum phred-scaled confidence threshold at which variants not 
at ‘trigger’ track sites should be emitted=30.0 
iv. Basic GATK options and basic analysis options 
7. Identify Snps 
a. Input/output format=VCF 
b. Genetic code for sequence= standard 
c. No upstream/downstream intervals (0 bases) 
d. Do not show downstream/intergenic/intron/upstream/5’UTR/3’UTR 
changes 
e. Filter out specific effects 
f. Filter out and do not report 
i. Synonymous coding 
ii. Synonymous start 
iii. Synonymous stop 
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